<SEC-DOCUMENT>0000950103-20-017822.txt : 20200914
<SEC-HEADER>0000950103-20-017822.hdr.sgml : 20200914
<ACCEPTANCE-DATETIME>20200914080151
ACCESSION NUMBER:		0000950103-20-017822
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200913
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200914
DATE AS OF CHANGE:		20200914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		201172319

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dp136480_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:GILD="http://gilead.com/20200913">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_GILD_gilead.com_20200913 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200913_20200913 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0000882095 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityCentralIndexKey">0000882095</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:booleantrue" id="xdx2ixbrl0023" name="dei:PreCommencementTenderOffer">true</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="gild-20200913.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-09-13to2020-09-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-13</xbrli:startDate>
        <xbrli:endDate>2020-09-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20200913__20200913_zQPEVxHupy0b"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Current Report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of Earliest Event
Reported): September 14, 2020 (<span id="xdx_906_edei--DocumentPeriodEndDate_c20200913__20200913_zmPRy3Mi9xu4"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 13, 2020</ix:nonNumeric></span>)</b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20200913__20200913_zf3ufFXioPGd"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityRegistrantName">Gilead Sciences, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 20pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified
in its Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 35%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20200913__20200913_zJgw25yFcKw4"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or Other </b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Jurisdiction</b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of Incorporation)</b></p>
</td>
    <td style="width: 31%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityFileNumber_c20200913__20200913_zdECk4sDV216"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityFileNumber">0-19731</ix:nonNumeric></span></b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission File Number)</b></p>
</td>
    <td style="white-space: nowrap; width: 34%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20200913__20200913_zRHSA5P1goN7"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityTaxIdentificationNumber">94-3047598</ix:nonNumeric></span></b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p>
</td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 50%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20200913__20200913_zPutNelDHyrg"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityAddressAddressLine1">333 Lakeside Drive</ix:nonNumeric></span></b></p>

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20200913__20200913_z0Tlc9Kg1ew1"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityAddressCityOrTown">Foster City</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20200913__20200913_zREh5Ayh9881"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></p>
</td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><b><span id="xdx_905_edei--EntityAddressPostalZipCode_c20200913__20200913_zTAhjUfsEU3j"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:EntityAddressPostalZipCode">94404</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center"><b>(Address of Principal Executive Offices)</b></td>
    <td style="font-size: 10pt; text-align: center"><b>(Zip Code)</b></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90F_edei--CityAreaCode_c20200913__20200913_z4RS7dOpckDk"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20200913__20200913_zY4vpFFPmyBi"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:LocalPhoneNumber">574-3000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed
Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_902_edei--WrittenCommunications_c20200913__20200913_zPsJ1VgCKNBh"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td>Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_901_edei--SolicitingMaterial_c20200913__20200913_zDvsWcaPfN95"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td><td>Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_904_edei--PreCommencementTenderOffer_dxL_c20200913__20200913_z6Dtbw5gzsX4" title="::XDX::true"><span style="-sec-ix-hidden: xdx2ixbrl0023">&#9746;</span></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20200913__20200913_zZr0w6sL2GB8"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%">
        <p style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Title
        of each class</p>
</td>
    <td style="width: 31%">
        <p style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Trading
        Symbol(s)</p>
</td>
    <td style="width: 34%">
        <p style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Name
        of each exchange on which registered</p>
</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span id="xdx_903_edei--Security12bTitle_c20200913__20200913_zajAnB4CcL1g"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_909_edei--TradingSymbol_c20200913__20200913_ztd7biN9Qk26"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" name="dei:TradingSymbol">GILD</ix:nonNumeric></span></td>
    <td style="font-size: 10pt; text-align: center"><span id="xdx_900_edei--SecurityExchangeName_c20200913__20200913_z27RUqbZKFD"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20200913__20200913_z7vKMqffZTzd"><ix:nonNumeric contextRef="From2020-09-13to2020-09-13" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in">Item 1.01.</td><td>Entry into a Material Definitive Agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 13, 2020, Gilead Sciences,
Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Parent</span>&#8221; or &#8220;<span style="text-decoration: underline">Gilead</span>&#8221;), entered into an Agreement and Plan of
Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;), among Parent, Immunomedics, Inc., a Delaware corporation (&#8220;Immunomedics&#8221;),
and Maui Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Merger Agreement, and upon
the terms and subject to the conditions thereof, Purchaser will commence a tender offer (the &#8220;<span style="text-decoration: underline">Offer</span>&#8221;), to purchase
all of the issued and outstanding shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of common stock, par value $0.01 per share, of Immunomedics,
other than any Shares held immediately prior to the effective time of the Merger by Immunomedics (or held in Immunomedics&#8217;
treasury) and any Shares held immediately prior to the effective time of the Merger by Parent, Purchaser or any other direct or
indirect wholly owned subsidiary of Parent at a price of $88.00 per Share (the &#8220;<span style="text-decoration: underline">Offer Price</span>&#8221;), net to the seller
in cash, without interest and subject to any required withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Offer will initially remain open for
a minimum of 20 business days from the date of commencement of the Offer. If at the scheduled expiration time of the Offer any
of the conditions to the Offer have not been satisfied (unless such condition is waivable by Purchaser or Parent and has been waived),
Purchaser will, and Parent will cause Purchaser to, extend the Offer to permit the satisfaction of all Offer conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The obligation of Purchaser to
consummate the Offer is subject to the satisfaction or waiver of customary conditions, including, among others, (i) there
being validly tendered and not validly withdrawn prior to the expiration of the Offer a number of Shares that, considered
together with all other Shares (if any) beneficially owned by Parent and its affiliates, represent one more Share than 50% of
the total number of Shares outstanding at the expiration of the Offer, (ii) the expiration or termination of the waiting
period applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended (the &#8220;<span style="text-decoration: underline">HSR Act</span>&#8221;), (iii) the absence of any law or order
prohibiting the consummation of the Offer or the Merger in any jurisdiction in which Parent or Immunomedics has material
business operations and (iv) other customary conditions set forth in Annex I to the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Following the consummation of the Offer
and subject to the terms and conditions of the Merger Agreement, Purchaser will merge with and into Immunomedics pursuant to Section
251(h) of the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline">DGCL</span>&#8221;), with Immunomedics being the surviving
corporation (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;). At the effective time of the Merger, each Share (other than (i) Shares held by Immunomedics
(or held in Immunomedics&#8217; treasury), (ii) Shares held by Parent, Purchaser, or any other direct or indirect wholly owned
subsidiary of Parent and (iii) Shares held by stockholders who have properly exercised and perfected their demands for appraisal
of such Shares in accordance with the DGCL and have neither withdrawn nor lost such rights prior to the effective time of the Merger)
will be converted into the right to receive an amount in cash equal to the Offer Price, without interest and subject to any required
withholding of taxes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Merger Agreement includes customary
representations, warranties and covenants of Immunomedics, Parent and Purchaser.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Immunomedics has agreed to customary &#8220;no-shop&#8221;
restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in discussions or negotiations
with third parties regarding alternative acquisition proposals. Notwithstanding these restrictions, Immunomedics may under certain
circumstances provide information to and participate in discussions or negotiations with third parties with respect to a bona fide
written alternative acquisition proposal that the board of directors of Immunomedics has determined constitutes or would reasonably
be expected to result in a Superior Offer (as defined in the Merger Agreement), if failing to do so would be inconsistent with
the board&#8217;s fiduciary duties under applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Merger Agreement also provides that,
in connection with the termination of the Merger Agreement under specified circumstances, including termination by Immunomedics
to accept and enter into an agreement with respect to a Superior Offer (as defined in the Merger Agreement), Immunomedics will
pay Parent a termination fee of approximately $732.1 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing description of the
Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety
by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The
Merger Agreement has been filed to provide information to investors regarding its terms. It is not intended to provide any
other factual information about Parent, Purchaser or Immunomedics, their respective businesses, or the actual conduct of
their respective businesses during the period prior to the consummation of the Offer, the Merger or the other transactions
contemplated by the Merger Agreement. The Merger Agreement and this summary should not be relied upon as disclosure about
Parent or Immunomedics. None of Immunomedics&#8217; stockholders or any other third parties should rely on the
representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or
conditions of Parent, Purchaser, Immunomedics or any of their respective subsidiaries or affiliates. The Merger Agreement
contains representations and warranties that are the product of negotiations among the parties thereto and that the parties
made to, and solely for the benefit of, each other as of specified dates. The assertions embodied in those representations
and warranties are subject to qualifications and limitations agreed to by the respective parties and are also qualified in
important part by confidential disclosure schedules delivered in connection with the signing of the Merger Agreement. The
representations and warranties (i) may have been made for the purpose of allocating contractual risk between the parties to
the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to
the contracting parties that differ from what an investor may view as material and (ii) may have been made only as of the date of the Merger Agreement or as of another date or dates as may be specified in the Merger Agreement, and information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the public disclosures of Immunomedics or Parent, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in">Item 8.01.</td><td>Other Events.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 13, 2020, Parent and Immunomedics
issued a joint press release announcing their entry into the Merger Agreement, a copy of which is attached as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated by reference herein.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Forward-Looking Statements </span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Current Report on Form 8-K contains
forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Immunomedics
and the acquisition of Immunomedics by Gilead that are subject to risks, uncertainties and other factors. All statements other
than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding
the intent, belief or current expectation of the companies&#8217; and members of their senior management team. Forward-looking
statements include, without limitation, statements regarding the business combination and related matters, prospective performance
and opportunities, post-closing operations and the outlook for the companies&#8217; businesses, including, without limitation,
the ability of Gilead to advance Immunomedics&#8217; product pipeline and successfully commercialize Trodelvy&#894; expectations
for achieving full U.S. Food and Drug Administration approval based on Immunomedics&#8217; confirmatory data for Trodelvy and Immunomedics&#8217;
development of Trodelvy for additional indications; clinical trials (including the anticipated timing of clinical data, the funding
therefor, anticipated patient enrollment, trial outcomes, timing or associated costs)&#894; the possibility of unfavorable results
from clinical trials&#894; regulatory applications and related timelines, including the filing and approval timelines for Biologics
License Applications and supplements; filings and approvals relating to the transaction&#894; the expected timing of the completion
of the transaction&#894; the ability to complete the transaction considering the various closing conditions&#894; difficulties
or unanticipated expenses in connection with integrating the companies&#894; and any assumptions underlying</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in">any
of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and
involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results
may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that
could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as
to the timing of the tender offer and merger&#894; uncertainties as to how many of Immunomedics&#8217; stockholders will tender
their stock in the offer&#894; the possibility that competing offers will be made&#894; the possibility that various closing conditions
for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant
approval for the consummation of the transaction&#894; the effects of the transaction on relationships with employees, other business
partners or governmental entities&#894; the difficulty of predicting the timing or outcome of regulatory approvals or actions,
if any&#894; Immunomedics&#8217; ability to meet post-approval compliance obligations (on topics including but not limited to
product quality, product distribution and supply chain requirements, and promotional and marketing compliance); imposition of
significant post-approval regulatory requirements on Immunomedics&#8217; products, including a requirement for a post-approval
confirmatory clinical study, or failure to maintain (if received) or obtain full regulatory approval for Immunomedics&#8217; products
due to a failure to satisfy post-approval regulatory requirements, such as the submission of sufficient data from a confirmatory
clinical study&#894; the impact of competitive products and pricing&#894; other business effects, including the effects of industry,
economic or political conditions outside of the companies&#8217; control&#894; transaction costs&#894; actual or contingent liabilities&#894;
adverse impacts on business, operating results or financial condition in the future due to pandemics, epidemics or outbreaks,
such as COVID-19; and other risks and uncertainties detailed from time to time in the companies&#8217; periodic reports filed
with the U.S. Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;), including current reports on Form 8-K, quarterly
reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Immunomedics and the Schedule
TO and related tender offer documents to be filed by Gilead and Purchaser. All forward-looking statements are based on information
currently available to Gilead and Immunomedics, and Gilead and Immunomedics assume no obligation and disclaim any intent to update
any such forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Additional Information and Where to Find It</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The tender offer described in this Current
Report on Form 8-K has not yet commenced. This Current Report on Form 8-K is for informational purposes only and is neither an
offer to purchase nor a solicitation of an offer to sell shares of Immunomedics, nor is it a substitute for any tender offer materials
that Gilead, Purchaser or Immunomedics will file with the SEC. A solicitation and an offer to buy shares of Immunomedics will be
made only pursuant to an offer to purchase and related materials that Gilead intends to file with the SEC. At the time the tender
offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the SEC, and Immunomedics will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the tender offer. IMMUNOMEDICS&#8217; STOCKHOLDERS AND OTHER INVESTORS
ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER
TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD
BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related Letter of Transmittal
and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders
of Immunomedics at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available
for free at the SEC&#8217;s web site at www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Immunomedics.
Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or
by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement.
Copies of the documents filed with the SEC by Immunomedics will be available free of charge under the &#8220;Investors&#8221; section
of Immunomedics&#8217; internet website at Immunomedics.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the Offer to Purchase, the
related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead
and Immunomedics file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead&#8217;s
and Immunomedics&#8217; filings with the SEC are also available for free to the public from commercial document-retrieval services
and at the website maintained by the SEC at www.sec.gov.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 90.25pt">Item 9.01.</td><td>Financial Statements and Exhibits.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 11%">
        <p style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exhibit
Number&#160;</p></td>
    <td style="width: 89%">
        <p style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Description&#160;</p></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><a href="dp136480_ex0201.htm">2.1*</a></td>
    <td style="font-size: 10pt"><a href="dp136480_ex0201.htm">Agreement and Plan of Merger, dated September 13, 2020, among Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc.</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><a href="dp136480_ex9901.htm">99.1</a></td>
    <td style="font-size: 10pt"><a href="dp136480_ex9901.htm">Joint Press Release, dated September 13, 2020.</a></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">104</td>
    <td style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">*</td><td>Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. Gilead agrees to furnish supplementally a copy of any omitted
schedule to the SEC upon request.</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">GILEAD SCIENCES, INC.</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">By:</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Brett A. Pletcher</td></tr>
<tr style="vertical-align: top">
    <td style="width: 55%; font-size: 10pt">&#160;</td>
    <td style="width: 7%; font-size: 10pt">&#160;</td>
    <td style="width: 6%; font-size: 10pt">Name:</td>
    <td style="width: 32%; font-size: 10pt">Brett A. Pletcher</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">Title:</td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President, Corporate Affairs and General
Counsel</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: September 14, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwkAMRU/QO4RZSzutuLBLi4pYRUoRt6NNZbCdlMxY9Uje0rFFDIGQ/P/yhZiINa10gwynRZFDiW3XKIdQYI2M5oLekW22KfhZ4FVbx8q4Yf2BGXkGPTMLp2d/H5y9tlilIOdRPI0SCTJJYwmHnQi+ekam1hUap1UDylRwYOpYo1P8Gj+U6kmG2teQdES2mkwKcShH+Q2JjBPYU68exDcLeZ6JYDJUINZM9+4bc7eOWlg22PosO6L/Dj7ZqkkS -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>dp136480_ex0201.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 2.1</B></FONT><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>


<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">AGREEMENT
AND PLAN OF MERGER<BR>
<BR>
among:<BR>
<BR>
IMMUNOMEDICS, INC.,<BR>
<BR>
a Delaware corporation;<BR>
<BR>
GILEAD SCIENCES, INC.,<BR>
<BR>
a Delaware corporation; and<BR>
<BR>
MAUI MERGER SUB, INC.,</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">a Delaware corporation</FONT></P>

<P STYLE="margin: 0pt 0; font: 11pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0pt 0; font: 11pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Dated
as of September 13, 2020</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>




<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>


<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->




<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><U>PAGE</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    1 <BR>
THE OFFER</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; width: 90%; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    1.01.&nbsp;&nbsp;<I>The Offer</I></FONT></TD>
    <TD STYLE="padding: 0pt; width: 10%; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    1.02.&nbsp;&nbsp;<I>Company Actions</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    2 <BR>
MERGER TRANSACTION</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.01.&nbsp;&nbsp;<I>Merger of Purchaser into the Company</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.02.&nbsp;&nbsp;<I>Effect of the Merger</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.03.&nbsp;&nbsp;<I>Closing; Effective Time</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.04.&nbsp;&nbsp;<I>Certificate of Incorporation and Bylaws; Directors and Officers</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.05.&nbsp;&nbsp;<I>Conversion of Shares</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.06.&nbsp;&nbsp;<I>Surrender of Certificates; Stock Transfer Books</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.07.&nbsp;&nbsp;<I>Dissenters&rsquo; Rights</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.08.&nbsp;&nbsp;<I>Treatment of Equity Awards</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    2.09.&nbsp;&nbsp;<I>Further Action</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    3 <BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.01.&nbsp;&nbsp;<I>Due Organization</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.02.&nbsp;&nbsp;<I>Organizational Documents</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.03.&nbsp;&nbsp;<I>Capitalization, Etc</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.04.&nbsp;&nbsp;<I>Authority; Binding Nature of Agreement</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.05.&nbsp;&nbsp;<I>SEC Filings; Financial Statements</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.06.&nbsp;&nbsp;<I>Absence of Changes; No Material Adverse Effect</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.07.&nbsp;&nbsp;<I>Title to Assets</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.08.&nbsp;&nbsp;<I>Real Property</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.09.&nbsp;&nbsp;<I>Intellectual Property</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.10.&nbsp;&nbsp;<I>Contracts</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.11.&nbsp;&nbsp;<I>Liabilities</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.12.&nbsp;&nbsp;<I>Compliance with Legal Requirements</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.13.&nbsp;&nbsp;<I>Regulatory Matters</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.14.&nbsp;&nbsp;<I>Certain Business Practices</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.15.&nbsp;&nbsp;<I>Governmental Authorizations</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.16.&nbsp;&nbsp;<I>Tax Matters</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.17.&nbsp;&nbsp;<I>Employee Matters; Benefit Plans</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.18.&nbsp;&nbsp;<I>Environmental Matters</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.19.&nbsp;&nbsp;<I>Insurance</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.20.&nbsp;&nbsp;<I>Legal Proceedings; Orders</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.21.&nbsp;&nbsp;<I>Takeover Laws</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.22.&nbsp;&nbsp;<I>Non-Contravention; Consents</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.23.&nbsp;&nbsp;<I>Opinions of Financial Advisors</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    3.24.&nbsp;&nbsp;<I>Brokers and Other Advisors</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">i</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    4 <BR>
REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt; width: 90%"><FONT STYLE="font-size: 10pt">Section
    4.01.&nbsp;&nbsp;<I>Due Organization</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt; width: 10%"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.02.&nbsp;&nbsp;<I>Purchaser</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.03.&nbsp;&nbsp;<I>Authority; Binding Nature of Agreement</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.04.&nbsp;&nbsp;<I>Non-Contravention; Consents</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.05.&nbsp;&nbsp;<I>Disclosure</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.06.&nbsp;&nbsp;<I>Absence of Litigation</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.07.&nbsp;&nbsp;<I>Funds</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.08.&nbsp;&nbsp;<I>Ownership of Shares</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.09.&nbsp;&nbsp;<I>Acknowledgement by Parent and Purchaser</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    4.10.&nbsp;&nbsp;<I>Brokers and Other Advisors</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    5 <BR>
CERTAIN COVENANTS OF THE COMPANY</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    5.01.&nbsp;&nbsp;<I>Access and Investigation</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    5.02.&nbsp;&nbsp;<I>Operation of the Company&rsquo;s Business</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    5.03.&nbsp;&nbsp;<I>No Solicitation</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    5.04.&nbsp;&nbsp;<I>Compliance with ISRA</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    6 <BR>
ADDITIONAL COVENANTS OF THE PARTIES</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.01.&nbsp;&nbsp;<I>Company Board Recommendation</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.02.&nbsp;&nbsp;<I>Filings, Consents and Approvals</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.03.&nbsp;&nbsp;<I>Employee Benefits</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.04.&nbsp;&nbsp;<I>ESPP</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.05.&nbsp;&nbsp;<I>Indemnification of Officers and Directors</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.06.&nbsp;&nbsp;<I>Stockholder Litigation</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.07.&nbsp;&nbsp;<I>Additional Agreements</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.08.&nbsp;&nbsp;<I>Disclosure</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.09.&nbsp;&nbsp;<I>Takeover Laws</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.10.&nbsp;&nbsp;<I>Section 16 Matters</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.11.&nbsp;&nbsp;<I>Rule 14d-10 Matters</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.12.&nbsp;&nbsp;<I>Stock Exchange Delisting; Deregistration</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    6.13.&nbsp;&nbsp;<I>401(k) Plan</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    7<BR>
 CONDITIONS PRECEDENT TO THE MERGER</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    7.01.&nbsp;&nbsp;<I>No Restraints</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    7.02.&nbsp;&nbsp;<I>Consummation of Offer</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    8 <BR>
TERMINATION</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    8.01.&nbsp;&nbsp;<I>Termination</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    8.02.&nbsp;&nbsp;<I>Effect of Termination</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    8.03.&nbsp;&nbsp;<I>Expenses; Termination Fees</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">52</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Article
    9 <BR>
MISCELLANEOUS PROVISIONS</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding: 0pt; text-align: center; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.01.&nbsp;&nbsp;<I>Amendment</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.02.&nbsp;&nbsp;<I>Waiver</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.03.&nbsp;&nbsp;<I>No Survival of Representations and Warranties</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">ii</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt; width: 90%"><FONT STYLE="font-size: 10pt">Section
    9.04.&nbsp;&nbsp;<I>Entire Agreement; Counterparts</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt; width: 10%"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.05.&nbsp;&nbsp;<I>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.06.&nbsp;&nbsp;<I>Assignability</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.07.&nbsp;&nbsp;<I>No Third Party Beneficiaries</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.08.&nbsp;&nbsp;<I>Transfer Taxes</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.09.&nbsp;&nbsp;<I>Notices</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.10.&nbsp;&nbsp;<I>Severability</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.11.&nbsp;&nbsp;<I>Obligation of Parent</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Section
    9.12.&nbsp;&nbsp;<I>Construction</I></FONT></TD>
    <TD STYLE="padding: 0pt; text-align: right; text-indent: 0pt"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%"><FONT STYLE="font-size: 10pt">Exhibit A</FONT></TD>
    <TD STYLE="width: 87%"><FONT STYLE="font-size: 10pt">Certain Definitions</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Annex I</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to the Offer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Annex II</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amended and Restated Certificate of Incorporation of Immunomedics, Inc.</FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">iii</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">AGREEMENT
AND PLAN OF MERGER</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>THIS AGREEMENT
AND PLAN OF MERGER </B>(&ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of September 13, 2020, by and among: Gilead
Sciences, Inc., a Delaware corporation (&ldquo;<U>Parent</U>&rdquo;); Maui Merger Sub, Inc., a Delaware corporation and a wholly
owned subsidiary of Parent (&ldquo;<U>Purchaser</U>&rdquo;); and Immunomedics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;).
Certain capitalized terms used in this Agreement are defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Exhibit
A.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">RECITALS</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Parent has agreed to cause Purchaser to commence a tender offer (as it may be amended from time to time as permitted under
this Agreement, the &ldquo;<U>Offer</U>&rdquo;) to acquire all of the outstanding shares of Company Common Stock (the &ldquo;<U>Shares</U>&rdquo;),
other than the Excluded Shares, for $88.00 per share, net to the seller in cash, without interest (as such amount may be amended
or adjusted in accordance with the terms of this Agreement, the &ldquo;<U>Offer Price</U>&rdquo;), upon the terms and subject
to the conditions of this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As soon as practicable following the consummation of the Offer, Purchaser will be merged with and into the Company (the
&ldquo;<U>Merger</U>&rdquo;), with the Company continuing as the surviving corporation in the Merger (the &ldquo;<U>Surviving
Corporation</U>&rdquo;), on the terms and subject to the conditions set forth in this Agreement, whereby (i) each issued and outstanding
Share not owned by Parent, Purchaser or the Company as of the Effective Time (other than Excluded Shares and Dissenting Shares)
shall be converted into the right to receive the Offer Price, in cash, without interest, and (ii) the Company shall become a wholly
owned Subsidiary of Parent as a result of the Merger.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">(C)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The board of directors of the Company (the &ldquo;<U>Board of Directors</U>&rdquo;) has unanimously (i) determined that
this Agreement and the Transactions, including the Offer and the Merger, are fair to, and in the best interest of, the Company
and its stockholders, (ii) declared it advisable to enter into this Agreement, (iii)&nbsp;approved the execution, delivery and
performance by the Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (iv)
resolved that the Merger shall be effected under Section 251(h) of the DGCL, and (v) resolved to recommend that the stockholders
of the Company accept the Offer and tender their Shares to Purchaser pursuant to the Offer (the preceding <U>clauses (i)</U> through
<U>(v)</U>, the &ldquo;<U>Company Board Recommendation</U>&rdquo;), in each case, on the terms and subject to the conditions of
this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">(D)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The board of directors of each of Parent and Purchaser have approved this Agreement and declared it advisable for Parent
and Purchaser, respectively, to enter into this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">(E)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Parent, Purchaser and the Company acknowledge and agree that the Merger shall be effected pursuant to Section 251(h) of
the DGCL and shall, subject to the satisfaction of the conditions set forth in this Agreement, be consummated as soon as practicable
following the consummation of the Offer.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">AGREEMENT</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The Parties,
intending to be legally bound, agree as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
1<BR>
THE OFFER</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 1.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>The Offer</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Commencement of the Offer</B>. Provided that this Agreement shall not have been terminated in accordance with <B>&lrm;</B>Article
8, as promptly as practicable after the date of this Agreement but in no event more than 10 business days after the date of this
Agreement (subject to the Company having timely provided any information required to be provided by it pursuant to Sections <B>&lrm;</B>1.01(e)
and <B>&lrm;</B>1.02(b)), Purchaser shall (and Parent shall cause Purchaser to) commence (within the meaning of Rule 14d-2 under
the Exchange Act) the Offer to purchase all of the outstanding Shares (other than Shares to be cancelled pursuant to Sections
<B>&lrm;</B>2.05(a)(i) and <B>&lrm;</B>2.05(a)(ii) (collectively, the &ldquo;<U>Excluded Shares</U>&rdquo;)), at a price per Share
equal to the Offer Price, net to the seller in cash, without interest and subject to any withholding of Tax in accordance with
<B>&lrm;</B>Section 2.06(e).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Terms and Conditions of the Offer</B>. The obligations of Purchaser to (and of Parent to cause Purchaser to) accept
for payment, and pay for, any Shares validly tendered (and not validly withdrawn) pursuant to the Offer shall be subject to the
satisfaction or waiver (to the extent permitted under applicable Legal Requirements) of the conditions set forth in <U>Annex I</U> (collectively, the &ldquo;<U>Offer Conditions</U>&rdquo;), and no other conditions. The Offer shall be made by means of an
offer to purchase (the &ldquo;<U>Offer to Purchase</U>&rdquo;) that contains the terms set forth in this Agreement, the Minimum
Condition, the Termination Condition and the other Offer Conditions. Purchaser expressly reserves the right to (i) increase the
amount of cash constituting the Offer Price, (ii) waive any Offer Condition (to the extent permitted under applicable Legal Requirements)
and (iii) make any other changes in the terms and conditions of the Offer not inconsistent with the terms of this Agreement; <I>provided</I>,
<I>however</I>, notwithstanding anything to the contrary contained in this Agreement, without the prior written consent of the
Company, Parent and Purchaser shall not (A) decrease the Offer Price, (B) change the form of consideration payable in the Offer
(provided that nothing herein shall limit the ability of Parent and Purchaser to increase the cash consideration payable in the
Offer), (C) decrease the maximum number of Shares sought to be purchased in the Offer, (D) impose conditions or requirements to
the Offer in addition to the Offer Conditions, (E) amend, modify or waive the Minimum Condition, Termination Condition or the
conditions set forth in <U>clause (e)</U> or <B>&lrm;</B><U>(g)</U> of <B>&lrm;</B>Annex I, (F) otherwise amend or modify any
of the other terms of the Offer in a manner that adversely affects, or would reasonably be expected to adversely affect any holder
of Shares in its capacity as such, (G) terminate the Offer or accelerate, extend or otherwise change the Expiration Date, in each
case, except as provided in Sections <B>&lrm;</B>1.01(c) or <B><U>&lrm;</U></B>1.01(d) or (H) provide any &ldquo;subsequent offering
period&rdquo; (or any extension thereof) within the meaning of Rule 14d-11 promulgated under the Exchange Act. The Offer may not
be withdrawn prior to the Expiration Date (or any rescheduled Expiration Date) of the Offer, unless this Agreement is terminated
in accordance with <B>&lrm;</B>Article 8.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Expiration and Extension of the Offer</B>. The Offer shall initially be scheduled to expire at one minute after 11:59
p.m. Eastern Time on the date that is 20 business days (determined as set forth in Rule 14d-1(g)(3) and Rule 14e-1(a) under the
Exchange Act) following the Offer Commencement Date (unless otherwise agreed to in writing by Parent and the Company) (the &ldquo;<U>Initial
Expiration Date</U>&rdquo;, and such date or such subsequent date to which the Initial Expiration Date of the Offer is extended
in accordance with the terms of this Agreement, the &ldquo;<U>Expiration Date</U>&rdquo;). Notwithstanding anything to the contrary
contained in this Agreement, but subject to the Parties&rsquo; respective termination rights under <B>&lrm;</B>Article 8: (i)
if, as of the then-</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">scheduled Expiration
Date, any Offer Condition is not satisfied (unless such condition is waivable by Purchaser or Parent and has been waived) Purchaser
shall, and Parent shall cause Purchaser to, extend the Offer for additional periods of up to 10 business days per extension, to
permit such Offer Condition to be satisfied; and (ii) Purchaser shall, and Parent shall cause Purchaser to, extend the Offer from
time to time for any period required by any Legal Requirement, any interpretation or position of the SEC, the staff thereof or
NASDAQ applicable to the Offer; <I>provided</I>, <I>however</I>, that in no event shall Purchaser (1) be required to extend the
Offer beyond the earlier to occur of (x)&nbsp;the valid termination of this Agreement in accordance with <B>&lrm;</B>Article 8
and (y)&nbsp;the End Date (such earlier occurrence, the &ldquo;<U>Extension Deadline</U>&rdquo;) or (2) be permitted to extend
the Offer beyond the Extension Deadline without the prior written consent of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Termination of Offer</B>. Nothing in this <B>&lrm;</B>Section 1.01 shall be deemed to impair, limit or otherwise restrict
in any manner the right of the Company, Parent or Purchaser to terminate this Agreement pursuant to <B>&lrm;</B>Article 8. In
the event that this Agreement is validly terminated pursuant to <B>&lrm;</B>Article 8, Purchaser shall (and Parent shall cause
Purchaser to) immediately, irrevocably and unconditionally terminate the Offer and shall not acquire any Shares pursuant to the
Offer. If the Offer is terminated or withdrawn by Purchaser in accordance with the terms of this Agreement, Purchaser shall immediately
return, and shall cause any depository acting on behalf of Purchaser to return, in accordance with applicable Legal Requirements,
all tendered Shares to the registered holders thereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Offer Documents</B>. As promptly as practicable on the Offer Commencement Date, Parent and Purchaser shall (i) file
with the SEC a tender offer statement on Schedule TO with respect to the Offer (together with any exhibits, amendments or supplements
thereto, the &ldquo;<U>Offer Documents</U>&rdquo;) that will contain or incorporate by reference the Offer to Purchase, form of
the related letter of transmittal and summary advertisement, (ii) make all deliveries, mailings and telephonic notices required
by Rule 14d-3 under the Exchange Act and (iii) cause the Offer to Purchase and related documents to be disseminated to holders
of Shares as and to the extent required by applicable Legal Requirements. Parent and Purchaser agree that they shall cause the
Offer Documents filed by either Parent or Purchaser with the SEC to (x)&nbsp;comply in all material respects with the Exchange
Act and other applicable Legal Requirements and (y)&nbsp;not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading; <I>provided</I>, <I>however</I>, that no covenant is made by Parent or Purchaser with
respect to information supplied by or on behalf of the Company for inclusion or incorporation by reference in the Offer Documents.
Each of Parent, Purchaser and the Company agrees to respond promptly to any comments (including oral comments) of the SEC or its
staff and to promptly correct any information provided by it for use in the Offer Documents if and to the extent that such information
shall have become false or misleading in any material respect, and Parent and Purchaser further agree to take all steps necessary
to promptly cause the Offer Documents as so corrected to be filed with the SEC and to be disseminated to holders of Shares, in
each case as and to the extent required by applicable Legal Requirements. The Company hereby consents to the inclusion of the
Company Board Recommendation in the Offer Documents. The Company shall promptly furnish or otherwise make available to Parent
and Purchaser or Parent&rsquo;s legal counsel all information concerning the Acquired Companies and the Company&rsquo;s stockholders
that may be required or reasonably requested in connection with any action contemplated by this <B>&lrm;</B>Section 1.01(e). The
Company and its counsel shall be given reasonable opportunity to review and comment on the Offer Documents (including any response
to any comments (including oral comments) of the SEC or its staff with respect thereto) prior to the filing thereof with the SEC,
and Parent and Purchaser shall give reasonable consideration to any such comments made by the Company or its counsel. Parent and
Purchaser agree to provide the</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Company and
its counsel with any comments (including oral comments) Parent, Purchaser or their counsel may receive from the SEC or its staff
with respect to the Offer Documents promptly after receipt of those comments (including oral comments).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Funds</B>. Without limiting the generality of <B>&lrm;</B>Section 9.11, Parent shall cause to be provided to Purchaser,
on a timely basis, all of the funds necessary to purchase all Shares that Purchaser becomes obligated to purchase pursuant to
the Offer, and shall cause Purchaser to perform, on a timely basis, all of Purchaser&rsquo;s obligations under this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Adjustments</B>. If, between the date of this Agreement and the Offer Acceptance Time, the outstanding Shares are changed
into a different number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse
stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then the Offer Price shall
be appropriately adjusted.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Acceptance</B>. Subject only to the satisfaction or, to the extent waivable by Purchaser or Parent, waiver by Purchaser
or Parent of each of the Offer Conditions, Purchaser shall (and Parent shall cause Purchaser to) (i) immediately after the Expiration
Date irrevocably accept for payment all Shares tendered (and not validly withdrawn) pursuant to the Offer (the time of such acceptance,
the &ldquo;<U>Offer Acceptance Time</U>&rdquo;) and (ii) as promptly as practicable after the Offer Acceptance Time (and in any
event within three business days) pay for such Shares.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 1.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Company Actions</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Schedule 14D-9</B>. Subject to <B>&lrm;</B>Section 6.01(b), as promptly as practicable on the Offer Commencement Date,
following the filing of the Offer Documents, the Company shall (i) file with the SEC a Tender Offer Solicitation/Recommendation
Statement on Schedule 14D-9 (together with any exhibits, amendments or supplements thereto, the &ldquo;<U>Schedule 14D-9</U>&rdquo;)
that shall reflect the Company Board Recommendation and include the fairness opinion of the Company&rsquo;s financial advisor
referenced in <B>&lrm;</B>Section 3.23 and the notice and other information required by Section 262(d)(2) of the DGCL and (ii)
cause the Schedule 14D-9 and related documents to be disseminated to holders of Shares as and to the extent required by applicable
Legal Requirements, including by setting the Stockholder List Date as the record date for purposes of receiving the notice required
by Section 262(d)(2) of the DGCL. The Company agrees that it shall cause the Schedule 14D-9 to (x)&nbsp;comply in all material
respects with the Exchange Act and other applicable Legal Requirements and (y)&nbsp;not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that no covenant is made
by the Company with respect to information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by reference
in the Schedule 14D-9. Each of Parent, Purchaser and the Company agrees to respond promptly to any comments (including oral comments)
of the SEC or its staff and to promptly correct any information provided by it for use in the Schedule 14D-9 if and to the extent
that such information shall have become false or misleading in any material respect, and the Company further agrees to take all
steps necessary to promptly cause the Schedule 14D-9 as so corrected to be filed with the SEC and to be disseminated to holders
of Shares, in each case as and to the extent required by applicable Legal Requirements. Parent and Purchaser shall promptly furnish
or otherwise make available to the Company or the Company&rsquo;s legal counsel all information concerning Parent or Purchaser
that may be required or reasonably requested in connection with any action contemplated by this <B>&lrm;</B>Section 1.02(a). Parent
and its counsel shall be given reasonable opportunity to review and comment on the Schedule 14D-9 (including any response to any
comments (including oral</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">comments) of
the SEC or its staff with respect thereto) prior to the filing thereof with the SEC, and the Company shall give reasonable consideration
to any such comments made by Parent or its counsel. The Company agrees to provide Parent and its counsel with any comments (including
oral comments) the Company or its counsel may receive from the SEC or its staff with respect to the Schedule 14D-9 promptly after
receipt of those comments (including oral comments).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Stockholder Lists</B>. The Company shall promptly after the date hereof furnish Parent with a list of its stockholders,
mailing labels and any available listing or computer file containing the names and addresses of all record holders of Shares and
lists of securities positions of Shares held in stock depositories, in each case as of the most recent practicable date, and shall
provide to Parent such additional information (including updated lists of stockholders, mailing labels and lists of securities
positions) and such other assistance as Parent may reasonably request in connection with the Offer and the Merger (the date of
the list used to determine the Persons to whom the Offer Documents and the Schedule 14D-9 are first disseminated, which date shall
not be more than 10 business days prior to the date the Offer Documents and the Schedule 14D-9 are first disseminated, the &ldquo;<U>Stockholder
List Date</U>&rdquo;). Subject to applicable Legal Requirements, and except for such steps as are necessary to disseminate the
Offer Documents and any other documents necessary to consummate the Transactions, Parent and Purchaser and their agents shall
hold in confidence in accordance with the Confidentiality Agreement the information contained in any such labels, listings and
files.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>Share Registry</B>. The Company shall register (and shall instruct its transfer agent to register) the transfer of the
Shares accepted for payment by Purchaser effective immediately after the Offer Acceptance Time.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
2<BR>
MERGER TRANSACTION</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Merger of Purchaser into the Company</I>. Upon the terms and subject to the conditions set forth in this Agreement and
in accordance with Section 251(h) of the DGCL, at the Effective Time, the Company and Parent shall consummate the Merger, whereby
Purchaser shall be merged with and into the Company, the separate existence of Purchaser shall cease, and the Company will continue
as the Surviving Corporation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Effect of the Merger</I>. The Merger shall have the effects set forth in this Agreement and in the applicable provisions
of the DGCL. Without limiting the generality of the foregoing, at the Effective Time, all of the property, rights, privileges,
immunities, powers and franchises of the Company and Purchaser shall vest in the Surviving Corporation, and all of the debts,
liabilities and duties of the Company and Purchaser shall become the debts, liabilities and duties of the Surviving Corporation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Closing; Effective Time.</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Unless this Agreement shall have been terminated pursuant to <B>&lrm;</B>Article 8, and unless otherwise mutually agreed
in writing between the Company, Parent and Purchaser, the consummation of the Merger (the &ldquo;<U>Closing</U>&rdquo;) shall
take place at the offices of Davis Polk &amp; Wardwell LLP, 450 Lexington Avenue, New York, New York, 10017, as soon as practicable
following (but in any event on the same date as) the Offer Acceptance Time except if the conditions set forth in <B>&lrm;</B>Section
7.01 shall not be satisfied or, to the extent permitted by applicable Legal Requirements, waived as of such date, in which case
the Closing shall take place on the first business day on which all conditions set forth in <B>&lrm;</B>Section 7.01 are satisfied
or, to the extent</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">permitted by
applicable Legal Requirements, waived, unless another date or place is agreed to in writing by the Company and Parent prior to
the Offer Acceptance Time. The date on which the Closing occurs is referred to in this Agreement as the &ldquo;<U>Closing Date</U>&rdquo;.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Subject to the provisions of this Agreement, as soon as practicable on the Closing Date, the Company and Purchaser shall
file or cause to be filed a certificate of merger with the Secretary of State of the State of Delaware with respect to the Merger,
in such form as required by, and executed and acknowledged in accordance with, the relevant provisions of the DGCL, and the Parties
shall take all such further actions as may be required by applicable Legal Requirements to make the Merger effective. The Merger
shall become effective upon the date and time of the filing of that certificate of merger with the Secretary of State of the State
of Delaware or such later date and time as is agreed upon in writing by the Parties and specified in the certificate of merger
(such date and time, the &ldquo;<U>Effective Time</U>&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.04.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Certificate of Incorporation and Bylaws; Directors and Officers</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As of the Effective Time, the certificate of incorporation of the Company shall, by virtue of the Merger and without any
further action, be amended and restated to read in its entirety as set forth on <U>Annex II</U> and, as so amended and restated,
shall be the certificate of incorporation of the Surviving Corporation until thereafter changed or amended as provided therein
or by applicable Legal Requirements, subject to <B>&lrm;</B>Section 6.05(a).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As of the Effective Time, the bylaws of the Surviving Corporation shall be amended and restated to conform to the bylaws
of Purchaser as in effect immediately prior to the Effective Time, until thereafter changed or amended as provided therein or
by applicable Legal Requirements, subject to <B>&lrm;</B>Section 6.05(a), except that references to the name of Purchaser shall
be replaced by references to the name of the Surviving Corporation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As of the Effective Time, the directors and officers of the Surviving Corporation shall be the respective individuals who
served as the directors and officers of Purchaser as of immediately prior to the Effective Time, until their respective successors
are duly elected and qualified, or their earlier death, resignation or removal. Prior to the Closing, each director of the Company
and, if so requested by Parent, each officer of the Company, shall execute and deliver a letter effectuating his or her resignation
as a member of the Board of Directors and an officer of the Company, respectively, to be effective as of the Effective Time.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.65in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.05.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Conversion of Shares</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Purchaser, the Company
or any stockholder of the Company:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Shares held immediately prior to the Effective Time by the Company (or held in the Company&rsquo;s treasury) shall
be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Shares held immediately prior to the Effective Time by Parent, Purchaser or any other direct or indirect wholly owned
Subsidiary of Parent shall be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange
therefor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>except as provided in <U>clauses (i)</U> and <U>(ii)</U> above and subject to <B><I>&lrm;</I></B>Section 2.05(b), each
Share outstanding immediately prior to the Effective Time (other than any</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">Dissenting
Shares, which shall have only those rights set forth in <B><I>&lrm;</I></B>Section 2.07) shall be converted into the right to
receive the Offer Price (the &ldquo;<U>Merger Consideration</U>&rdquo;), in each case without any interest thereon, subject to
any withholding of Taxes in accordance with <B><I>&lrm;</I></B>Section 2.06(e); and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>each share of the common stock, $0.01 par value per share, of Purchaser then outstanding shall be converted into one share
of common stock of the Surviving Corporation. From and after the Effective Time, subject to this <B><I>&lrm;</I></B>Section 2.05(a),
all Shares shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and each applicable holder
of such Shares shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration therefor
upon the surrender of such shares of Company Common Stock in accordance with <B><I>&lrm;</I></B>Section 2.06.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>If, between the date of this Agreement and the Effective Time, the outstanding Shares are changed into a different number
or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation
of shares, reclassification, recapitalization or other similar transaction, then the Merger Consideration shall be appropriately
adjusted.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.06.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Surrender of Certificates; Stock Transfer Books</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Prior to the Offer Acceptance Time, Parent shall designate a bank or trust company reasonably acceptable to the Company
to act as agent (the &ldquo;<U>Depository Agent</U>&rdquo;) for the holders of Shares to receive the aggregate Offer Price to
which holders of such Shares shall become entitled pursuant to <B>&lrm;</B>Section 1.01(b) and to act as agent (the &ldquo;<U>Paying
Agent</U>&rdquo;) for the holders of Shares to receive the aggregate Merger Consideration to which holders of such Shares shall
become entitled pursuant to <B>&lrm;</B>Section 2.05. Promptly after (and in any event no later than the third business day after)
the Offer Acceptance Time, Parent shall deposit, or shall cause to be deposited, with the Depository Agent cash sufficient to
make the payment of the aggregate Offer Price payable pursuant to <B>&lrm;</B>Section 1.01(h). On or prior to the Closing Date,
Parent shall deposit, or shall cause to be deposited, with the Paying Agent cash sufficient to pay the aggregate Merger Consideration
payable pursuant to <B>&lrm;</B>Section 2.05 (together with the amount deposited pursuant the immediately preceding sentence,
the &ldquo;<U>Payment Fund</U>&rdquo;). The Payment Fund shall not be used for any purpose other than to pay the aggregate Offer
Price in the Offer and the aggregate Merger Consideration in the Merger. The Payment Fund shall be invested by the Paying Agent
if so directed by the Surviving Corporation; <I>provided </I>that such investments shall be (w) in obligations of or guaranteed
by the United States of America, (x)&nbsp;in commercial paper obligations rated A-1 or P-1 or better by Moody&rsquo;s Investors
Service, Inc. or Standard &amp; Poor&rsquo;s Corporation, respectively, (y)&nbsp;in certificates of deposit, bank repurchase agreements
or banker&rsquo;s acceptances of commercial banks with capital exceeding one billion dollars, or (z)&nbsp;in money market funds
having a rating in the highest investment category granted by a recognized credit rating agency at the time of acquisition or
a combination of the foregoing and, in any such case, no such instrument shall have a maturity exceeding three months. To the
extent Parent becomes aware that (i) there are any losses with respect to any such investments or (ii) the Payment Fund has diminished
for any reason below the level required for the Paying Agent to make prompt cash payment pursuant to <B>&lrm;</B>Section 1.01(h)
and <B>&lrm;</B>Section 2.05, Parent shall, or shall cause the Surviving Corporation to, promptly replace or restore the cash
in the Payment Fund so as to ensure that the Payment Fund is, at all times during the duration of the Payment Fund, maintained
at a level sufficient for the Paying Agent to make such payments pursuant to <B>&lrm;</B>Section 1.01(h) and <B>&lrm;</B>Section
2.05.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Promptly after the Effective Time (but in no event later than three business days thereafter), the Surviving Corporation
shall cause to be delivered to each Person who was, at the Effective Time, a holder of record of (i) Shares represented by a certificate
evidencing such Shares (the &ldquo;<U>Certificates</U>&rdquo;) or (ii) Book-Entry Shares, who, in each case was entitled to receive
the Merger Consideration pursuant to <B>&lrm;</B>Section 2.05, (A) a form of letter of transmittal, which shall be in reasonable
and customary form and shall specify that delivery shall be effected, and risk of loss and title to the Certificates shall pass,
only upon proper delivery of the Certificates (or affidavits of loss in lieu thereof in accordance with <B>&lrm;</B>Section 2.06(f),
if applicable) to the Paying Agent, or a customary agent&rsquo;s message in respect to Book-Entry Shares, and (B) instructions
for use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for the Merger Consideration issuable
and payable in respect of such Shares pursuant to <B>&lrm;</B>Section 2.05. Upon surrender to the Paying Agent of Certificates
(or affidavits of loss in lieu thereof in accordance with <B>&lrm;</B>Section 2.06(f), if applicable) or Book-Entry Shares, together
with such letter of transmittal in the case of Certificates, duly completed and validly executed in accordance with the instructions
thereto, and such other documents as may be required pursuant to the instructions thereto, the holder of such Certificates or
Book-Entry Shares shall be entitled to receive in exchange therefor the Merger Consideration for each Share formerly evidenced
by such Certificates or Book-Entry Shares, and such Certificates and Book-Entry Shares shall then be cancelled. No interest shall
accrue or be paid on the Merger Consideration payable upon the surrender of any Certificates or Book-Entry Shares for the benefit
of the holder thereof. If the payment of any Merger Consideration is to be made to a Person other than the Person in whose name
the surrendered Certificates formerly evidencing the Shares is registered on the stock transfer books of the Company, it shall
be a condition of payment that the Certificate so surrendered shall be endorsed properly or otherwise be in proper form for transfer
and that the Person requesting such payment shall have paid all transfer and other similar Taxes required by reason of the payment
of the Merger Consideration to a Person other than the registered holder of the Certificate surrendered, or shall have established
to the satisfaction of Parent that such transfer or other similar Taxes either have been paid or are not applicable. None of Parent,
Purchaser and the Surviving Corporation shall have any liability for the transfer and other similar Taxes described in this <B>&lrm;</B>Section
2.06(b) under any circumstance. Payment of the applicable Merger Consideration with respect to Book-Entry Shares shall only be
made to the Person in whose name such Book-Entry Shares are registered. Until surrendered as contemplated by this <B>&lrm;</B>Section
2.06(b), each Certificate and Book-Entry Share shall be deemed at any time after the Effective Time to represent only the right
to receive the applicable Merger Consideration as contemplated by <B>&lrm;</B>Section 2.05.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>At any time following 12 months after the Effective Time, Parent shall be entitled to require the Paying Agent to deliver
to it any funds (with respect to the aggregate Merger Consideration to which holders of Shares shall become entitled pursuant
to <B>&lrm;</B>Section 2.05) which had been made available to the Paying Agent and not disbursed to holders of Certificates or
Book-Entry Shares (including all interest and other income received by the Paying Agent in respect of all funds made available
to it), and, thereafter, such holders shall be entitled to look to the Surviving Corporation (subject to abandoned property, escheat
and other similar Legal Requirements) only as general creditors thereof with respect to the Merger Consideration that may be payable
upon due surrender of the Certificates or Book-Entry Shares held by them, without any interest thereon. Notwithstanding the foregoing,
neither the Surviving Corporation nor the Paying Agent shall be liable to any holder of Certificates or Book-Entry Shares for
the Merger Consideration delivered in respect of such share to a public official pursuant to any abandoned property, escheat or
other similar Legal Requirements. Any amounts remaining unclaimed by such holders at such time at which such amounts would otherwise
escheat to or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">become property
of any Governmental Body shall become, to the extent permitted by applicable Legal Requirements, the property of the Surviving
Corporation or its designee, free and clear of all claims or interest of any Person previously entitled thereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>At the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the
Shares shall be closed and thereafter there shall be no further registration of transfers of Shares on the records of the Company.
From and after the Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time shall cease to
have any rights with respect to such Shares except as otherwise provided herein or by applicable Legal Requirements. If, after
the Effective Time, Certificates or Book-Entry Shares are presented to the Surviving Corporation for any reason, they shall be
cancelled and exchanged as provided in this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each of the Company, the Surviving Corporation, Parent and Purchaser, and their Affiliates, the Paying Agent or the Depository
Agent, as the case may be, shall be entitled to deduct and withhold, or cause to be deducted and withheld, from any amounts otherwise
payable pursuant to this Agreement, such amounts as are required to be deducted and withheld under any Legal Requirement with
respect to Taxes. Any amounts so deducted and withheld and paid over to the applicable Governmental Body in accordance with applicable
Legal Requirements shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such
deduction or withholding was made.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the holder
of the Shares formerly represented by that Certificate, or by a representative of that holder, claiming that Certificate to be
lost, stolen or destroyed and, if required by the Surviving Corporation, the posting by that holder of a bond, in such reasonable
amount as Parent may direct, as indemnity against any claim that may be made against it with respect to such Certificate (which
shall not exceed the Merger Consideration payable with respect to such Certificate), the Paying Agent will pay (less any amounts
entitled to be deducted or withheld pursuant to <B>&lrm;</B>Section 2.06(e)), in exchange for such lost, stolen or destroyed Certificate,
the applicable Merger Consideration to be paid in respect of the Shares formerly represented by such Certificate, as contemplated
by this <B>&lrm;</B>Article 2.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.07.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Dissenters&rsquo; Rights</I>. Notwithstanding anything in this Agreement to the contrary, Shares outstanding immediately
prior to the Effective Time, and held by holders who are entitled to appraisal rights under Section 262 of the DGCL and have properly
exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in Section 262 of
the DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment
under the DGCL (the &ldquo;<U>Dissenting Shares</U>&rdquo;), shall not be converted into the right to receive Merger Consideration,
but shall, by virtue of the Merger, be automatically cancelled and no longer outstanding, shall cease to exist and shall be entitled
to only such consideration as shall be determined pursuant to Section 262 of the DGCL; <I>provided </I>that if any such holder
shall have failed to perfect or shall have effectively withdrawn or lost such holder&rsquo;s right to appraisal and payment under
the DGCL, such holder&rsquo;s Shares shall be deemed to have been converted as of the Effective Time into the right to receive
the Merger Consideration (less any amounts entitled to be deducted or withheld pursuant to <B>&lrm;</B>Section 2.06(e)), and such
Shares shall not be deemed to be Dissenting Shares. The Company shall give prompt notice to Parent and Purchaser of any demands
received by the Company for appraisal of any Dissenting Shares, withdrawals of such demands and any other instruments served pursuant
to Section 262 of the DGCL, in each case prior to the Effective Time. Parent and Purchaser shall have the right to direct and
participate in all negotiations and proceedings with respect to such demands, and the</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Company shall
not, without the prior written consent of Parent and Purchaser, settle or offer to settle, or make any payment with respect to,
any such demands, approve any withdrawal of any such demands or agree or commit to do any of the foregoing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.08.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Treatment of Equity Awards</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested (including any
Company Option subject to performance-based vesting conditions) and which has a per share exercise price that is less than the
Merger Consideration, shall be cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A)
the Merger Consideration over (B) the exercise price payable per Share under such Company Option, multiplied by (ii) the total
number of Shares subject to such Company Option immediately prior to the Effective Time. For the avoidance of doubt, at the Effective
Time, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price
that is equal to or greater than the Merger Consideration, shall be cancelled without additional consideration.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>At the Effective Time, each Company RSU that is then outstanding, whether or not vested, shall be cancelled and converted
into the right to receive a cash payment equal to (i) the Merger Consideration multiplied by (ii) the total number of Shares subject
to such Company RSU immediately prior to the Effective Time. </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As soon as reasonably practicable after the Effective Time (but in no event later than the second payroll date following
the Effective Time), Parent shall cause the Surviving Corporation to, and the Surviving Corporation shall, pay the consideration
payable pursuant to Section 2.08(a) and Section 2.08(b), net of any applicable withholding Taxes, to the holders of Company Options
and Company RSUs through, to the extent applicable, the Surviving Corporation&rsquo;s payroll.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.65in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Prior to the Offer Acceptance Time, the Company shall take all actions that are necessary (under the Company Equity Plans
and award agreements pursuant to which Company Options and Company RSUs are outstanding or otherwise) to effect the transactions
described in this <B>&lrm;</B>Section 2.08.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 2.09.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Further Action</I>. The Parties agree to take all necessary action to cause the Merger to become effective in accordance
with this <B>&lrm;</B>Article 2 as soon as practicable following the consummation of the Offer without a meeting of the Company&rsquo;s
stockholders, as provided in Section 251(h) of the DGCL. If, at any time after the Effective Time, any further action is reasonably
determined by Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation
with full right, title and possession of and to all rights and property of Purchaser and the Company, the officers and directors
of the Surviving Corporation and Parent shall be fully authorized (in the name of Purchaser, in the name of the Company and otherwise)
to take such action.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
3<BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The Company
hereby represents and warrants to Parent and Purchaser as follows (it being understood that each representation and warranty contained
in this <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article 3 is subject to (a) exceptions and disclosures
set forth in the section or subsection of the Company Disclosure Schedule corresponding to the particular Section or subsection
in this <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Article 3; (b) any exception or disclosure set forth
in any other section or subsection of the Company Disclosure Schedule to the extent it is reasonably apparent on the face of such
disclosure that such exception or disclosure is applicable to qualify such representation and warranty; and (c) disclosure in
the Company SEC Documents, and publicly available prior to the date of this Agreement (other than any general cautionary or forward-looking
statements contained in the &ldquo;Risk Factors&rdquo; or &ldquo;Forward-Looking Statements&rdquo; sections of such Company SEC
Documents); <I>provided </I>that this clause <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(c) shall not
be applicable to <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.03 and <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section
3.04):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Due Organization</I>. The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware, and the Company&rsquo;s only Subsidiaries are set forth in Exhibit 21.1 to the Company&rsquo;s Annual
Report on Form 10-K for the fiscal year ended December 31, 2019. Each Subsidiary of the Company is duly organized, validly existing
and in good standing (with respect to jurisdictions that recognize such concept) under the laws of its jurisdiction of organization.
Each Acquired Company has all necessary power and authority: (i) to conduct its business in the manner in which its business is
currently being conducted and (ii) to own and use its assets in the manner in which its assets are currently owned and used, in
each case, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. Each Acquired Company is qualified or licensed to do business as a foreign corporation or other entity, and is in good
standing (with respect to jurisdictions that recognize such concept), in each jurisdiction where the nature of its business requires
such qualification or licensing, except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Organizational Documents</I>. The Company has delivered or made available to Parent copies of the certificate of incorporation,
bylaws and other organizational documents of the Company and each of its Subsidiaries, including all amendments thereto, as in
effect on the date hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Capitalization, Etc</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
The authorized capital stock of the Company consists of: (i)
275,000,000 Shares, of which 231,156,742 Shares had been issued and were outstanding as of the close of business on September 9,
2020 (the &ldquo;<U>Capitalization Date</U>&rdquo;), and (ii) 10,000,000 shares of Company Preferred Stock, of which no shares are
outstanding. From the Capitalization Date to the execution of this Agreement, the Company has not issued any Shares except pursuant
to the exercise of Company Options or the settlement of Company RSUs, in each case outstanding as of the Capitalization Date in
accordance with their terms and, from the Capitalization Date to the execution of this Agreement, the Company has not issued any
Company Options, Company RSUs or other equity or equity-based awards, in each case, other than pursuant to any offer of employment
or Contract, in either case dated on or prior to the Capitalization Date. All of the outstanding equity interests of the Acquired
Companies have been duly authorized and validly issued, and are fully paid and nonassessable.</FONT></P>

<P STYLE="margin: 0pt 0; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;The
Company owns all of the authorized and outstanding capital stock and other equity interests of each of the Company&rsquo;s Subsidiaries,
except as set forth on <B>&lrm;</B>Section 3.03(b) of the Company Disclosure Schedule. The outstanding capital stock and other
equity interests of the Company&rsquo;s Subsidiaries owned by the Company are owned free and clear of all Encumbrances and transfer
restrictions, except for Encumbrances or transfer restrictions of general applicability as may be provided under the Securities
Act or applicable securities laws. Except as set forth on <B>&lrm;</B>Section 3.03(b) of the Company Disclosure Schedule, the
Company does not own, directly or indirectly, any capital stock or other equity interests in, or subscriptions, options, calls,
warrants or rights (whether or not currently exercisable) to acquire, or other securities convertible into or exchangeable or
exercisable for, any capital stock or other equity interests of any Entity.</FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.65in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(i) None of the outstanding equity interests of any Acquired Company are entitled or subject to any preemptive right, right
of repurchase or forfeiture, right of participation, right of maintenance or any similar right; (ii) there are no outstanding
bonds, debentures, notes or other indebtedness of any Acquired Company having a right to vote on any matters on which the holders
of the outstanding equity interests of such Acquired Company have a right to vote; and (iii) there is no Contract to which any
Acquired Company is bound relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging
or otherwise disposing of (or from granting any option or similar right with respect to), any equity interests of such Acquired
Company. The Shares constitute the only outstanding class of securities of the Company registered under the Securities Act. No
Subsidiary of the Company owns any Shares.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
As of the close of business on the Capitalization Date: (i) 7,398,865
Shares were subject to issuance pursuant to Company Options granted and outstanding under the Company Equity Plans, (ii) 126,026
Shares were subject to issuance pursuant to Company RSUs granted and outstanding under the Company Equity Plans, (iii) 10,454,510
Shares were reserved for future issuance under the Company Equity Plans and (iv) 500,000 Shares were reserved for future issuance
under the Company ESPP.</FONT></P>

<P STYLE="margin: 0pt 0; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as set forth in this <B>&lrm;</B>Section 3.03 and except for the Company Options and Company RSUs outstanding as
of the date of this Agreement (and Shares issuable upon the exercise or settlement thereof), there are no: (i) outstanding shares
of capital stock or other securities of any Acquired Company; (ii) outstanding subscriptions, options, calls, warrants or rights
(whether or not currently exercisable) to acquire any shares of the capital stock, restricted stock unit, stock-based performance
unit or any other right that is linked to, or the value of which is in any way based on or derived from the value of any shares
of capital stock or other securities of any Acquired Company, in each case other than derivative securities not issued by any
Acquired Company; (iii) outstanding securities, instruments, bonds, debentures, notes or obligations that are or may become convertible
into or exchangeable for any shares of the capital stock or other securities of any Acquired Company; (iv) stockholder rights
plans (or similar plans commonly referred to as a &ldquo;poison pill&rdquo;) or Contracts under which any Acquired Company is
or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (v) voting trusts
or other Contract to which any Acquired Company is a party with respect to the voting of capital stock of any Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT> <B>&lrm;</B>Section 3.03(f) of the Company Disclosure Schedule sets forth a listing of all Persons who hold outstanding
Company Options or Company RSUs as of the close of business on the Capitalization Date, indicating, with respect to each Company
Option and Company RSU, the number of Shares subject thereto, the date of grant, the Company Equity Plan pursuant to</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">which the award
was granted, the vesting schedule and, for Company Options, the per Share exercise price and expiration date. Other than Shares
reserved for future issuance under the Company ESPP or as set forth in
this <B>&lrm;</B>Section 3.03(f), as of the Capitalization Date, there is no issued, reserved for issuance, outstanding or authorized
stock option, stock appreciation, phantom stock, profit participation or similar equity or equity-based awards with respect to
any Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.04.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Authority; Binding Nature of Agreement</I>. The Company has the corporate power and authority to execute and deliver
and to perform its obligations under this Agreement and to consummate the Transactions. The Board of Directors has (a) determined
that this Agreement and the Transactions, including the Offer and the Merger, are fair to, and in the best interest of, the Company
and its stockholders, (b) declared it advisable to enter into this Agreement, (c) approved the execution, delivery and performance
by the Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (d) resolved that
the Merger shall be effected under Section 251(h) of the DGCL and (e) resolved to recommend that the stockholders of the Company
accept the Offer and tender their Shares to Purchaser pursuant to the Offer, which resolutions, subject to <B>&lrm;</B>Section
6.01, have not been subsequently withdrawn or modified in a manner adverse to Parent as of the date of this Agreement. This Agreement
has been duly executed and delivered by the Company, and assuming due authorization, execution and delivery by Parent and Purchaser,
this Agreement constitutes the legal, valid and binding obligation of the Company and is enforceable against the Company in accordance
with its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and other similar laws of general applicability relating to or affecting creditors&rsquo; rights, and by general equitable principles.
If the Merger is consummated in accordance with Section 251(h) of the DGCL as contemplated hereby, no vote of the Company&rsquo;s
stockholders or any holder of Shares is necessary to authorize or adopt this Agreement or to consummate the Transactions, assuming
the accuracy of the representations set forth in <B>&lrm;</B>Section 4.08.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.05.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>SEC Filings; Financial Statements</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, the Company has filed or furnished on a timely basis all reports, schedules, forms, statements and
other documents (including exhibits and all other information incorporated therein) required to be filed or furnished by the Company
with the SEC (as supplemented, modified or amended since the time of filing, the &ldquo;<U>Company SEC Documents</U>&rdquo;).
As of their respective dates, or, if amended prior to the date of this Agreement, as of the date of (and giving effect to) the
last such amendment (and, in the case of registration statements and proxy statements, on the date of effectiveness and the dates
of the relevant meetings, respectively), the Company SEC Documents complied in all material respects with the requirements of
the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2001, as amended (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;),
as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to those Company SEC Documents,
and, except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded
(prior to the date of this Agreement) by a later filed Company SEC Document, none of the Company SEC Documents when filed or furnished
contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
The financial statements (including any related notes and schedules)
contained or incorporated by reference in the Company SEC Documents: (i)&nbsp;complied as to form in all material respects with
the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with United States generally
accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;)</FONT></P>

<P STYLE="margin: 0pt 0; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in"><FONT STYLE="font-size: 10pt">applied
on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or,
in the case of unaudited interim financial statements, as may be permitted by the SEC on Form 10-Q, 8-K or any successor form
under the Exchange Act); and (iii)&nbsp;fairly presented, in all material respects, the financial position of the Acquired Companies
as of the respective dates thereof and the results of operations and cash flows of the Acquired Companies for the periods covered
thereby (subject, in the case of the unaudited financial statements, to the absence of notes and to normal and recurring year-end
adjustments that are not, individually or in the aggregate, material).</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Company maintains a system of &ldquo;internal control over financial reporting&rdquo; (as defined in Rule 13a-15 under
the Exchange Act), which is designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures
that: (i)&nbsp;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions
and dispositions of the assets of the Acquired Companies; (ii)&nbsp;provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and that receipts and expenditures are being
made only in accordance with authorizations of management and the Board of Directors; and (iii)&nbsp;provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of the Acquired Companies
that could have a material effect on its financial statements. The Company&rsquo;s management has completed an assessment of the
effectiveness of the Company&rsquo;s system of internal control over financial reporting in compliance with the requirements of
Section 404 of the Sarbanes-Oxley Act for the fiscal year ended December 31, 2019, and, except as set forth in the Company SEC
Documents filed prior to the date of this Agreement, that assessment concluded that those controls were effective. To the knowledge
of the Company, since January 1, 2020, neither the Company nor the Company&rsquo;s independent registered accountant has identified
or been made aware of: (1)&nbsp;any significant deficiency or material weakness in the design or operation of the internal control
over financial reporting utilized by the Company, which is reasonably likely to adversely affect the Company&rsquo;s ability to
record, process, summarize and report financial information; or (2)&nbsp;any fraud, whether or not material, that involves the
management or other employees of the Company who have a significant role in the Company&rsquo;s internal control over financial
reporting.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Company maintains disclosure controls and procedures as defined in and required by Rule 13a-15 or 15d-15 under the
Exchange Act that are reasonably designed to ensure that all information required to be disclosed in the Company&rsquo;s reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the SEC and that all such information is accumulated and communicated to the Company&rsquo;s management
as appropriate to allow timely decisions regarding required disclosure and to enable the principal executive officer of the Company
and the principal financial officer of the Company to make the certifications required under the Exchange Act with respect to
such reports. The Company is in compliance in all material respects with all current listing and corporate governance requirements
of NASDAQ.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No Acquired Company is a party to, nor does it have any obligation or other commitment to become a party to, &ldquo;off-balance
sheet arrangements&rdquo; (as defined in Item 303(a) of Regulation S-K under the Exchange Act) where the result, purpose or intended
effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Acquired
Companies in the Company SEC Documents.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the
SEC with respect to the Company SEC Documents. To the knowledge of the Company, none of the Company SEC Documents is the subject
of ongoing SEC review and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened
in writing, in each case regarding any accounting practices of the Company, except as has not had, and would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each document required to be filed by the Company with the SEC in connection with the Offer, including the Schedule 14D-9
(the &ldquo;<U>Company Disclosure Documents</U>&rdquo;), and any amendments or supplements thereto, when filed, distributed or
otherwise disseminated to the Company&rsquo;s stockholders, as applicable, will comply as to form in all material respects with
the applicable requirements of the Exchange Act. The Company Disclosure Documents, at the time of the filing of such Company Disclosure
Documents or any supplement or amendment thereto with the SEC and at the time such Company Disclosure Documents or any supplements
or amendments thereto are first distributed or otherwise disseminated to the Company&rsquo;s stockholders, will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to
make the statements made therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The information with respect to the Acquired Companies that the Company furnishes to Parent or Purchaser specifically for
use in the Offer Documents, at the time of the filing of, at any time such document is amended or supplemented and at the time
of any distribution or dissemination of the Offer Documents, will not contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of
the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Notwithstanding the foregoing, the Company makes no representation with respect to statements made or incorporated by reference
therein based on information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by reference in the
Company Disclosure Documents.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.06.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Absence of Changes; No Material Adverse Effect</I>. Except as expressly contemplated by this Agreement, from December
31, 2019, through the date of this Agreement:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(i) &nbsp;each Acquired Company has operated in all material respects in the ordinary course of business consistent with
past practice, and (1) no Acquired Company has taken any action or failed to take any action that would have constituted a breach
of Sections <B>&lrm;</B>5.02(b)(i), <B>&lrm;</B>5.02(b)(ii), <B>&lrm;</B>5.02(b)(vi), <B>&lrm;</B>5.02(b)(viii), <B>&lrm;</B>5.02(b)(x),
<B>&lrm;</B>5.02(b)(xiii), <B>&lrm;</B>5.02(b)(xv), <B>&lrm;</B>5.02(b)(xvi), <B>&lrm;</B>5.02(b)(xvii), <B>&lrm;</B>5.02(b)(xviii)
or <B>&lrm;</B>5.02(b)(xix) had such action been taken after the execution of this Agreement without the prior consent of Parent;
and</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.65in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>there has not occurred any change, circumstance, condition, development, effect, event, occurrence or state of facts that,
individually or in the aggregate, has had or would reasonably be expected to have, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.07.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Title to Assets</I>. The Acquired Companies have good and valid title to all assets (excluding Intellectual Property
Rights) owned by the Acquired Companies as of the date of this Agreement, and all of such assets are owned by the Acquired Companies
free and clear of any Encumbrances (other than Permitted Encumbrances), in each case, except as has not had, and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.08.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Real Property</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No Acquired Company owns any real property.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each Acquired Company holds valid and existing leasehold interests in the real property that is leased or subleased by
such Acquired Company from another Person (the &ldquo;<U>Leased Real Property</U>&rdquo;), free and clear of all Encumbrances
other than Permitted Encumbrances, in each case, except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect. Since January 1, 2019, no Acquired Company has received any notice regarding (i)
any material violation or breach or default under any lease related to the Leased Real Property that has not since been cured,
(ii) any material pending or threatened in writing condemnation of any portion of the Leased Real Property or (iii) building,
fire or zoning code violations with respect to the Leased Real Property, in each case in this clause <B>&lrm;</B>(iii) that is
material to the Acquired Companies.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.09.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Intellectual Property</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>&lrm;</B>Section 3.09(a) of the Company Disclosure Schedule sets forth a list of all Registered IP (including issued
Patents and Patent applications, Trademark registrations and applications, and Copyright registrations and applications), which
constitutes Owned Registered IP. All such Registered IP is, to the knowledge of the Company, (i)&nbsp;subsisting, (ii)&nbsp;other
than any pending applications therefor, not invalid or unenforceable, and (iii)&nbsp;is not subject to any outstanding order,
judgment or decree adversely affecting any Acquired Company&rsquo;s use thereof or rights thereto. The Acquired Companies are
the sole and exclusive beneficial owners (and in the case of Registered IP, record owners) of all Company IP.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
No interference, opposition, reissue, reexamination proceeding, cancellation proceeding, investigation or other Legal Proceeding
(other than routine examination proceedings with respect to pending applications) is pending, or threatened in writing against,
any Acquired Company in which the claim construction, validity, enforceability, priority, inventorship or ownership of any Owned
Registered IP or, to the knowledge of the Company, Licensed Registered IP is being or has been contested or challenged.</FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.65in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Acquired Companies own and possess all right, title and interest
in and to or have the valid right to use all Company IP, free and clear of all Encumbrances other than Permitted Encumbrances.
No Acquired Company has granted any Encumbrance on any Company Licensed IP other than any Permitted Encumbrance.</P>

<P STYLE="margin: 0pt 0; font: 11pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Acquired Companies have used commercially reasonable efforts to maintain the confidentiality of material Trade Secrets
owned, purported to be owned, or used by any Acquired Company, including requiring all Persons to whom such material Trade Secrets
have been disclosed by any Acquired Company to execute written non-disclosure agreements, other than disclosures made in the ordinary
course of business consistent with past practice, such as in connection with an industry publication or presentation approved
by an Acquired Company, or as embodied in a new Patent application filed by an Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><B>&lrm;</B>Section 3.09(e)(i) of the Company Disclosure Schedule sets forth each In-bound License and <B>&lrm;</B>Section
3.09(e)(ii) of the Company Disclosure Schedule sets forth each Out-bound License.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
(i) To the knowledge of the Company, the operation of the Acquired Companies&rsquo; respective businesses as currently
conducted since January 1, 2019 through the date of this Agreement and as contemplated to be conducted does not and will not
infringe, misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any Intellectual
Property Rights owned by any other Person, except as has not been, and would not reasonably be expected to be, individually
or in the aggregate, material to the operation of the business of the Acquired Companies, and (ii) since January 1, 2019
through the date of this Agreement, there has been no Legal Proceeding pending or threatened in any written notice or other
written communication directed to any Acquired Company (or to the knowledge of the Company, to any other Person) relating to
any allegations of the foregoing against any Acquired Company, including any such allegations (including in the form of an
invitation to enter into a license) against any Acquired Company.</FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 0.65in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
Since January 1, 2019 through the date of this Agreement, to
the knowledge of the Company, (i) no Person is infringing, misappropriating or otherwise violating, or has infringed, misappropriated
or otherwise violated, any Company IP or Company Licensed IP, except as has not been, and would not reasonably be expected to be,
individually or in the aggregate, material to the operation of the business of the Acquired Companies, and (ii) there has been
no Legal Proceeding pending or threatened in writing relating to any allegations of the foregoing made by any Acquired Company
or any of its licensors, as applicable, including any such allegations against any Person by any Acquired Company or such licensors
(or to the knowledge of the Company, by any other Person).</P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
None of the Company IP is subject to any outstanding injunction, order, decree, charge, consent, judgment, covenant not to sue,
settlement, ruling or other disposition of dispute, in each case, that adversely restricts the use, transfer, registration or
licensing of any such Company IP by any Acquired Company, or otherwise adversely affects the ownership, validity, scope, use,
registrability, or enforceability of any such Company IP. None of the Acquired Companies or, to the knowledge of the Company,
any of their respective licensors have received any written notice that any Company Licensed IP is subject to any outstanding
injunction, order, decree, charge, consent, judgment, settlement, ruling or other disposition of dispute, in each case, that adversely
restricts the use, transfer, registration or licensing of any such Company Licensed IP by any Acquired Company, or otherwise adversely
affects the ownership, validity, scope, use, registrability or enforceability of any such Company Licensed IP.</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 2pt 0pt 0; text-indent: 33.95pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each current and former employee, officer and direct independent contractor of any Acquired Company who is or was involved
in the creation or development of any material Company IP has signed a valid and enforceable agreement containing a present assignment
of such Intellectual Property Rights to the Acquired Companies and confidentiality provisions protecting such Intellectual Property
Rights, and, to the Company&rsquo;s knowledge, there is no material breach under any such agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No material Company IP was developed with any funding, facilities, personnel, or other material support or resources from
any Governmental Body, any foundation, nonprofit, charity, non-governmental organization, or any public or private university,
college, or other educational institution or research center, in a manner that would give any of such entities an ownership interest
in any material Company IP. None of the Acquired Companies or, to the knowledge of the Company, any of their respective licensors
has failed to comply with any invention disclosure, election of title or patent reporting requirements with respect to any material
Company IP or material Company Licensed IP developed with funding, facilities, personnel or other material support or resources
from any Governmental Body.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 3pt 0pt 0; text-indent: 36.4pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect, (i)&nbsp;the Company IT Assets operate in accordance with their specifications and related documentation and perform in
a manner that permits the Acquired Companies to conduct their respective business as currently conducted, (ii)&nbsp;the Acquired
Companies have taken commercially reasonable actions, consistent with current industry standards, to protect the confidentiality,
integrity and security of the Company IT Assets</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">(and all data
and other information and transactions stored or contained therein or processed or transmitted thereby) against any unauthorized
use, access, interruption, modification or corruption, including the implementation of commercially reasonable data backup, disaster
avoidance and recovery procedures and business continuity procedures, and (iii)&nbsp;since January 1, 2019, there has been no
unauthorized use, access or security breaches, or interruption, modification, loss or corruption of any of the Company IT Assets
(or any data or other information or transactions stored or contained therein or processed or transmitted thereby).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each Acquired Company is in compliance with applicable Legal Requirements, as well as its own policies and contractual
obligations, relating to privacy, data protection, and the collection and use of personally identifiable information collected,
used, or held for use by the Acquired Companies, except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect, and, as of the date of this Agreement, no Legal Proceedings or claims are pending
or threatened in writing against any Acquired Company alleging a violation of any Person&rsquo;s privacy with respect to personally
identifiable information.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The consummation of the Transactions will not result in the loss or impairment of or payment of any additional amounts
with respect to, nor require the consent of any other Person in respect of, any Acquired Company&rsquo;s right to own or use any
of the material Company IP owned by any Acquired Company or, to the knowledge of Company, use any of material Intellectual Property
Rights licensed to any Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Contracts</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
Section 3.10(a) of the Company Disclosure Schedule identifies each Contract to which any Acquired Company is a party, or by which
it is bound, that constitutes a Material Contract as of the date of this Agreement and identifies, with respect to each Material
Contract, the clause of Section 3.10(a) to which it applies. For purposes of this Agreement, each of the following to which any
Acquired Company is a party or by which it is bound as of the date of this Agreement (other than nondisclosure agreements entered
into (x) in the ordinary course of business consistent with past practice or (y) in connection with discussions, negotiations
and transactions related to this Agreement or other potential strategic transactions) constitutes a &ldquo;<U>Material Contract</U>&rdquo;:</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract that is a settlement, conciliation or similar agreement with or approved by any Governmental Body and pursuant
to which (A) any Acquired Company will be required after the date of this Agreement to pay any monetary obligations or (B) that
contains material obligations or limitations on any Acquired Company&rsquo;s conduct;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract (A) materially limiting the freedom or right of any Acquired Company to engage in any line of business or
to compete with any other Person in any location or line of business, (B) containing any &ldquo;most favored nations&rdquo; terms
and conditions (including with respect to pricing) granted by any Acquired Company, or (C) containing exclusivity obligations
or otherwise materially limiting the freedom or right of any Acquired Company to sell, distribute or manufacture any products
or services for any other Person;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract that requires by its terms or is reasonably expected to require the payment or delivery of cash or other consideration
to any Acquired Company</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">in
an amount having a value in excess of $4,000,000 in the fiscal year ending December 31, 2019, or by any Acquired Company in an
amount having a value in excess of $4,000,000 in the fiscal year ending December 31, 2019, and in each case (A) that cannot be
cancelled by such Acquired Company without penalty or further payment without more than sixty (60) days&rsquo; notice and (B)
excluding commercially available off-the-shelf software licenses and Software-as-a-Service offerings, generally available patent
license agreements, material transfer agreements, clinical trial agreements and non-exclusive outbound license agreements (in
each case, entered into in the ordinary course of business);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
material distribution, wholesale, third-party logistics, pharmacy benefit manager or payer Contract;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 26pt 0pt 0.5in; text-align: justify; text-indent: 38.1pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract relating to Indebtedness in excess of $500,000 (whether incurred, assumed, guaranteed or secured by any asset)
of any Acquired Company;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract with any Person constituting a material joint venture, collaboration, partnership or similar profit sharing
arrangement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract that by its express terms requires any Acquired Company, or any successor to, or acquirer of, any Acquired
Company, to make any payment to another Person as a result of a change of control of any Acquired Company (a &ldquo;<U>Change
of Control Payment</U>&rdquo;) or gives another Person a right to receive or elect to receive a Change of Control Payment;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract that prohibits the declaration or payment of dividends or distributions in respect of the capital stock of
any Acquired Company, the pledging of the capital stock or other equity interest of any Acquired Company or the issuance of any
guaranty by any Acquired Company;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any (A) In-bound License and (B) Out-bound License;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract pursuant to which any Acquired Company has continuing obligations or interests involving (A) &ldquo;milestone&rdquo;
or other similar contingent payments, including upon the achievement of regulatory or commercial milestones which would result
in a payment in excess of $2,000,000, or (B) payment of royalties or other amounts calculated based upon any revenues or income
of any Acquired Company, in each case that cannot be terminated by such Acquired Company without penalty without more than sixty
(60) days&rsquo; notice;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>each Contract for the acquisition or divestiture of a business or of material assets that contains continuing representations,
covenants, indemnities or other obligations (including &ldquo;earn out&rdquo; or other contingent payment obligations), but excluding
any material transfer agreements, clinical trial agreements and non-exclusive licenses, in each case, that were entered into in
the ordinary course of business;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract that relates to any swap, forward, futures, or other similar derivative transaction with a notional value
in excess of $500,000;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract between any Acquired Company and any Governmental Body;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract for material Leased Real Property;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any other Contract that is currently in effect and has been filed (or is required to be filed) by the Company as an exhibit
pursuant to Item 601(b)(10) of Regulation S-K under the Securities Act or that would be required to be disclosed under Item 404
of Regulation S-K under the Securities Act; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>any Contract (A) with any Affiliate, director, executive officer (as such term is defined in the Exchange Act), Person
holding 5% or more of the Shares, or, to the knowledge of the Company, any Affiliate (other than the Company) or immediate family
member of any of the foregoing or (B) in which any of the foregoing Persons has a direct or indirect material financial interest.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Company has either delivered or made available to Parent an accurate and complete copy of each Material Contract or
has publicly filed each Material Contract in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC.
Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect,
(i)&nbsp;no Acquired Company nor, to the knowledge of the Company, any other party is in material breach of, or material default
under, any Material Contract and no Acquired Company nor to the knowledge of the Company, any other party to a Material Contract
has taken or failed to take any action that with or without notice, lapse of time or both would constitute a material breach of
or material default under any Material Contract; (ii)&nbsp;each Material Contract is, with respect to the Acquired Companies party
thereto and, to the knowledge of the Company, each other party thereto, a valid and binding agreement in full force and effect,
enforceable in accordance with its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&rsquo; rights, and
by general equitable principles; and (iii)&nbsp;since January 1, 2019 through the date of this Agreement, no Acquired Company
has received or delivered any notice regarding any violation or breach or default under any Material Contract that has
not since been cured.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Liabilities</I>. The Acquired Companies do not have any liabilities of any nature (whether accrued, absolute, contingent
or otherwise), which would be required to be reflected or reserved against on a consolidated balance sheet of the Company prepared
in accordance with GAAP or the notes thereto, except for: (a) liabilities reflected or reserved against in the financial statements
or notes thereto included in the Company SEC Documents filed prior to the date of this Agreement; (b) liabilities or obligations
incurred pursuant to the terms of this Agreement; (c) liabilities for performance of obligations under Contracts binding upon
the Acquired Companies (other than resulting from any breach or acceleration thereof); (d) liabilities incurred in the ordinary
course of business consistent with past practice since December 31, 2019 (it being understood that breaches of Legal Requirements
shall not be deemed to be liabilities incurred in the ordinary course of business consistent with past practice); and (e) liabilities
that have not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Compliance with Legal Requirements</I>. Each Acquired Company is, and since January 1, 2019 has been, in compliance
with all applicable Legal Requirements, except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect. Since January 1, 2019 through the date of this Agreement, no Acquired Company has been
given written notice of, or been charged with, any violation of, any applicable Legal Requirement, except as has not had, and
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Regulatory Matters</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, each Acquired Company has filed, maintained or furnished with the applicable regulatory authorities
(including the FDA, European Medicines Agency (&ldquo;<U>EMA</U>&rdquo;) or any other Governmental Body performing functions similar
to those performed by the FDA, EMA or otherwise having jurisdiction over the pricing, reimbursement, safety, efficacy, approval,
development, testing, labeling, manufacture, or storage of pharmaceutical products (such other Governmental Bodies, collectively,
the &ldquo;<U>Specified Governmental Bodies</U>&rdquo;)) all required material filings, declarations, listings, registrations,
reports, submissions, applications, amendments, modifications, notices and other documents, including but not limited to adverse
event reports. All such material filings, declarations, listings, registrations, reports, submissions, applications, amendments,
modifications, notices and other documents filed or submitted after January 1, 2019: (i) have been made available to Parent and
(ii) were in compliance with applicable Legal Requirements, including all applicable Health Care Laws in all material respects
when filed, and no material deficiencies have been asserted by any applicable Governmental Body with respect to any such filings,
declarations, listing, registrations, reports, submissions, applications, amendments, modifications, notices and other documents.
Since January 1, 2019, any updates, changes, corrections or modifications to such materials required under applicable Legal Requirements,
including all applicable Health Care Laws, have been submitted in compliance with such Legal Requirements in all material respects.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>All preclinical and clinical investigations sponsored or conducted by or on behalf of any Acquired Company or, to the knowledge
of the Company, by any Acquired Company&rsquo;s research, development, collaboration or similar partners with respect to any Product
Candidates of any Acquired Company while acting in such capacity (each such party a &ldquo;<U>Collaboration Partner</U>&rdquo;),
have been since January 1, 2019, and are being, conducted in material compliance with all applicable Legal Requirements, rules,
regulations and binding guidances, including Good Clinical Practices requirements, other Health Care Laws, applicable research
protocols and federal and state laws, rules, regulations and binding guidances relating to patient privacy requirements or restricting
the use and disclosure of individually identifiable health information. Since January 1, 2019, except as has not had, and would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, no clinical trial sponsored or
conducted by or on behalf of any Acquired Company or by any Collaboration Partner has been terminated, delayed or suspended prior
to completion for safety or other non-business reasons, and neither the FDA, the EMA nor any other Specified Governmental Body,
clinical investigator or contract research organization that has participated or is participating in, or institutional review
board that has or has had jurisdiction over, a clinical trial conducted or sponsored by or on behalf of any Acquired Company or
by any Collaboration Partner has commenced, or, to the knowledge of the Company, threatened in writing to initiate, any action
to place a clinical hold order on, or otherwise terminate, materially delay or suspend, any proposed or ongoing clinical trial
conducted or proposed to be conducted by or on behalf of any Acquired Company or by any Collaboration Partner, or alleged any
violation of any Health Care Law in connection with any such clinical trial. The Acquired Companies or an agent on their behalf
periodically reviews clinical trial sites participating in any Acquired Company-sponsored trial for compliance with all applicable
Health Care Laws.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, no Acquired Company nor, to the knowledge of the Company, any Company Associate, employee, agent,
clinical investigator or Collaboration Partner has (i) made an untrue statement of a material fact or fraudulent statement to
the FDA, EMA or any other Specified Governmental Body, (ii) failed to disclose a material fact required to be disclosed to the
FDA, EMA, Centers for Medicare and Medicaid Services or any other</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Specified Governmental
Body or (iii) committed any other act, made any statement or failed to make any statement, that (in any such case) establishes
a reasonable basis for the FDA to invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final
Policy or for the EMA or any other Specified Governmental Body to invoke any similar policy. No Acquired Company nor, to the knowledge
of the Company, any Collaboration Partner, is the subject of any pending or, to the knowledge of the Company, threatened in writing
investigation or other action by the FDA pursuant to its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities
Final Policy or by the EMA or any other Governmental Body in any similar investigation or other action. Since January 1, 2019,
no Acquired Company nor any Company Associate or clinical investigator of any Product Candidates or, to the knowledge of the Company,
any Collaboration Partner has been suspended, debarred or convicted of any crime or engaged in any conduct that would reasonably
be expected to result in (A) debarment under 21 U.S.C. Section 335a or any similar Legal Requirement or (B) exclusion under 42
U.S.C. Section 1320a-7 or any similar Legal Requirement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Product Candidates are being, and since January 1, 2019, have been, developed, tested, labeled, manufactured, and stored,
as applicable, in all material respects with all Health Care Laws. Since January 1, 2019, except as has not had, and would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect (i) each Acquired Company and, to
the knowledge of the Company, each Collaboration Partner, are not and have not been subject to any enforcement, regulatory or
administrative proceedings against or affecting any Acquired Company or any Product Candidate relating to or arising under any
Health Care Law or other applicable Legal Requirement, and no such enforcement, regulatory or administrative proceeding has been
threatened in writing, (ii) no Acquired Company nor, to the knowledge of the Company, any Collaboration Partner, has received
written notice of any pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or
other Legal Proceeding, and to the knowledge of the Company, there is not pending any allegation that any operation or activity
of any Acquired Company or any Collaboration Partner relating to any Acquired Company&rsquo;s business or any Product Candidate
is in violation of any Health Care Law or other applicable Legal Requirement and (iii) as of the date of this Agreement, no Acquired
Company has received any FDA Forms 483 or other Specified Governmental Body notices of violations, inspectional observations,
&ldquo;warning letters,&rdquo; &ldquo;untitled letters&rdquo; or other similar written administrative, regulatory or enforcement
notice.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect: (i) no investigational new drug application or similar document filed by or on behalf of any Acquired
Company with the FDA, EMA or any other Specified Governmental Body has, to the knowledge of the Company, been terminated or suspended,
and (ii) no Acquired Company nor, to the knowledge of the Company, any Collaboration Partner, has received any written notice
from a Governmental Body that any Product Candidate cannot be developed, tested, labeled, manufactured or stored, substantially
in the manner presently performed or contemplated by any Acquired Company or any Collaboration Partner.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect, each Acquired Company and, to the knowledge of the Company, its Collaboration Partners have prepared,
submitted and implemented timely responses and, as applicable, any corrective action plans required to be prepared and submitted
in response to all (i) internal or third-party audits, inspections, investigations or examinations of the Product Candidates and
each Acquired Company&rsquo;s business; (ii) adverse event reports relating to the Product Candidates; (iii) material</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">patient complaints
relating to the Product Candidates; (iv) medical incident reports relating to the Product Candidates; and (v) material corrective
and preventive actions relating to the Product Candidates and each Acquired Company&rsquo;s business.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, no Acquired Company has submitted any claim for payment to any government healthcare program in
connection with any referrals related to any Product Candidate, or engaged in any other conduct, that violated in any material
respect any applicable self-referral Legal Requirement, including the U.S. Federal Ethics in Patient Referrals Act, 42 U.S.C.
&sect; 1395nn (known as the Stark Law), any anti-kickback Legal Requirement, including the U.S. Federal Anti-Kickback Statute,
42 U.S.C. &sect; 1320a-7b, any false claims Legal Requirement, including the U.S. Federal False Claims Act, 31 U.S.C. &sect; 3729
<I>et seq.</I>, or any other applicable similar state or non-U.S. Legal Requirement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, each Acquired Company has operated its business in compliance in all material respects with all
applicable Legal Requirements, clinical trial protocols, and contractual or other requirements relating to medical records and
medical information privacy that regulate or limit the maintenance, use, disclosure or transmission of medical records, clinical
trial data, patient information or other personal information made available to or collected by the Acquired Companies in connection
with the operation of the Acquired Companies&rsquo; businesses, including the Standards for Privacy of Individually Identifiable
Health Information at 45 C.F.R. Parts 160 and 164 (subparts A and E), the Security Standards at 45 C.F.R. Parts 160 and 164 (subparts
A and C), the Standards for Electronic Transactions and Code Sets at 45 C.F.R. Parts 160 and 162 promulgated under the U.S. Health
Insurance Portability and Accountability Act of 1996, as amended by the U.S. Health Information Technology for Economic and Clinical
Health Act of 2009, including the regulations promulgated thereunder (collectively &ldquo;<U>HIPAA</U>&rdquo;), the U.S. Health
Information Technology for Economic and Clinical Health Act (Pub. L. No. 111-5) (&ldquo;<U>HITECH</U>&rdquo;) and HITECH implementing
regulations, Directive 95/46/EC and all comparable Legal Requirements relating to any of the foregoing (the &ldquo;<U>Health Care
Data Requirements</U>&rdquo;). Each Acquired Company has implemented in all material respects any confidentiality, security and
other measures required by the Health Care Data Requirements. Each Acquired Company is, and has at all times since January 1,
2019, been in compliance in all material respects with the applicable privacy and security requirements of HIPAA and HITECH in
conducting the Acquired Companies&rsquo; businesses. As of the date hereof, since January 1, 2019, no Acquired Company has suffered
any accidental, unauthorized, or unlawful destruction, loss, alteration, or disclosure of, or access to, personal data or suffered
a security breach in relation to any other data which it holds. As of the date hereof, since January 1, 2019, no material breach
has occurred with respect to any unsecured Protected Health Information, as that term is defined in 45 C.F.R. &sect;160.103, maintained
by or for any Acquired Company that is subject to the notification requirements of 45 C.F.R. Part 164, Subpart D, and, as of the
date hereof, no information security or privacy breach event has occurred that would require notification under any comparable
Legal Requirements.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Certain Business Practices</I>. No Acquired Company nor, to the knowledge of the Company, any of its Representatives
(in each case, acting in the capacity of a Representative, and for the benefit, of the Acquired Companies) has since January 1,
2019 (i) used any funds (whether of the Acquired Companies or otherwise) for contributions, gifts, entertainment or other expenses
relating to political activity in violation of applicable Legal Requirements, (ii) made any payment to foreign or domestic government
officials or employees or to foreign or domestic political parties or campaigns in violation of applicable Legal Requirements
or (iii) violated any provision of any Anti-Corruption Laws or any rules or regulations promulgated thereunder, anti-money laundering
laws or any rules or regulations promulgated thereunder or any other applicable Legal Requirement of similar effect, in each case</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">of <B>&lrm;</B>(i),
<B>&lrm;</B>(ii) and <B>&lrm;</B>(iii), except as has not had, and would not reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect. Since January 1, 2019 through the date of this Agreement, no Acquired Company has received
any written communication from a Governmental Body that alleges any of the foregoing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Governmental Authorizations</I>. The Governmental Authorizations held by the Acquired Companies are valid and in full
force and effect, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. Each Acquired Company is in compliance with the terms and requirements of such Governmental Authorizations, except
as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Tax Matters</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Except for
matters that, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each of the Tax Returns required to be filed by each Acquired Company with any Governmental Body (the &ldquo;<U>Company
Returns</U>&rdquo;) have been filed, and such Tax Returns (taking into account any amendments thereto) are complete and accurate.
All Taxes required to have been paid by each Acquired Company (whether or not shown on the Company Returns) have been paid to
the relevant Governmental Body.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each Acquired Company has complied with all applicable Legal Requirements relating to the payment, collection, withholding
and remittance of Taxes (including information reporting requirements) with respect to payments made to any employee, creditor,
stockholder, customer or other third party.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(i) There is no audit, examination or Legal Proceeding that is ongoing, pending or has been threatened in writing with
regard to any Company Return and (ii) no written claim has been received by any Acquired Company from any Governmental Body in
any jurisdiction where such Acquired Company does not file Tax Returns or pay Taxes that such Acquired Company is or may be required
to file a Tax Return or be subject to Tax in that jurisdiction. No tolling, extension or waiver of the statute of limitation period
applicable to any of the Company Returns has been granted and is currently in effect (other than pursuant to customary extensions
of the due date for filing a Tax Return).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No audit, examination or Legal Proceeding involving the IRS or any other Governmental Body is ongoing, pending or has been
threatened in writing against or with respect to any Acquired Company in respect of any Tax, and no deficiency of Taxes has been
asserted in writing as a result of any audit, examination or Legal Proceeding by any Governmental Body that has not been paid,
accrued for or been contested in good faith and in accordance with applicable Legal Requirements.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No Acquired Company (i) has ever been a member of an affiliated group (within the meaning of Section 1504(a) of the Code)
filing a consolidated federal income Tax Return (other than a group the common parent of which is or was the Company), and (ii)
has material liability for the Taxes of any other Person under Section 1.1502-6 of the Treasury Regulations (or any corresponding
or similar provision of any state, local or non-U.S. Tax law), or as a transferee or successor or otherwise (other than pursuant
to agreements not primarily related to Taxes and entered into in the ordinary course of business).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>During the two-year period ending on the date hereof, none of the Acquired Companies has been either a &ldquo;distributing
corporation&rdquo; or a &ldquo;controlled corporation&rdquo; in a distribution of stock intended to qualify for tax-free treatment
under Section 355 of the Code.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No Acquired Company has participated in any &ldquo;listed transaction&rdquo; within the meaning of Treasury Regulations
Section 1.6011-4(b)(2) in any tax year for which the statute of limitations has not expired.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No Acquired Company is a party to, bound by, or has any obligation under any Tax sharing, Tax allocation or Tax indemnity
agreement or similar Contract or arrangement relating to the apportionment, sharing, assignment, indemnification or allocation
of any Tax or Tax asset (other than customary gross-up or indemnification provisions in credit agreements, derivatives, leases,
employment agreements and similar agreements entered into in the ordinary course of business).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>There are no Encumbrances with respect to Taxes upon any of the assets or properties of any Acquired Company, other than
Permitted Encumbrances.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No representation or warranty is made with respect to the amount or availability of any Tax attribute (including a net
operating loss or Tax credit) for any taxable period or portion thereof beginning after the Closing Date.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Employee Matters; Benefit Plans</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as required by applicable Legal Requirements, the employment of each of the Acquired Companies&rsquo; employees
is terminable by the applicable Acquired Company at will, subject to any severance rights contained in any applicable Employee
Plan.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
No Acquired Company is a party to, or bound by, any collective
bargaining agreement or any other labor-related Contract, agreement, understanding or arrangement with any labor union or labor
organization representing any of its employees; and no employees of any Acquired Company are represented by any labor union or
labor organization with respect to their employment with any Acquired Company. Since January 1, 2019, there has not been any unfair
labor practice charge, material grievance, material arbitration, strike, lockout, or other union organizing activity or dispute,
or any threat thereof, by any employees of any Acquired Company with respect to their employment with the Acquired Companies.</P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019, each Acquired Company has been in material compliance with all applicable Legal Requirements related
to employment and employment practices, including all laws respecting terms and conditions of employment, health and safety, wages
and hours, employee and independent contractor classification, child labor, immigration, employment discrimination, disability
rights or benefits, equal opportunity, plant closures and layoffs, affirmative action, workers&rsquo; compensation, labor relations,
employee leave issues and unemployment insurance.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 21pt 0pt 0; text-indent: 33.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;Since
January 1, 2019, to the knowledge of the Company as of the date of this Agreement, no allegations of sexual harassment or misconduct
have been made against any officer or director of any Acquired Company.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 21pt 0pt 0; text-indent: 33.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 3pt 0pt 0; text-indent: 34.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of the Company as of the date of this Agreement, no current or former employee of any Acquired Company, at the level
of vice president or higher, is in violation in any material respect of any term of any employment agreement, nondisclosure agreement,
common law nondisclosure obligation, non-competition agreement or restrictive covenant obligation: (i) with or to any Acquired
Company or (ii) with or to a former employer of any such employee relating to the right of any such employee to be employed by
any Acquired Company or the knowledge or use of trade secrets in proprietary information.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 3pt 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>To the knowledge of the Company as of the date of this Agreement, no current employee of any Acquired Company, at the level
of vice president or higher, has expressed a current intention to terminate his or her employment with an Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Section 3.17(g) of the Company Disclosure Schedule sets forth a list of each material Employee Plan (other than any employment
or severance agreement for non-executive employees of any Acquired Company; equity grant notices, agreements and instruments that
do not materially deviate from the forms delivered or made available to Parent prior to the execution of this Agreement in accordance
with Section 3.17(m); and agreements with consultants entered into in the ordinary course of business consistent with past practice).
The Company has either delivered or made available to Parent prior to the execution of this Agreement with respect to each material
Employee Plan copies of: (i) all plan documents and all amendments thereto, and all related trust or other funding documents,
(ii) the most recent annual actuarial valuation, if any, and the most recent annual report (Form Series 5500 and all schedules
and financial statements attached thereto), (iii) all material correspondence to or from the IRS, the United States Department
of Labor or any other Governmental Body with respect to an Employee Plan and (iv) the most recent determination letter received
from the IRS with respect to the Employee Plan (if applicable).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>No Acquired Company nor any other Person that would be, or at any relevant time would have been, considered a single employer
with any Acquired Company under the Code or ERISA has during the past six years sponsored, maintained, contributed to, or been
required to contribute to a plan subject to Title IV of ERISA or Code Section 412, including any &ldquo;single employer&rdquo;
defined benefit plan or any &ldquo;multiemployer plan,&rdquo; each as defined in Section 4001 of ERISA.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1pt 0pt 0; text-indent: 33.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each of the Employee Plans that is intended to be qualified under Section 401(a) of the Code has obtained a favorable determination
letter (or opinion letter, if applicable) as to its qualified status under the Code, and, to the knowledge of the Company, there
are no existing circumstances or any events that have occurred that would reasonably be expected to affect materially and adversely
the qualified status of any such Employee Plan. Each of the Employee Plans has been operated in compliance with its terms and
all applicable Legal Requirements, including ERISA and the Code, except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect. To the knowledge of the Company, no Acquired Company is or
could reasonably be expected to be subject to a liability pursuant to Section 502 of ERISA or a Tax imposed pursuant to Section
4975 or 4976 of the Code, except as has not had, and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect. There are no pending, or, to the knowledge of the Company, threatened in writing or anticipated claims by,
on behalf of or with respect to any Employee Plan, by any employee or beneficiary covered under any such plan, or otherwise involving
any such plan (other than routine claims for benefits), except as has not had, and would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except to the extent required under Section 601 et seq. of ERISA or 4980B of the Code (or any other similar state or local
Legal Requirement), or where the full cost of such benefit is borne entirely by the applicable individual (or his or her eligible
dependents or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">beneficiaries),
no Acquired Company nor any Employee Plan has any present or future obligation to provide post-employment or post-service welfare
benefits to or make any payment to, or with respect to, any present or former employee, officer, director or individual independent
contractor of any Acquired Company, including pursuant to any retiree medical benefit plan or other retiree welfare plan.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as provided in Section 2.08, the consummation of the Transactions will not (either alone or in combination with
other events or circumstances) (i) entitle any current or former employee, director, officer, independent contractor or other
service provider of any Acquired Company to severance pay, unemployment compensation or any other payment, (ii) accelerate the
time of payment or vesting, or increase the amount of, compensation or benefits due to any such employee, director, officer, independent
contractor or (iii) directly or indirectly cause any Acquired Company to transfer or set aside any assets to fund any payments
or benefits under any Employee Plan.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The consummation of the Transactions will not (either alone or in combination with other events or circumstances) result
in any &ldquo;excess parachute payment&rdquo; within the meaning of Section 280G of the Code.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Company has delivered or made available to Parent copies of the Company Equity Plans and the standard forms of agreements
and instruments relating to or issued under the Company Equity Plans. Each outstanding Company Option has an exercise price equal
to or above the fair market value on the date of grant (within the meaning of Section 409A of the Code) and is otherwise not subject
to Section 409A of the Code.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each Employee Plan maintained for the benefit of any employee or service provider (or former employee or service provider)
who performs services outside the United States is now and has been operated in compliance with its terms and all applicable Legal
Requirements, except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.18.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Environmental Matters</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Each Acquired Company is and, since January 1, 2019, has been in compliance with all applicable Environmental Laws, which
compliance includes obtaining, maintaining and complying with all Governmental Authorizations required under Environmental Laws
for the operation of its business, except as has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Since January 1, 2019 through the date of this Agreement, except as has not had, and would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect, no Acquired Company has received any written notice, report
or other information of or entered into any legally binding agreement, order, settlement, judgment, injunction or decree involving
uncompleted, outstanding or unresolved material violations, liabilities or requirements on the part of any Acquired Company relating
to or arising under Environmental Laws.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect, to the knowledge of the Company, there are and, since January 1, 2019, have been no Hazardous Materials present or Releases
on, at, under or from any property or facility, including the Leased Real Property.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.19.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Insurance</I>. The Company has delivered or made available to Parent a copy of all material insurance policies relating
to the business, assets and operations of the Acquired Companies. Except as has not had, and would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect, the Acquired Companies maintain insurance coverage in such
amounts and covering such risks as are in accordance with normal industry practice for companies in the biotechnology industry
of similar size and stage of development. To the knowledge of the Company, all such insurance policies are in full force and effect,
no notice of cancellation or material modification has been received (other than a notice in connection with ordinary renewals),
and there is no existing default or event which, with the giving of notice or lapse of time or both, would constitute a default,
by any insured thereunder except for such defaults as have not had, and would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect. There is no claim pending under any of the Acquired Companies&rsquo; insurance
policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies except for such claims
as have not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.20.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Legal Proceedings; Orders</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
As of the date of this Agreement, there are no material Legal Proceedings pending and served (or, to the knowledge of the Company,
pending and not served or threatened in writing) against any Acquired Company or, to the knowledge of the Company, against any
present or former officer, director or employee of any Acquired Company in such individual&rsquo;s capacity as such, except as
has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and would
not reasonably be expected to have a material adverse effect on ability of the Company to consummate the Offer and the Merger
on or before the End Date .</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;
As of the date of this Agreement, to the knowledge of the Company, there is no order, writ, injunction or judgment to which any
Acquired Company is subject that is reasonably likely to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>To the knowledge of the Company, as of the date of this Agreement, no material investigation or review by any Governmental
Body with respect to any Acquired Company is pending or is being threatened in writing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.21.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Takeover Laws</I>. Assuming the accuracy of the representations and warranties of Parent and Purchaser set forth in
<B>&lrm;</B><U>Section 4.08</U>, the Board of Directors has taken all actions necessary or appropriate, and will take after the
date hereof, all actions that may be necessary or appropriate, so that the restrictions applicable to business combinations contained
in Section 203 of the DGCL and any other Takeover Law are, and will be, to the extent such restrictions can be rendered inapplicable
by action of the Board of Directors under Legal Requirements, inapplicable to the execution, delivery and performance of this
Agreement and to the consummation of the Offer, the Merger and the other Transactions.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.22.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Non-Contravention; Consents</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
Assuming compliance with the applicable provisions of the DGCL, the HSR Act, Takeover Laws and the rules and regulations of the
SEC and NASDAQ, the execution and delivery of this Agreement by the Company and the consummation of the Transactions will not:
(i) cause a violation of any of the provisions of the certificate of incorporation or bylaws of the Company; (ii) cause a violation
by any Acquired Company of any Legal Requirement or order applicable to any Acquired Company, or to which any Acquired Company
is subject; (iii) require any consent under, conflict with, result in breach of, or constitute a default under (or an event that
with notice or lapse of time or both would become a default), or give rise to any right of termination, amendment, cancellation,
acceleration adverse to any Acquired Company, or other adverse change of any right or obligation or the loss of any benefit to
which any Acquired Company is entitled, under any provision of any Material Contract; or (iv) result in an Encumbrance (other
than a Permitted Encumbrance) on any of the property or assets of any Acquired Company, in the case of each of <U>clauses (ii)
</U>, <U>(iii)</U> and <U>(iv)</U> except as would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect and would not reasonably be expected to have a material adverse effect on ability of the Company to consummate
the Offer and the Merger on or before the End Date .</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1pt 0pt 0">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except for the filing of the certificate of merger with the Secretary
of State of the State of Delaware or as may be required by the Exchange Act (including the filing with the SEC of the Schedule
14D -9 and such reports under the Exchange Act as may be required in connection with this Agreement and the Transactions), the
DGCL, Takeover Laws, the HSR Act and the applicable rules and regulations of the SEC and any national securities exchange, no Acquired
Company is required to give notice to, make any filing with, or obtain any Consent from any Governmental Body in connection with
the execution and delivery of this Agreement by the Company, or the consummation by the Company of the Merger or the other Transactions,
except those that the failure to make or obtain would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect and would not reasonably be expected to have a material adverse effect on ability of the Company to consummate the
Offer and the Merger on or before the End Date.</P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.23.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Opinions of Financial Advisors</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Board of Directors has received the written opinion of Centerview Partners LLC financial advisor to the Company, that,
as of the date of such opinion, and based upon and subject to the various assumptions made, procedures followed, matters considered,
and qualifications and limitations set forth therein, the $88.00 Merger Consideration per Share to be paid to the holders
of the Shares (except as otherwise provided in Sections <B>&lrm;</B>2.05(a)(i), <B>&lrm;</B>2.05(a)(ii) and <B>&lrm;</B>2.07 and
other than any Shares held by any Affiliate of the Company or Parent) pursuant to this Agreement is fair, from a financial point
of view, to such holders. The Company will make available to Parent solely for informational purposes and on a non-reliance basis,
a signed copy of such opinion as soon as possible on or after the date of this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Board of Directors (in such capacity) has received the oral opinion of BofA Securities, Inc. (together with Centerview
Partners LLC, the &ldquo;<U>Financial Advisors</U>&rdquo;), as financial advisor to the Company, on or prior to the date of this
Agreement, to be confirmed by delivery of a written opinion, to the effect that, as of the date of such opinion and based upon
and subject to various assumptions and limitations described in such written opinion, the Offer Price to be received in the Transactions
by the holders of Shares pursuant to this Agreement is fair, from a financial point of view, to such holders. The Company shall
provide a copy of such written opinion to Parent solely for informational purposes promptly after receipt thereof by the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 3.24.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Brokers and Other Advisors</I>. Except for the Financial Advisors, no broker, finder, investment banker, financial advisor
or other Person is entitled to any brokerage, finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission, or
the reimbursement of expenses in connection therewith, in connection with the Transactions based upon arrangements made by or
on behalf of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
4<BR>
REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Parent and
Purchaser represent and warrant to the Company as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Due Organization</I>. Each of Parent and Purchaser is a corporation or other Entity duly organized, validly existing
and in good standing under the laws of its jurisdiction of organization. Each of Parent and Purchaser has all necessary power
and authority: (a) to conduct its business in the manner in which its business is currently being conducted; and (b) to own and
use its assets in the manner in which its assets are currently owned and used, except where the failure has not had, and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Purchaser</I>. Purchaser was formed solely for the purpose of engaging in the Transactions and activities incidental
thereto and has not engaged, and prior to the Effective Time will not engage, in any business activities or conducted any operations
other than in connection with the Transactions and those incident to Purchaser&rsquo;s formation. Either Parent or a wholly owned
Subsidiary of Parent owns beneficially and of record all of the outstanding capital stock of Purchaser, free and clear of all
Encumbrances and transfer restrictions, except for Encumbrances or transfer restrictions of general applicability as may be provided
under the Securities Act or applicable securities laws.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Authority; Binding Nature of Agreement</I>. Parent and Purchaser have the corporate power and authority to execute and
deliver and perform their obligations under this Agreement and to consummate the Transactions. The board of directors of each
of Parent and Purchaser have approved this Agreement and declared it advisable for Parent and Purchaser, respectively, to enter
into this Agreement and approved the execution, delivery and performance by Parent and Purchaser of this Agreement and the consummation
of the Transactions, including the Offer and the Merger. This Agreement has been duly executed and delivered by Parent and Purchaser,
and assuming due authorization, execution and delivery by the Company, this Agreement constitutes the legal, valid and binding
obligation of Parent and Purchaser and is enforceable against Parent and Purchaser in accordance with its terms, except as such
enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of
general applicability relating to or affecting creditors&rsquo; rights, and by general equitable principles.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.04.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Non-Contravention; Consents</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Assuming compliance with the applicable provisions of the DGCL, the HSR Act and the applicable rules and regulations of
the SEC and any national securities exchange, the execution and delivery of this Agreement by Parent and Purchaser, and the consummation
of the Transactions, will not: (i) cause a violation of any of the provisions of the certificate of incorporation or bylaws of
Parent or Purchaser; (ii) cause a violation by Parent or Purchaser of any Legal Requirement or order applicable to Parent or Purchaser,
or to which Parent or Purchaser are subject; (iii) require any consent under, conflict with, result in breach of, or constitute
a default under (or an event that with notice or lapse of time or both would become a default), or give rise to any right of termination,
amendment, cancellation, acceleration adverse to Parent or Purchaser, or other adverse change of any right or obligation or the
loss of any benefit to which Parent or Purchaser is entitled, under any provision of any material Contract, or (iv) result in
an Encumbrance (other than a Permitted Encumbrance) on any of the property or assets</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">of Parent or
Purchaser, except in the case of <U>clauses <B>&lrm;</B>(ii), <B>&lrm;</B>(iii) and (iv)</U>, as would not reasonably be expected
to have, individually or in the aggregate, a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required
by the Exchange Act (including the filing with the SEC of the Offer Documents), Takeover Laws, the DGCL, the HSR Act and the applicable
rules and regulations of the SEC and any national securities exchange, neither Parent nor Purchaser, nor any of Parent&rsquo;s
other Affiliates, is required to give notice to, make any filing with or obtain any Consent from any Governmental Body in connection
with the execution and delivery of this Agreement by Parent or Purchaser, or the consummation by Parent or Purchaser of the Offer,
the Merger or the other Transactions, except those that the failure to make or obtain as would not, individually or in the aggregate,
reasonably be expected to have a Parent Material Adverse Effect. No vote of Parent&rsquo;s or Purchaser&rsquo;s stockholders is
necessary to approve this Agreement or any of the Transactions (except in the case of Purchaser as has been obtained prior to
the execution hereof).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.05.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Disclosure</I>. None of the Offer Documents will contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. None of the information with respect to Parent or Purchaser supplied or to be supplied
by or on behalf of Parent or Purchaser or any of their Subsidiaries, specifically for inclusion or incorporation by reference
in the Schedule 14D-9 will, (a) at the time such document is filed with the SEC, (b) at any time such document is amended or supplemented
or (c) at the time such document is first published, sent or given to the Company&rsquo;s stockholders, contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. For clarity, the representations and warranties
in this <B>&lrm;</B>Section 4.05 will not apply to statements or omissions included or incorporated by reference in the Offer
Documents or the Schedule 14D-9 based upon information supplied to Parent by the Company or any of its Representatives on behalf
of the Company specifically for inclusion therein.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.06.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Absence of Litigation</I>. As of the date of this Agreement, there is no Legal Proceeding pending and served or, to
the knowledge of Parent, pending and not served, against Parent or Purchaser, except as would not, and would not reasonably be
expected to, individually or in the aggregate, have a Parent Material Adverse Effect. As of the date of this Agreement, neither
Parent nor Purchaser is subject to any continuing order of, consent decree, settlement agreement or similar written agreement
with, or continuing investigation by, any Governmental Body, or any order, writ, judgment, injunction, decree, determination or
award of any Governmental Body, except as would not, and would not reasonably be expected to, individually or in the aggregate,
have a Parent Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.07.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Funds</I>. As of the Offer Acceptance Time Parent will have available funds in an amount sufficient to consummate the Transactions
by payment in cash of the aggregate Offer Price, the aggregate Merger Consideration payable following the Effective Time and the
aggregate amounts payable pursuant to the terms hereof to holders of Company Options and Company RSUs.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.08.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Ownership of Shares</I>. Except for any Shares acquired in the Offer, neither Parent nor any of Parent&rsquo;s Affiliates
directly or indirectly owns, and at all times for the</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">past three
years, neither Parent nor any of Parent&rsquo;s Affiliates has owned, beneficially or otherwise, any Shares or any securities,
Contracts or obligations convertible into or exercisable or exchangeable for Shares. Neither Parent nor Purchaser is, nor for
the past three years has been, an &ldquo;interested stockholder&rdquo; of the Company under Section 203(c) of the DGCL.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.09.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Acknowledgement by Parent and Purchaser</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Neither Parent nor Purchaser is relying, and neither Parent nor Purchaser has relied, on any representations or warranties
whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties in
<B>&lrm;</B>Article 3, including the Company Disclosure Schedule. Such representations and warranties by the Company constitute
the sole and exclusive representations and warranties of the Company in connection with the Transactions and each of Parent and
Purchaser understands, acknowledges and agrees that all other representations and warranties of any kind or nature whether express,
implied or statutory (including as to accuracy or completeness of any information) are specifically disclaimed by the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>In connection with the due diligence investigation of the Acquired Companies by Parent and Purchaser and their respective
Affiliates, stockholders or Representatives, Parent and Purchaser and their respective Affiliates, stockholders and Representatives
have received and may continue to receive after the date hereof from the Company and its Affiliates, stockholders and Representatives
certain estimates, projections, forecasts and other forward-looking information, as well as certain business plan information,
regarding the Acquired Companies and their businesses and operations. Parent and Purchaser acknowledge that there are uncertainties
inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such
business plans, and that Parent and Purchaser will have no claim against the Company, or any of its Affiliates, stockholders or
Representatives, or any other Person with respect thereto unless any such information is expressly included in a representation
or warranty contained in this Agreement. Accordingly, Parent and Purchaser acknowledge and agree that neither the Company nor
any of its Affiliates, stockholders or Representatives, nor any other Person, has made or is making any express or implied representation
or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans unless any such
information is expressly included in a representation or warranty contained in this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 4.10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Brokers and Other Advisors</I>. Except for Persons, if any, whose fees and expenses shall be paid by Parent or Purchaser,
no broker, finder, investment banker, financial advisor or other Person is entitled to any brokerage, finder&rsquo;s, financial
advisor&rsquo;s or other similar fee or commission, or the reimbursement of expenses in connection therewith, in connection with
the Transactions based upon arrangements made by or on behalf of Parent, Purchaser, or any of their respective Subsidiaries.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
5<BR>
CERTAIN COVENANTS OF THE COMPANY</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 5.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Access and Investigation</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>During the period from the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement
pursuant to <B>&lrm;</B>Article 8 (the &ldquo;<U>Pre-Closing Period</U>&rdquo;), upon reasonable advance notice to the Company,
the Company shall, and shall cause its Subsidiaries and Representatives to, provide Parent and Parent&rsquo;s Representatives
with reasonable</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">access during
normal business hours of the Company to the Company and its Subsidiaries and their respective Representatives, designated personnel
and assets and to all existing books, records, documents and information relating to the Acquired Companies, and promptly provide
Parent and Parent&rsquo;s Representatives with all reasonably requested information regarding the business of the Acquired Companies
and such additional financial, operating and other data and information regarding the Acquired Companies, as Parent may reasonably
request, in each case for any reasonable purpose related to the consummation of the Transactions; <I>provided</I>, <I>however</I>,
that any such access shall be conducted at a reasonable time, under the supervision of appropriate personnel of the Acquired Companies
and in such a manner as not to unreasonably interfere with the normal operation of the business of the Acquired Companies. Any
such access shall be subject to the Company&rsquo;s reasonable security measures and insurance requirements and shall not include
invasive testing. Nothing herein shall require the Company to disclose any information to Parent if such disclosure would, in
its reasonable discretion and after notice to Parent (i) jeopardize any attorney-client or other legal privilege (so long as the
Company has reasonably cooperated with Parent to permit such inspection of or to disclose such information on a basis that does
not waive such privilege with respect thereto) or (ii) contravene any applicable Legal Requirement or Contract (so long as the
Company has reasonably cooperated with Parent to permit disclosure to the extent permitted by Legal Requirements or the contractual
counterparty); <I>provided, however</I>, in the case of <U>clause <B>&lrm;</B>(ii)</U>, that the Parties shall cooperate in seeking
to find a way to allow disclosure of such information to the extent doing so could reasonably (in the good faith belief of the
Company (after consultation with outside counsel)) be managed through the use of customary &ldquo;clean room&rdquo; arrangements
pursuant to which non-employee Representatives of Parent could be provided access to such information. With respect to the information
disclosed pursuant to this <B>&lrm;</B>Section 5.01, Parent shall comply with, and shall instruct Parent&rsquo;s Representatives
to comply with, all of its obligations under the Mutual Confidential Disclosure Agreement, effective as of January 1, 2019 and
as amended thereafter, between the Company and Parent (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;). Notwithstanding anything
to the contrary herein, the Company may satisfy its obligations set forth above by electronic means if physical access is not
reasonably feasible or would not be permitted under the applicable Legal Requirements (including any COVID-19 Measures).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(i) Subject to applicable Legal Requirements, each of the Company and Parent shall promptly notify the other of (A) any
notice or other communication received by such Party from any Governmental Body in connection with this Agreement, the Offer,
the Merger or the other Transactions, or from any Person alleging that the consent of such Person is or may be required in connection
with the Offer, the Merger or the other Transactions; or (B) any Legal Proceeding commenced or, to any Party&rsquo;s knowledge,
threatened in writing against, such Party or any of its Subsidiaries or otherwise relating to, involving or affecting such Party
or any of its Subsidiaries, in each case in connection with, arising from or otherwise relating to the Offer, the Merger or any
other Transaction.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(A) The Company shall give prompt notice to Parent of any change, circumstance, condition, development, effect, event,
occurrence or state of facts that has had or would reasonably be expected to have a Material Adverse Effect, or would reasonably
be expected to make the satisfaction of any of the Offer Conditions impossible or unlikely, and (B) Parent shall give prompt notice
to the Company of any change, circumstance, condition, development, effect, event, occurrence or state of facts that has had or
would reasonably be expected to have a Parent Material Adverse Effect, or would reasonably be expected to make the satisfaction
of any of the Offer Conditions impossible or unlikely.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>For the avoidance of doubt, the delivery of any notice pursuant to this <B><I>&lrm;</I></B>Section 5.01(b) shall not cure
any breach of any representation or warranty requiring disclosure of such matter prior to the date of this Agreement or otherwise
limit or affect the remedies available hereunder to any Party. The failure to deliver any such notice shall not affect any Offer
Condition or any of the conditions set forth in <B><I>&lrm;</I></B>Article 7 or give rise to any right to terminate under <B><I>&lrm;</I></B>Article
8.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 5.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Operation of the Company&rsquo;s Business. </I>During the Pre- Closing Period, except (w) as expressly required by this
Agreement or as required by applicable Legal Requirements or to the extent necessary to comply with any obligation under any Contracts
made available to Parent on or prior to the date of this Agreement, (x) with the written consent of Parent (which consent shall
not be unreasonably withheld, conditioned or delayed), (y) in the case of Section 5.02(a), Section 5.02(b)(v) and Section 5.02(b)(xi),
in connection with any action taken, or omitted to be taken, pursuant to any COVID-19 Measures or which is otherwise taken, or
omitted to be taken, in response to COVID-19 or any other pandemic, epidemic or disease outbreak, as determined by the Company
in its reasonable discretion, or (z) as set forth in Section 5.02 of the Company Disclosure Schedule:</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1pt 0pt 0; text-indent: 34.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;the
Company shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to (i) conduct its business in
the ordinary course consistent with past practice and (ii) preserve intact its material assets, properties, Contracts, licenses
and business organization and to preserve satisfactory business relationships with licensors, licensees, lessors, Governmental
Bodies and others having material business dealings with the Acquired Companies (<I>provided, however</I>, that no action by the
Company or its Subsidiaries with respect to matters specifically addressed by any provision of Section 5.02(b) shall be deemed
a breach of this Section 5.02(a) unless such action would constitute a breach of such other provision); and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1pt 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>the Company shall not (and shall cause its Subsidiaries not to):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(A) establish a record date for, declare, set aside or pay any dividend or make any other distribution in respect of any
shares of its equity interests, or (B) repurchase, redeem or otherwise reacquire any of its equity interests, or any rights, warrants
or options to acquire any of its equity interests or any restricted stock units, other than: (1) repurchases of Shares outstanding
as of the date hereof pursuant to the Company&rsquo;s right (under written commitments in effect as of the date hereof that have
been delivered or made available to Parent) to purchase Shares held by a Company Associate in connection with the termination
of such Person&rsquo;s employment or engagement by the Company; (2) cancellation of Company Options or Company RSUs (or Shares
issued upon the exercise or settlement thereof) outstanding on the date hereof pursuant to the terms of any such Company Option
or Company RSU (in effect as of the date hereof) between the Company and a Company Associate or member of the Board of Directors
upon termination of such Person&rsquo;s employment or engagement by the Company; or (3) in connection with withholding to satisfy
the exercise price and/or Tax obligations with respect to Company Options or Company RSUs in accordance with the present terms
of such Company Option or Company RSU;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>split, combine, subdivide or reclassify any Shares or other equity interests;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;sell,
issue, grant, deliver, pledge, transfer, encumber or authorize the sale, issuance, grant, delivery, pledge, transfer or encumbrance
of (A) any capital stock, equity interest or other security, (B) any option, call, warrant, restricted securities, restricted
stock unit or right to acquire any capital stock, voting securities, equity interest or other security or (C) any instrument convertible
into, exchangeable for or settled in any capital stock, voting securities, equity interest or other security (except that the
Company may issue Shares as required to be issued upon (x) the exercise of Company Options outstanding as of the date of this
Agreement in accordance with their present terms or (y) the settlement of Company RSUs outstanding as of the date of this Agreement
in accordance with their present terms);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 37.5pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
except as set forth in Section 2.08 or as required pursuant to
an Employee Plan as in effect on the date of this Agreement, establish, adopt, terminate or materially amend any Employee Plan
(or any plan, program, arrangement or agreement that would be an Employee Plan if it were in existence on the date hereof) or any
collective bargaining agreement or other labor agreement, or amend or waive any of its material rights under, or accelerate the
payment or vesting of compensation or benefits under, any provision of any of the Employee Plans or grant any employee or director
any increase in compensation, bonuses or severance, retention or other payments or benefits (except that the Acquired Companies
may: (A) provide increases in salary, wages or benefits to non-executive employees in the ordinary course of business; (B) amend
any Employee Plan to the extent required by applicable Legal Requirements; (C) enter into at-will employment agreements with new
non-executive employees in the ordinary course of business; and (D) enter into agreements with consultants in the ordinary course
of business);</P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>other than offers of employment or engagement made by any Acquired Company as of the date of this Agreement that has been
made available to Parent, hire any employee or retain any consultant or promote any employee (other than non-executive employees
in the ordinary course of business consistent with past practice with compensation generally consistent with similarly situated
employees);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;commence,
alone or with any third party, any clinical trial in respect of any Product Candidate;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 8pt 0pt 0.5in; text-align: justify; text-indent: 38.1pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>terminate, allow to lapse or expire, suspend, modify or otherwise take any step to limit the effectiveness or validity
of, or fail to maintain as valid and in full force and effect, any applicable material Governmental Authorization;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)&nbsp;&nbsp;&nbsp;qualify
any new site for manufacturing of any Product Candidate;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>amend or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational
documents;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>form any Subsidiary, acquire any equity interest in any other
Entity or enter into any joint venture or clinical or commercial collaboration agreement or any other material collaboration, development,
partnership or similar material arrangement;</P>

<P STYLE="margin: 0pt 0; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>make or authorize any capital expenditure (except that the Acquired Companies may make capital expenditures in the ordinary
course of business consistent with past practice that do not exceed $2,000,000 individually or $5,000,000 in the aggregate);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
acquire, lease, license, sublicense, pledge, sell or otherwise dispose of, divest or spin-off, abandon, waive, covenant not
to assert, relinquish or permit to lapse (other than any Patent expiring at the end of its statutory term and not capable of
being extended), transfer or assign any material right or other material asset or property (except</FONT></FONT> <FONT STYLE="font-size: 10pt">(A)
non-exclusive licenses or sublicenses of Patents in the ordinary course of business
consistent with past practice (including entering into clinical trial agreements solely with respect to clinical trials that
are ongoing as of the date of this Agreement and material transfer agreements in the ordinary course of business consistent
with past practice pursuant to which an Acquired Company solely and exclusively owns any and all Intellectual Property Rights
conceived, developed or reduced to practice thereunder) in amounts not exceeding $2,000,000 individually or $5,000,000 in the
aggregate, (B) pursuant to dispositions of obsolete, surplus or worn out assets that are no longer useful in the conduct of
the business of the Acquired Companies in amounts not exceeding $2,000,000 individually or in the aggregate or (C) capital
expenditures permitted by <U>clause (xi)</U> of this Section 5.02(b));</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>lend money or make capital contributions or advances to or make investments in, any Person, or incur or guarantee any Indebtedness
in excess of $500,000 (except for advances to employees and consultants for travel and other business related expenses in the
ordinary course of business consistent with past practice and in compliance with the Company&rsquo;s policies related thereto);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(A) other than in the ordinary course of business consistent with past practice, amend or modify in any material respect,
or waive or release any material rights under or voluntarily terminate, any Material Contract, or (B) enter into any contract
that would constitute a Material Contract if it were in effect on the date of this Agreement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>except as required by applicable Legal Requirements, (A) make any material change to any accounting method, principle or
practice or accounting period used for Tax purposes; (B) make, change or revoke any material Tax election; (C) file a material
amended Tax Return; (D) enter into a &ldquo;closing agreement&rdquo; within the meaning of Section 7121 of the Code (or any corresponding
or similar provision of any state, local or non-U.S. Tax law) with any Governmental Body regarding any material Tax liability
or assessment; (E) request any letter ruling from the IRS (or any comparable ruling from any other taxing authority); (F) settle
or compromise any material audit, examination or Legal Proceeding relating to Taxes or surrender a right to a material Tax refund;
(G) waive or extend the statute of limitations with respect to any material Tax or material Tax Return (other than pursuant to
customary extensions of the due date for filing a Tax Return); or (H) enter into any Tax allocation, indemnity or sharing agreement
(other than customary gross-up or indemnification provisions in credit agreements, derivatives, leases, employment agreements
and similar agreements entered into in the ordinary course of business);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
settle, release, waive or compromise any Legal Proceeding or other claim (or threatened Legal Proceeding or other claim), other
than any settlement, release, waiver or compromise that (1) results solely in monetary obligations involving only the payment
of monies by the Acquired Companies of not more than $2,000,000 in the aggregate (excluding monetary obligations that are funded
by an insurance policy of the Acquired Companies) and (2) results in no monetary or other material non-monetary obligation of
the Acquired Companies; <I>provided, however</I> that the settlement, release, waiver or compromise of any Legal Proceeding or
claim brought by the stockholders of any Acquired Company against any Acquired Company and/or its directors relating to the Transactions
or a breach of this Agreement or any other agreements contemplated hereby shall be subject to Section 2.07 or Section 6.06, as
applicable, and <I>provided further</I> the foregoing shall not permit any Acquired Company to settle, release, waive or compromise
any Legal Proceeding or claim (x) that provides for the grant to any third party of a license or other grant by any Acquired Company
of rights to any material Company IP or material Company Licensed IP or (y) that would impose any material restrictions or changes
on the business or operations of, or the admission of wrongdoing by, any Acquired Company, or commence any material Legal Proceeding,
other than in the ordinary course of business consistent with past practice;</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 3pt 0pt 0.5in; text-indent: 32.65pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xvii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>enter into any collective bargaining agreement or other agreement with any labor organization (except to the extent required
by applicable Legal Requirements);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xviii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>adopt or implement any stockholder rights plan (or similar plans or arrangements);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xix)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>adopt a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation, restructuring, recapitalization
or other reorganization of any Acquired Company; or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>authorize any of, or agree or commit to take, any of the actions described in the foregoing <U>clauses <B><I>&lrm;</I></B>(i)
</U>through <B><I><U>&lrm;</U></I></B><U>(xix)</U> of this <B><I>&lrm;</I></B>Section 5.02(b).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, nothing contained herein shall give to Parent or Purchaser, directly or indirectly, rights to control or direct
the operations of the Acquired Companies prior to the Offer Acceptance Time. Prior to the Effective Time, each of Parent and the
Company shall exercise, consistent with the terms and conditions hereof, complete control and supervision of its and its Subsidiaries&rsquo;
respective operations.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 5.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>No Solicitation</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as permitted by this <B>&lrm;</B>Section 5.03, during the Pre-Closing Period, the Acquired Companies shall not,
and shall cause their officers and directors not to, and shall use reasonable best efforts to cause their other Representatives
not to, directly or indirectly, (i) continue any solicitation, knowing encouragement, discussions or negotiations with any Persons
that may be ongoing with respect to an Acquisition Proposal; (ii) (A) solicit, initiate or knowingly facilitate or encourage (including
by way of furnishing non-public information) any inquiries regarding, or the making of any proposal or offer that constitutes,
or would reasonably be expected to lead to, an Acquisition Proposal (other than discussions solely to clarify the terms and conditions
of such proposal or offer), (B) engage in, continue or otherwise participate in any discussions or negotiations regarding, or
furnish to any other Person any non-public information in connection with, or for the purpose of soliciting or knowingly encouraging
or facilitating, an Acquisition Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition
Proposal (other than to state that the terms of this provision prohibit such discussion), (C) approve, adopt, endorse or recommend
or enter into any letter of intent, acquisition agreement, agreement in principle or similar agreement with respect to an Acquisition
Proposal or any proposal or offer that would reasonably be expected to lead to an Acquisition Proposal (other than an Acceptable
Confidentiality Agreement) or (D) take any action to exempt any Person (other than Parent and its Subsidiaries) from the restrictions
on &ldquo;business combinations&rdquo; or any similar provision contained in applicable Takeover Laws or the Company&rsquo;s organizational
and other governing documents; (iii) subject to the fiduciary duties of the Board of Directors, waive or release any Person from,
forebear in the enforcement of, or amend any standstill agreement or any standstill provisions of any other Contract; or (iv)
resolve or agree to do any of the foregoing. As promptly as reasonably practicable (and in any event within two business days)
following the date hereof, the Company shall discontinue electronic or physical data room access granted, and request the prompt
return or destruction (to the extent provided for by the applicable confidentiality agreement) of all non-public information or
documents previously furnished to any Person (other than Parent, its Affiliates and their respective Representatives) that has
made or has indicated an intention to make an Acquisition Proposal and all material incorporating such information created by
any such Person.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>If at any time on or after the date of this Agreement and prior to the Offer Acceptance Time the Company or any of its
Representatives receives a <I>bona fide </I>written Acquisition Proposal from any Person or group of Persons, which Acquisition
Proposal was made</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">on or after
the date of this Agreement and did not result from a material breach of this <B>&lrm;</B>Section 5.03, and the Board of Directors
determines in good faith, after consultation with its financial advisor and outside legal counsel, that such Acquisition Proposal
constitutes or would reasonably be expected to result in a Superior Offer and that the failure to take such action described in
<U>clauses (x)</U> and <U>(y)</U> below would be inconsistent with its fiduciary duties under applicable Legal Requirements, then,
notwithstanding anything in <B>&lrm;</B>Section 5.03(a) to the contrary, the Company and its Representatives may (x)&nbsp;furnish,
pursuant to an Acceptable Confidentiality Agreement, information (including non-public information) with respect to the Acquired
Companies to the Person or group of Persons who has made such Acquisition Proposal, <I>provided </I>that the Company shall as
promptly as practicable (and in any event within 36 hours) provide to Parent any non-public information concerning the Acquired
Companies that is provided to any Person to the extent access to such information was not previously provided to Parent or its
Representatives; and (y)&nbsp;engage in or otherwise participate in discussions or negotiations with the Person or group of Persons
making such Acquisition Proposal; <I>provided</I>, in the case of <U>clauses (x)</U> and <U>(y)</U>, that at or prior to the first
time that the Company furnishes any information to or participates in any discussions or negotiations with any Person on or after
the date of this Agreement, the Company shall provide written notice to Parent of such determination in good faith of the Board
of Directors as provided for above.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>During the Pre-Closing Period, the Company shall (i) promptly (and in any event within 36 hours after knowledge of receipt
by an executive officer or director of the Company) notify Parent orally and in writing if any proposals or offers with respect
to an Acquisition Proposal are received by the Company or any of its Representatives and provide to Parent a copy of any written
Acquisition Proposal (including any proposed term sheet, letter of intent, acquisition agreement or other agreement with respect
thereto) and a summary of any material unwritten terms and conditions thereof (and indicate the identity of such Person), and
(ii) keep Parent reasonably informed of any material developments, discussions or negotiations regarding any Acquisition Proposal
on a prompt basis (and in any event within 36 hours of any request by Parent for an update as to the status of any such material
development, discussion or negotiation).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Nothing in this <B>&lrm;</B>Section 5.03 or elsewhere in this Agreement shall prohibit the Company from disclosing to the
stockholders of the Company any &ldquo;stop, look and listen&rdquo; communication pursuant to Rule 14d-9(f) promulgated under
the Exchange Act or from taking and disclosing such other position or disclosure as is required under Rule 14e-2(a), Rule 14d-9
or Item 1012(a) of Regulation M-A promulgated under the Exchange Act or from taking any action necessary to comply with applicable
Legal Requirements; <I>provided, however</I>, that, the Board of Directors shall not effect a Company Adverse Change Recommendation
except in accordance with <B>&lrm;</B>Section 6.01(b).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.6pt">(e) The Company agrees that in the event
any of its Subsidiaries or any Representative of any Acquired Company acting on behalf of the Company takes any action that, if
taken by the Company, would constitute a breach of this Section 5.03, the Company shall be deemed to be in breach of this Section
5.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16pt 0pt 0; text-indent: 0.5in">Section 5.04. <I>Compliance with
ISRA</I>. The Company agrees to use commercially reasonable efforts to achieve compliance with the New Jersey Industrial Site Recovery
Act, 13:1K-6 et seq. and its implementing regulations, each as amended (&ldquo;<U>ISRA</U>&rdquo;) prior to Closing. The Company
shall use commercially reasonable efforts to consult with Parent with respect to filings with the New Jersey Department of Environmental
Protection in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
6<BR>
ADDITIONAL COVENANTS OF THE PARTIES</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Company Board Recommendation</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
Subject to Section 6.01(b), the Company hereby consents to the inclusion of a description of the Company Board Recommendation
in the Offer Documents. During the Pre-Closing Period, subject to Section 6.01(b), neither the Board of Directors nor any committee
thereof shall (i) (A) withdraw (or modify in a manner adverse to Parent or Purchaser), or publicly propose to withdraw (or modify
in a manner adverse to Parent or Purchaser), the Company Board Recommendation, (B) adopt, approve, recommend or declare advisable,
or publicly propose to adopt, approve, recommend or declare advisable, any Acquisition Proposal, (C) after public announcement
of an Acquisition Proposal (other than a tender offer or exchange offer), fail to publicly affirm the Company Board Recommendation
within five business days after a written request by Parent to do so (or, if earlier, by the close of business on the End Date),
<I>provided</I>, that Parent may only make such request once with respect to any Acquisition Proposal (<I>provided</I>, that</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">each time a Determination Notice is given Parent shall, subject
to the following provision, be entitled to make a new such request); and <I>provided</I>, <I>further</I>, that the Company shall
not be required to provide any such affirmation during the two or three business day periods, as applicable, following the giving
of a Determination Notice, (D) following the commencement of a tender offer or exchange offer relating to the Shares by a Person
unaffiliated with Parent, fail to publicly affirm the Company Board Recommendation and recommend that the Company&rsquo;s stockholders
reject such tender offer or exchange offer within 10 business days after the commencement of such tender offer or exchange offer
pursuant to Rule 14d-9(f) promulgated under the Exchange Act (or, if earlier, by the close of business on the End Date) or (E)
fail to include the Company Board Recommendation in the Schedule 14D-9 when filed with the SEC or disseminated to the Company&rsquo;s
stockholders (any action described in this <U>clause (i)</U> being referred to as a &ldquo;<U>Company Adverse Change Recommendation</U>&rdquo;)
or (ii) approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or cause or allow the Company
to execute or enter into any Contract, letter of intent, memorandum of understanding, agreement in principle or term sheet with
respect to, or that is intended to or would reasonably be expected to lead to, any Acquisition Proposal (other than an Acceptable
Confidentiality Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary contained in this Agreement, at any time prior to the Offer Acceptance Time, and
subject to compliance with the other provisions of this <B>&lrm;</B>Section 6.01:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>if the Company has received a <I>bona fide </I>written Acquisition Proposal from any Person that has not been withdrawn
and after consultation with outside legal counsel and its financial advisor, the Board of Directors shall have determined, in
good faith, that such Acquisition Proposal constitutes a Superior Offer, (x) the Board of Directors may make a Company Adverse
Change Recommendation, or (y) provided that the Company and its Subsidiaries are not in breach of <B><I>&lrm;</I></B>Section 5.03
in any material respect and in a manner that led to such Acquisition Proposal and subject to the other provisions of <B><I>&lrm;</I></B>Section
8.01(e), the Company may terminate this Agreement pursuant to <B><I>&lrm;</I></B>Section 8.01(e) to enter into a Specified Agreement
with respect to such Superior Offer, in each case, if and only if: (A) the Board of Directors determines in good faith, after
consultation with the Company&rsquo;s outside legal counsel and its financial advisor, that the failure to do so would be inconsistent
with the fiduciary duties of the Board of Directors under applicable Legal Requirements; (B) the Company shall have given Parent
prior written notice of its intention to consider making a Company Adverse Change Recommendation or terminating this Agreement
pursuant to <B><I>&lrm;</I></B>Section 8.01(e) at least three business days prior to making any such Company Adverse Change Recommendation
or termination (a &ldquo;<U>Determination Notice</U>&rdquo;) (which notice shall not constitute a Company Adverse Change Recommendation
or termination) and, if requested in writing by Parent during such three business day period, shall have negotiated, and caused
its Representatives to negotiate, in good faith with respect to any revisions to the terms of this Agreement or another proposal
to the extent proposed by Parent so that such Acquisition Proposal would cease to constitute a Superior Offer; and (C) (1) the
Company shall have provided to Parent information with respect to such Acquisition</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">Proposal
in accordance with <B><I>&lrm;</I></B>Section 5.03(c), as well as a copy of any acquisition agreement with respect to such
Acquisition Proposal and a copy of any financing commitments relating thereto (or, if not provided in writing to the Company,
a written summary of the material terms thereof), (2) the Company shall have given Parent the three business day period after
the Determination Notice to propose revisions to the terms of this Agreement or make another proposal so that such
Acquisition Proposal would cease to constitute a Superior Offer, and (3) after giving effect to the proposals made by Parent
during such period, if any, after consultation with outside legal counsel and its financial advisor, the Board of Directors
shall have determined, in good faith, that such Acquisition Proposal constitutes a Superior Offer and that the failure to
make the Company Adverse Change Recommendation or terminate this Agreement pursuant to <B><I>&lrm;</I></B>Section 8.01(e)
would be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements. Issuance of
any &ldquo;stop, look and listen&rdquo; communication by or on behalf of the Company pursuant to Rule 14d-9(f) promulgated
under the Exchange Act, taking and disclosing a position or otherwise making any disclosure as is required under Rule
14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under the Exchange Act or otherwise complying with
applicable Legal Requirements shall not, in and of itself, be considered a Company Adverse Change Recommendation and shall
not require the giving of a Determination Notice or compliance with the procedures set forth in this <B><I>&lrm;</I></B>Section
6.01. The provisions of this <B><I>&lrm;</I></B>Section 6.01(b)(i) shall also apply to any change to any of the financial
terms (including the form, amount and timing of payment of consideration) or other material amendment to any Acquisition
Proposal and require a new Determination Notice (<I>provided </I>that for the purposes of such subsequent Determination
Notice, all references to &ldquo;three business days&rdquo; shall be deemed to be &ldquo;two business days&rdquo;);
and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>other than in connection with a Superior Offer (which shall be subject to <B><I>&lrm;</I></B>Section 6.01(b)(i)), the Board
of Directors may make a Company Adverse Change Recommendation in response to an Intervening Event if: (A) the Board of Directors
determines in good faith, after consultation with the Company&rsquo;s outside legal counsel and its financial advisor, that the
failure to do so would be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements;
(B) the Company shall have given Parent a Determination Notice at least three business days prior to making any such Company Adverse
Change Recommendation and, if desired by Parent, during such three business day period shall have negotiated, and caused its Representatives
to negotiate, in good faith with respect to any revisions to the terms of this Agreement or another proposal to the extent proposed
by Parent so that a Company Adverse Change Recommendation would no longer be necessary; and (C) (1) the Company shall have specified
in reasonable detail the facts and circumstances that render a Company Adverse Change Recommendation necessary, (2) the Company
shall have given Parent the three business day period after the Determination Notice to propose revisions to the terms of this
Agreement or make another proposal so that a Company Adverse Change Recommendation would no longer be necessary, and (3) after
giving effect to the proposals made by Parent during such period, if any, after consultation with outside legal counsel and its
financial advisor, the Board of Directors shall have determined, in good faith, that the failure to make the Company Adverse Change
Recommendation would be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements.
The provisions of this <B><I>&lrm;</I></B>Section 6.01(b)(ii) shall also apply to any material change to the facts and circumstances
specified by the Company pursuant to <U>clause <B><I>&lrm;</I></B>(C)<B><I>&lrm;</I></B>(1)</U> above and require a new Determination
Notice</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">(<I>provided
</I>that for the purposes of such subsequent Determination Notice, all references to &ldquo;three business days&rdquo; shall be
deemed to be &ldquo;two business days&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Filings, Consents and Approvals</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
The Parties agree to use their reasonable best efforts to take promptly any and all steps necessary to avoid or eliminate each
and every impediment under the Antitrust Laws, that may be asserted by any Governmental Body, so as to enable the Closing to occur
as promptly as practicable, but in no case later than the End Date, including providing as promptly as reasonably practicable
and advisable all non-legally privileged information required by any Governmental Body pursuant to its evaluation of the Transactions
under the HSR Act. Subject to the terms of this Section 6.02, the Parties shall use their reasonable best efforts to obtain from
any Governmental Body all consents, approvals, authorizations or orders required to be obtained under the Antitrust Laws or to
avoid the entry or enactment of any injunction or other order or decree relating to any Antitrust Law that would delay, restrain,
prevent, enjoin or otherwise prohibit consummation of the Transactions. In furtherance and not in limitation of the foregoing,
Parent shall, and shall cause its Affiliates to, proffer and agree to (i) sell, license, divest or dispose of or hold separate
(through the establishment of a trust or otherwise) or agree to any other structural, behavioral or conduct remedy, before or
after the Offer Acceptance Time or the Effective Time, any entities, businesses, divisions, operations, products or product lines,
assets, Intellectual Property Rights or businesses of Parent, the Company (or any of their respective Subsidiaries or other Affiliates),
and (ii) agree to any other restriction on the conduct of such businesses, in each case as may be necessary to avoid or eliminate
each and every impediment under the Antitrust Laws that may be asserted by any Governmental Body with respect to the Transactions
contemplated hereby so as to enable the Closing to occur as promptly as practicable, but in no case later than the End Date; <I>provided</I>,
<I>however</I>, that nothing in this Agreement shall require Parent or any of its Affiliates to agree to any such remedy or restriction
if such actions would (x) materially and adversely affect the business of Parent and its Subsidiaries, taken as a whole following
consummation of the Transactions contemplated hereby, (y) require the sale, license, divestiture, disposal, or holding separate
of, IMMU-132 (Trodelvy) or (z) require any other structural, behavioral or conduct remedy involving any Product Candidate if,
in the case of this clause (z), any such remedy would have a material impact on the value or business prospects of the Product
Candidates taken as a whole to Parent and its Subsidiaries following the consummation of the Transactions. Nothing in this Section
6.02 shall permit the Company to take any of the actions listed in (i) or (ii) above without Parent&rsquo;s prior written consent
or require Parent or the Acquired Companies to take or agree to take any of the actions listed in (i) or (ii) above unless the
effectiveness of such action is conditioned upon Closing. In furtherance of the foregoing, if any lawsuit or other proceeding,
whether judicial or administrative, is brought or threatened to be brought challenging or seeking to restrain or prohibit the
consummation of the Transactions under the Antitrust Laws, each of Parent, Purchaser, and the Company shall contest and resist
any such action or proceeding to have vacated, lifted, reversed or overturned any decree, judgment, injunction, or other order,
whether temporary, preliminary or permanent, that results from such action or proceeding and that prohibits, prevents or restrains
consummation of the Transactions contemplated hereby on or before the End Date.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Subject to the terms and conditions of this Agreement, each of the Parties shall (and shall cause their respective Affiliates,
if applicable, to): (i) as promptly as reasonably practicable (but no later than 10 business days after the date of this Agreement),
make an appropriate filing of all Notification and Report forms as required by the HSR Act, with respect to the Transactions and
(ii) cooperate with each other in determining whether (and promptly preparing and making if so required) any other filings, notifications
or other consents are required to be made with, or obtained from, any other Governmental Bodies in connection with the Transactions.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Without limiting the generality of anything contained in this <B>&lrm;</B>Section 6.02, during the Pre-Closing Period,
each of the Parties shall (i)&nbsp;cooperate in all respects and consult with each other in connection with any filing or submission
in connection with any investigation or other</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">inquiry, including
allowing the other Party to have a reasonable opportunity to review in advance and comment on drafts of filings and submissions;
(ii)&nbsp;give the other Parties prompt notice of the making or commencement of any request, inquiry, investigation, action or
Legal Proceeding brought by a Governmental Body or brought by a third party before any Governmental Body, in each case, with respect
to the Transactions under the Antitrust Laws, (iii)&nbsp;keep the other Parties reasonably informed as to the status of any such
request, inquiry, investigation, action or Legal Proceeding, (iv)&nbsp;promptly inform the other Parties of, and wherever practicable
give the other party reasonable advance notice of, and the opportunity to participate in, any communication to or from the FTC,
DOJ or any other Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (v)&nbsp;promptly
furnish to the other Party, subject to an appropriate confidentiality agreement to limit disclosure to counsel and outside consultants,
with copies of documents provided to or received from any Governmental Body in connection with any such request, inquiry, investigation,
action or Legal Proceeding (except that documents, including &ldquo;4(c) and 4(d) documents&rdquo; as that term is defined under
the HSR Act, that contain valuation information can be redacted), (vi) subject to an appropriate confidentiality agreement to
limit disclosure to counsel and outside consultants, consult and cooperate with the other Parties and consider in good faith the
views of the other Parties in connection with any written analysis, appearance, presentation, memorandum, brief, argument, opinion
or proposal made or submitted in connection with any such request, inquiry, investigation, action or Legal Proceeding, and (vii)
except as may be prohibited by any Governmental Body or by any Legal Requirement, in connection with any such request, inquiry,
investigation, action or Legal Proceeding in respect of the Transactions, give the other Party reasonable prior notice and permit
authorized Representatives of the other Party to be present at each meeting or conference, including by telephone or videoconference,
relating to such request, inquiry, investigation, action or Legal Proceeding and to have access to and be consulted in advance
in connection with any argument, opinion or proposal made or submitted to any Governmental Body in connection with such request,
inquiry, investigation, action or Legal Proceeding. Each Party shall supply as promptly as practicable such information, documentation,
other material or testimony that may be requested by any Governmental Body, including by complying at the earliest reasonably
practicable date with any request for additional information, documents or other materials received by any Party or any of their
respective Subsidiaries from any Governmental Body in connection with the Transactions contemplated by this Agreement. Neither
Party shall commit to or agree with any Governmental Body to stay, toll or extend any applicable waiting period under the HSR
Act, or delay the consummation of the Transactions, or withdraw any notification filed under the HSR Act, without the prior written
consent of the other Party.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>During the Pre-Closing Period, the Company shall to the extent permissible under applicable Legal Requirements and reasonably
practicable and where doing so would not reasonably be expected to impair or adversely affect the Company, any of its plans with
respect to the Product Candidates or its ability to interact with any Governmental Body consistent with companies at similar stages
of development in the pharmaceutical industry (in each case as determined in good faith by the Company) (i) offer Parent the opportunity
to consult with the Acquired Companies prior to any proposed material meeting or other material communication with the FDA, EMA,
the Centers for Medicare &amp; Medicaid Services (&ldquo;<U>CMS</U>&rdquo;) or any other Specified Governmental Body relating
to any Product Candidate or material Governmental Authorization (it being understood that in no event shall the Company be required
to delay or modify any of its actions as a result of this <B>&lrm;</B>Section 6.02(d)), (ii) promptly inform Parent of, and provide
Parent with a reasonable opportunity to review, in advance, any material filing proposed to be made by or on behalf of any Acquired
Company, and any material correspondence or other material communication proposed to be submitted or otherwise transmitted to
the FDA, EMA, CMS or any other Specified Governmental Body by or on behalf of any Acquired Company, in</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">each case relating
to any Product Candidate or material Governmental Authorization (it being understood that in no event shall the Acquired Companies
be required to delay any such filings, correspondence or communication), (iii) keep Parent reasonably informed of any material
communication (written or oral) with or from the FDA, EMA, CMS or any other Specified Governmental Body or relating to any Product
Candidate or Governmental Authorization and (iv) promptly inform Parent and provide Parent with a reasonable opportunity (but
no more than two business days, to the extent practicable) to comment, in each case, prior to making any material change to any
study protocol, adding any new trial, making any material change to a manufacturing plan or process, making any material change
to a development timeline or initiating, or making any material change to, commercialization and reimbursement activities or materials
(including promotional and marketing activities and materials) relating to any Product Candidate. The Company shall promptly notify
Parent of any significant data relating to any Product Candidate, including information related to any significant adverse events
with respect to any Product Candidate, in each case which it discovers after the date hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Neither Party shall enter into any agreement, transaction, or any agreement to effect any transaction (including any merger
or acquisition) that would reasonably be expected to make it materially more difficult, or to materially increase the time required,
to (i) obtain the expiration or termination of the waiting period under the HSR Act, (ii) avoid the entry of, the commencement
of litigation seeking the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other order
that would materially delay or prevent the consummation of the transactions contemplated hereby, or (iii) obtain all authorizations,
consents, orders and approvals of Governmental Bodies necessary for the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Employee Benefits</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
For a period commencing at the Effective Time and ending on the one year anniversary of the Effective Time, Parent shall provide,
or cause to be provided, to each individual who is employed by an Acquired Company as of immediately prior to the Effective Time
and who continues to be actively employed by the Surviving Corporation (or any Affiliate thereof) during such period (a &ldquo;<U>Continuing
Employee</U>&rdquo;), (i) base salary or base wages and short-term cash incentive compensation opportunities, on a basis, in each
case, that is no less favorable than that in effect immediately prior to the execution of this Agreement, (ii) equity compensation
awards that are substantially comparable in the aggregate to the equity compensation awards generally provided to similarly-situated
employees of Parent and its Subsidiaries and (iii) all other employee benefits (excluding severance) that are no less favorable
in the aggregate than those provided in the aggregate (excluding severance) to such Continuing Employee by the Acquired Companies
immediately prior to the execution of this Agreement.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Parent agrees that all Continuing Employees shall be eligible to continue to participate in the Surviving Corporation&rsquo;s
health and welfare benefit plans (to the same extent such Continuing Employees were eligible to participate under the health and
welfare benefit plans of the Company immediately prior to the Effective Time); <I>provided, however</I>, that (i) nothing in this
Section 6.03 or elsewhere in this Agreement shall limit the right of Parent or the Surviving Corporation to amend or terminate,
in accordance with its terms, any such health or welfare benefit plan at any time, subject to the requirements set forth in Section
6.03(a), and (ii) if Parent or the Surviving Corporation terminates any such health or welfare benefit plan (upon expiration of
any appropriate transition period), then the Continuing Employees shall be eligible to participate in the Surviving Corporation&rsquo;s
(or an Affiliate&rsquo;s) health and welfare benefit plans to the extent that coverage under such plans is replacing comparable
coverage under an Employee</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Plan in which
such Continuing Employee participated immediately before the Effective Time. To the extent that service is relevant under any
benefit plan of Parent or an Affiliate and/or the Surviving Corporation, then Parent shall ensure that such benefit plan shall,
for all purposes (except pension accruals or as would result in any duplication of benefits), credit Continuing Employees for
service prior to the Effective Time with the Acquired Companies and their Affiliates or their respective predecessors; <I>provided</I>,
that, if such benefit plan replaces a benefit plan of an Acquired Company that recognized service for the same purpose, such service
will be recognized to the same extent that such service was recognized prior to the Effective Time under the corresponding benefit
plan of an Acquired Company. Nothing in this Section 6.03 or elsewhere in this Agreement shall be construed to create a right
in any Person to employment with Parent, the Surviving Corporation or any other Affiliate of the Surviving Corporation and the
employment of each Continuing Employee shall be &ldquo;at will&rdquo; employment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>To the extent permitted under applicable Legal Requirements, with respect to any employee benefit plans maintained for
the benefit of the Continuing Employees following the Effective Time, Parent shall, and shall cause the Surviving Corporation,
any of its Affiliates, and any successor thereto, to (i) cause there to be waived any eligibility requirements or pre-existing
condition limitations or waiting period requirements to the same extent waived or satisfied under comparable plans of the Company
or its Subsidiaries, and (ii) give effect, in determining any deductible, co-insurance and maximum out-of-pocket limitations,
amounts paid by such employees during the calendar year in which the Effective Time occurs under similar plans maintained by the
Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As soon as reasonably practicable (and in any event not later than ten days) following the date of this Agreement, the Company
shall make available to Parent a detailed set of calculations (together with all relevant backup data) reflecting the potential
impact of Section 280G of the Code with respect to each Person who could be entitled to any payment or benefit in connection with
the Transactions (either alone or in combination with other events or circumstances) which could potentially constitute a &ldquo;parachute
payment&rdquo; under Section 280G of the Code.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.6pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Effective Time occurs prior to the date in 2021 that annual bonus payments in respect of calendar year 2020 are paid to employees
of the Company and its Subsidiaries in the ordinary course of business consistent with past practice pursuant to the Company Bonus
Plan (the &ldquo;<U>Ordinary 2020 Bonus Payment Date</U>&rdquo;), then Parent shall, or shall cause the Surviving Corporation to,
pay to each Continuing Employee who participates in the Company Bonus Plan and (i) remains actively employed through the Ordinary
2020 Bonus Payment Date or (ii) experiences a severance qualifying termination of employment on or after the date that the Effective
Time occurs and prior to the Ordinary 2020 Bonus Payment Date, an annual bonus in respect of calendar year 2020 pursuant to the
Company Bonus Plan on the Ordinary 2020 Bonus Payment Date (but in no event later than March 15, 2021); <I>provided</I> that all
&ldquo;Company Performance Metrics&rdquo; (as defined in the Company Bonus Plan) in respect of calendar year 2020 shall be deemed
achieved at 150% of the target level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.6pt"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The provisions of this Section 6.03 are solely for the benefit of the Parties, and no provision of this Section 6.03 is
intended to, or shall, constitute the establishment or adoption of or an amendment to any employee benefit plan for purposes of
ERISA or otherwise, and no</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">current or
former employee or any other individual associated therewith shall be regarded for any purpose as a third party beneficiary of
this Agreement or have the right to enforce the provisions hereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.04.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
<I>ESPP</I> . The Company shall take all necessary actions to (a) suspend the Company ESPP as of the date of this Agreement, such
that no &ldquo;<U>Offering</U>&rdquo; (as defined in the Company ESPP) is in effect as of or following the date of this Agreement,
(b) ensure that no further Offering shall commence pursuant to the Company ESPP after the date of this Agreement, and (c) terminate
the Company ESPP effective as of immediately prior to, and conditional upon the occurrence of, the Offer Acceptance Time.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.05.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Indemnification of Officers and Directors</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>For a period of six years from the Effective Time, Parent agrees that all rights to indemnification, advancement of expenses
and exculpation from liabilities for acts or omissions occurring at or prior to the Effective Time (whether asserted or claimed
prior to, at or after the Effective Time) now existing in favor of the current or former directors or officers of the Acquired
Companies under the certificate of incorporation and bylaws (or other organizational documents) of each of the Acquired Companies,
in each case as in effect on the date of this Agreement, shall continue in full force and effect in accordance with their terms
and shall not be amended, repealed or otherwise modified in any manner that would adversely affect the rights thereunder of any
Indemnified Person (as defined below), and Parent shall cause the Acquired Companies to perform their obligations thereunder.
Without limiting the foregoing, during the period commencing at the Effective Time and ending on the sixth anniversary of the
Effective Time, Parent shall cause the Surviving Corporation and its Subsidiaries to, and the Surviving Corporation agrees that
it will, indemnify and hold harmless each individual who is as of the date of this Agreement, or who becomes prior to the Effective
Time, a director or officer of any Acquired Company or who is as of the date of this Agreement, or who thereafter commences prior
to the Effective Time, serving at the request of any Acquired Company as a director or officer of another Person (the &ldquo;<U>Indemnified
Persons</U>&rdquo;), against all claims, losses, liabilities, damages, judgments, inquiries, fines and reasonable fees, costs
and expenses, including attorneys&rsquo; fees and disbursements, incurred in connection with any claim, action, suit or proceeding,
whether civil, criminal, administrative or investigative (including with respect to matters existing or occurring at or prior
to the Effective Time, including this Agreement and the transactions and actions contemplated hereby), arising out of or pertaining
to the fact that the Indemnified Person</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">is or was a
director or officer of any Acquired Company or is or was serving at the request of any Acquired Company as a director or officer
of another Person, whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under
applicable Legal Requirements. In the event of any such claim, action, suit or proceeding, (x) each Indemnified Person will be
entitled to advancement of expenses incurred in the defense of any such claim, action, suit or proceeding from Parent, the Surviving
Corporation or its Subsidiaries, as applicable, in accordance with the organizational documents, in each case as in effect on
the date of this Agreement, as applicable, as in effect on the date of this Agreement; <I>provided </I>that any Indemnified Person
to whom expenses are advanced provides an undertaking, if and only to the extent required by the DGCL or the Surviving Corporation&rsquo;s
or any of its Subsidiaries&rsquo; certificate of incorporation or bylaws (or comparable organizational documents) or any such
indemnification or other similar agreements, as applicable, to repay such advances if it is ultimately determined by final adjudication
that such Indemnified Person is not entitled to indemnification and (y) Parent, the Surviving Corporation and its Subsidiaries,
as applicable, shall reasonably cooperate in the defense of any such matter.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>For a period of six years from and after the Effective Time, Parent and the Surviving Corporation shall either cause to
be maintained in effect the current policies of directors&rsquo; and officers&rsquo; liability insurance maintained by or for
the benefit of the Acquired Companies or provide substitute policies for the Acquired Companies and their current and former directors
and officers who are currently covered by the directors&rsquo; and officers&rsquo; liability insurance coverage currently maintained
by or for the benefit of the Acquired Companies, in either case, of not less than the existing coverage and having other terms
not less favorable to the insured persons than the directors&rsquo; and officers&rsquo; liability insurance coverage currently
maintained by or for the benefit of the Acquired Companies with respect to claims arising from facts or events that occurred at
or before the Effective Time (with insurance carriers having at least an &ldquo;A&rdquo; rating by A.M. Best with respect to directors&rsquo;
and officers&rsquo; liability insurance), except that in no event shall Parent or the Surviving Corporation be required to pay
with respect to such insurance policies an annual premium greater than 300% of the aggregate annual premium most recently paid
by the Acquired Companies prior to the date of this Agreement (the &ldquo;<U>Maximum Amount</U>&rdquo;), and if the Surviving
Corporation is unable to obtain the insurance required by this <B>&lrm;</B>Section 6.05(b) it shall obtain as much comparable
insurance as possible for the years within such six year period for a premium equal to the Maximum Amount. In lieu of such insurance,
prior to the Closing Date the Company may purchase a &ldquo;tail&rdquo; directors&rsquo; and officers&rsquo; liability insurance
policy for the Acquired Companies and their current and former directors and officers who are currently covered by the directors&rsquo;
and officers&rsquo; liability insurance coverage currently maintained by or for the benefit of the Acquired Companies, such tail
to provide coverage in an amount not less than the existing coverage and to have other terms not less favorable to the insured
persons than the directors&rsquo; and officers&rsquo; liability insurance coverage currently maintained by the Acquired Companies
with respect to claims arising from facts or events that occurred at or before the Effective Time; <I>provided </I>that in no
event shall the cost of any such tail policy exceed the Maximum Amount. Parent and the Surviving Corporation shall maintain such
policies in full force and effect, and continue to honor the obligations thereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>In the event that any Acquired Company or any of its respective successors or assigns (i) consolidates with or merges into
any other Person and is not the continuing or surviving corporation or Entity of such consolidation or merger or (ii) transfers
or conveys all or substantially all of its properties and assets to any Person, then, and in each such case, such Acquired Company,
as applicable, shall cause proper provision to be made so that the successors and assigns of such Acquired Company assume the
obligations set forth in this <B>&lrm;</B>Section 6.05.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp; </FONT>The
provisions of this <B>&lrm;</B>Section 6.05 (a) (i) shall survive the acceptance of Shares for payment pursuant to the Offer
and the consummation of the Merger and (ii) are intended to be for the benefit of, and will be enforceable by, each
indemnified or insured party (including the Indemnified Persons), his or her heirs, successors, assigns and representatives,
and (iii) are in addition to, and not in substitution for, any other rights to indemnification, advancement of expenses,
exculpation or contribution that any such Person may have by contract or otherwise. This <B>&lrm;</B>Section 6.05 may not be
amended, altered or repealed after the Offer Acceptance Time in such a manner as to adversely affect the rights of any
Indemnified Person or any of their successors, assigns or heirs without the prior written consent of the affected Indemnified
Person.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.06.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Stockholder Litigation</I>. In the event that any litigation related to this Agreement, the Offer, the Merger or the
other Transactions is brought by any stockholder or other holder of Acquired Company securities (whether directly or on behalf
of the Acquired Companies or otherwise) against any Acquired Company and/or its directors or officers, the Company shall promptly
notify Parent and shall keep Parent reasonably and promptly informed of any material developments with respect to such litigation.
The Company shall give Parent the (a) opportunity to participate in the defense of any such litigation, (b) right to review and
comment on all material filings or responses to be made by any Acquired Company in connection with such litigation (and shall
give due consideration to Parent&rsquo;s comments and other advice with respect to such litigation) and (c) right to consult on
any settlement with respect to such litigation, and no such settlement shall be agreed to without Parent&rsquo;s prior written
consent (such consent not to be unreasonably withheld, conditioned or delayed), <I>provided, however</I>, that the Company
shall otherwise control the defense and/or settlement and the disclosure of information in connection therewith shall be subject
to the provisions of <B>&lrm;</B>Section 5.01, including regarding attorney-client privilege or other applicable legal privilege.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.07.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Additional Agreements</I>. Subject to the terms and conditions of this Agreement, including <B>&lrm;</B>Section 6.02(a),
Parent and the Company shall use reasonable best efforts to take, or cause to be taken, all actions necessary to consummate the
Offer and the Merger and make effective the other Transactions. Without limiting the generality of the foregoing, subject to the
terms and conditions of this Agreement, each Party to this Agreement shall use commercially reasonable efforts to (a) make all
filings (if any) and give all notices (if any) required to be made and given by such Party pursuant to any Material Contract in
connection with the Offer and the Merger and the other Transactions to the extent requested in writing by Parent, (b) seek each
Consent (if any) required to be obtained pursuant to any Material Contract by such Party in connection with the Transactions to
the extent requested in writing by Parent; <I>provided</I>, <I>however</I>, each of the Parties acknowledges and agrees that obtaining
any such consent or approval shall not, in and of itself, be a condition to the Offer or the Merger and (c) seek to lift any restraint,
injunction or other legal bar to the Offer or the Merger brought by any third Person against such Party. Notwithstanding anything
in this <B>&lrm;</B>Section 6.07 to the contrary, neither Parent, the Company nor any of their respective Subsidiaries shall be
required to pay any consent or other similar fee, payment or consideration, make any other concession or provide any additional
security (including a guaranty), to obtain any third party consents.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.08.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Disclosure</I>. The initial press release relating to this Agreement shall be a joint press release issued by the Company
and Parent, and thereafter Parent and the Company shall consult with each other before issuing any further press release(s) or
otherwise making any public statement or making any announcement to Company Associates (to the extent not previously issued or
made in accordance with this Agreement) with respect to the Offer, the</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Merger, this
Agreement or any of the other Transactions and shall not issue any such press release, public statement or announcement to Company
Associates without the other Party&rsquo;s written consent. Notwithstanding the foregoing: (a) each Party may, without such consultation
or consent, make any public statement in response to questions from the press, analysts, investors or those attending industry
conferences, make internal announcements to employees and make disclosures in Company SEC Documents, so long as such statements
substantially reiterate (and are not inconsistent with) previous press releases, public disclosures or public statements made
jointly by the Parties (or individually, if approved by the other Party); (b) a Party may, without the prior consent of the other
Party but subject to giving advance notice to the other Party and consulting with the other Party with respect to the content
thereof, issue any such press release or make any such public announcement or statement that, after consultation with outside
legal counsel, is determined to be required by Legal Requirement; (c) the Company need not consult with Parent in connection with
such portion of any press release, public statement or filing to be issued or made pursuant to <B>&lrm;</B>Section 5.03(d); and
(d) neither Party need consult with the other in connection with such portion of any press release, public statement or filing
to be issued with respect to any Acquisition Proposal or Company Adverse Change Recommendation (but without limiting the Company&rsquo;s
obligations under <B>&lrm;</B>Section 5.03 or <B>&lrm;</B>Section 6.01).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.09.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Takeover Laws</I>. If any Takeover Law may become, or may purport to be, applicable to the Transactions, each of Parent
and the Company and the members of their respective Boards of Directors shall use their respective reasonable best efforts to
grant such approvals and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable
on the terms and conditions contemplated hereby and otherwise act to lawfully eliminate the effect of any Takeover Law on any
of the Transactions.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Section 16 Matters</I>. The Company, and the Board of Directors (or a duly formed committee thereof consisting of non-employee
directors (as such term is defined for the purposes of Rule 16b-3 promulgated under the Exchange Act)), shall, to the extent necessary,
take appropriate action, prior to or as of the Offer Acceptance Time, to approve, for purposes of Section 16(b) of the Exchange
Act, the disposition and cancellation or deemed disposition and cancellation of Shares, Company Options and Company RSUs in the
Merger by applicable individuals and to cause such dispositions and/or cancellations to be exempt under Rule 16b-3 promulgated
under the Exchange Act.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Rule 14d-10 Matters</I>. Prior to the Offer Acceptance Time and to the extent permitted by applicable Legal Requirements,
the compensation committee of the Board of Directors, at a meeting duly called and held, will approve, as an &ldquo;employment
compensation, severance or other employee benefit arrangement&rdquo; within the meaning of Rule 14d-10(d)(2) under the Exchange
Act, each agreement, arrangement or understanding between Purchaser, any Acquired Company or their respective Affiliates and any
of the officers, directors or employees of the Acquired Companies that are effective as of the date of this Agreement or are entered
into after the date of this Agreement and prior to the Offer Acceptance Time pursuant to which compensation is paid to such officer,
director or employee and will take all other action reasonably necessary to satisfy the requirements of the non-exclusive safe
harbor set forth in Rule 14d-10(d)(2) under the Exchange Act. Promptly upon Parent or any of its Affiliates entering into any
such arrangement with any of the officers, directors or employees of the Acquired Companies, Parent will provide to the Company
any and all information concerning such arrangements as may be needed by the Company to comply with this <B>&lrm;</B>Section 6.11.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Stock Exchange Delisting; Deregistration</I>. Prior to the Closing Date, the Company shall cooperate with Parent and
use its reasonable best efforts to take, or cause to be</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">taken, all
actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable laws and
rules and policies of NASDAQ to enable the delisting by the Surviving Corporation of the Shares from NASDAQ and the deregistration
of the Shares under the Exchange Act as promptly as practicable after the Effective Time.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 6.13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>401(k) Plan</I>. To the extent requested in writing by Parent at least 10 days prior to the Offer Acceptance Time, the
Company shall take all actions that may be necessary under the Company&rsquo;s 401(k) plan to terminate the Company&rsquo;s 401(k)
plan at least one day prior to the Effective Time. If the Company terminates the Company&rsquo;s 401(k) plan in accordance with
the preceding sentence, (1) prior to the Effective Time and thereafter (as applicable), the Company and Parent shall take any
and all actions as may be required, including amendments to the Company&rsquo;s 401(k) plan and/or the tax-qualified defined contribution
retirement plan designated by Parent (the &ldquo;<U>Parent 401(k) Plan</U>&rdquo;) to permit each Continuing Employee to make
rollover contributions of &ldquo;eligible rollover distributions&rdquo; (within the meaning of Section 401(a)(31) of the Code,
including of loans) in the form of cash, or notes (in the case of loans) or a combination thereof, in an amount equal to the full
account balance distributed or distributable to such Continuing Employee from the Company 401(k) plan to the Parent 401(k) Plan
and (2) each Continuing Employee shall become a participant in the Parent 401(k) Plan on the Closing Date (giving effect to the
service crediting provisions of <B>&lrm;</B>Section 6.03(b)); it being agreed that there shall be no gap in participation in a
tax-qualified defined contribution plan.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
7<BR>
CONDITIONS PRECEDENT TO THE MERGER</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The obligations
of the Parties to effect the Merger are subject to the satisfaction or, to the extent permitted by applicable Legal Requirements,
waiver as of the Closing of each of the following conditions:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 7.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>No Restraints</I>. There shall not have been issued by any Governmental Body of competent jurisdiction in any jurisdiction
in which Parent or the Company has material business operations, and remain in effect, any temporary restraining order, preliminary
or permanent injunction or other order preventing the consummation of the Merger, nor shall any Legal Requirement have been promulgated,
enacted, issued or deemed applicable to the Merger by any Governmental Body in any jurisdiction in which Parent or the Company
has material business operations which prohibits or makes illegal the consummation of the Merger.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 7.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Consummation of Offer</I>. Purchaser (or Parent on Purchaser&rsquo;s behalf) shall have accepted for payment all of
the Shares validly tendered pursuant to the Offer and not validly withdrawn.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
8<BR>
TERMINATION</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 8.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Termination</I>. This Agreement may be terminated prior to the Closing:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>by mutual written consent of Parent and the Company;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
by either Parent or the Company, if the Closing shall not have occurred on or prior to midnight Eastern Time, on March 13, 2021
(the &ldquo;<U>End Date</U>&rdquo;); <I>provided</I>, <I>however</I>, that in the</FONT></FONT> <FONT STYLE="font-size: 10pt">case
of this Section 8.01(b), (i) (x) if on the End Date all of the conditions set forth in <U>Annex I</U>, other than <U>clause (e)
</U>or <U>(g)</U> (solely in respect of any Antitrust Law) set forth in Annex I shall have been satisfied or waived by Parent
or Purchaser, to the extent waivable by Parent or Purchaser (other than conditions that by their nature are to be satisfied at
the Offer Acceptance Time, each of which is then capable of being satisfied), then the End Date shall automatically be extended
to June 13, 2021 (and all references to the End Date herein and in Annex I shall be as so extended) and (y) if on the End Date
(as extended by subclause (x) of this proviso) all of the conditions set forth in <U>Annex I</U>, other than <U>clause (e)</U>
or <U>(g)</U> (solely in respect of any Antitrust Law) set forth in Annex I shall have been satisfied or waived by Parent or Purchaser,
to the extent waivable by Parent or Purchaser (other than conditions that by their nature are to be satisfied at the Offer Acceptance
Time, each of which is then capable of being satisfied), then the End Date shall automatically be extended to September 13, 2021
(and all references to the End Date herein and in Annex I shall be as so extended) and (ii) the right to terminate this Agreement
pursuant to this Section 8.01(b) shall not be available to any Party whose material breach of this Agreement has caused or resulted
in the Offer not being consummated by such date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>by either Parent or the Company if a Governmental Body of competent jurisdiction shall have issued an order, injunction,
decree or ruling, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting
the acceptance for payment of Shares pursuant to the Offer or the Merger or making the consummation of the Offer or the Merger
illegal, which order, decree, ruling or other action shall be final and nonappealable; <I>provided</I>, <I>however</I>, that the
right to terminate this Agreement pursuant to this <B>&lrm;</B>Section 8.01(c) shall not be available to any Party whose material
breach of this Agreement has caused or resulted in such final and nonappealable order, injunction, decree, ruling or other action
or that has failed to comply with its obligations under <U>Section 6.02</U> with respect to the removal of such order, injunction
decree, ruling or other action;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>by Parent, if the Board of Directors shall have effected a Company Adverse Change Recommendation;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>by the Company, if the Board of Directors has made a Company Adverse Change Recommendation in order to accept a Superior
Offer and concurrently enter into a binding written definitive acquisition agreement providing for the consummation of a transaction
for a Superior Offer (a &ldquo;<U>Specified Agreement</U>&rdquo;); <I>provided </I>that (i) the Company and the Board of Directors
shall have complied with <B>&lrm;</B>Section 6.01(b) with respect to such Superior Offer and (ii) the Company shall have paid
the Termination Fee immediately before or simultaneously with and as a condition to such termination;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>by Parent, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant
or obligation in this Agreement on the part of the Company shall have occurred such that a condition set forth in <U>clause <B>&lrm;</B>(b)
</U>or <U>(c)</U> of <B>&lrm;</B>Annex I would not be satisfied and cannot be cured by the Company by the End Date, or if capable
of being cured in such time period, shall not have been cured within forty-five (45) days of the date Parent gives the Company
written notice of such breach or failure to perform; <I>provided</I>, <I>however</I>, that Parent shall not have the right to
terminate this Agreement pursuant to this <B>&lrm;</B>Section 8.01(f) if either Parent or Purchaser is then in material breach
of any representation, warranty, covenant or obligation hereunder; or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>by the Company, if (i) a breach of any representation or warranty contained in this Agreement or failure to perform any
covenant or obligation in this Agreement on the part of Parent or Purchaser shall have occurred, in each case, if such breach
or failure would reasonably be expected to prevent Parent or Purchaser from consummating the Offer and the Merger by the End Date
and such breach or failure cannot be cured by Parent or Purchaser, as applicable, by the End Date, or, if capable of being cured
in such time period, shall not have been cured within forty-five (45) days of the date the Company gives Parent written notice
of such breach or failure to perform; <I>provided</I>, <I>however</I>, that the Company shall not have the right to terminate
this Agreement pursuant to this <B>&lrm;</B>Section 8.01(g) if the Company is then in material breach of any representation, warranty,
covenant or obligation hereunder or (ii) Purchaser fails to commence the Offer on or prior to the 10th business day following
the date of this Agreement or if Purchaser fails to (x) accept for payment all Shares validly tendered (and not validly withdrawn)
pursuant to the Offer within the period specified in Section 1.1(h) following the expiration of the Offer, (y)&nbsp;purchase all
Shares validly tendered (and not validly withdrawn) pursuant to the Offer within the period specified in Section 1.1(h) following
the Offer Acceptance Time, or (z) otherwise consummate the Offer in accordance with the terms of this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 8.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Effect of Termination</I>. In the event of the termination of this Agreement as provided in <B>&lrm;</B>Section 8.01,
written notice thereof shall be given to the other Party or Parties, specifying the provision hereof pursuant to which such termination
is made, and this Agreement shall be of no further force or effect and there shall be no liability on the part of Parent, Purchaser
or the Company or any of their respective former, current or future officers, directors, partners, stockholders, managers, members
or Affiliates following any such termination; <I>provided</I>, <I>however</I>, that (a) the final sentence of <B>&lrm;</B>Section
1.02(b), the final sentence of <B>&lrm;</B>Section 5.01(a), this <B>&lrm;</B>Section 8.02, <B>&lrm;</B>Section 8.03 and <B>&lrm;</B>Article
9 (other than <B>&lrm;</B>Section 9.05(b)) shall survive the termination of this Agreement and shall remain in full force and
effect, (b) the Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect
in accordance with its terms and (c) except as set forth in <B>&lrm;</B>Section 8.03, the termination of this Agreement shall
not relieve any Party from any liability for fraud or willful and material breach of this Agreement prior to termination.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 8.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Expenses; Termination Fees</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as set forth in this <B>&lrm;</B>Section 8.03, all fees and expenses incurred in connection with this Agreement
and the Transactions shall be paid by the Party incurring such expenses, whether or not the Offer and Merger are consummated.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>In the event that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>this Agreement is terminated by the Company pursuant to <B><I>&lrm;</I></B>Section 8.01(e), the Company shall pay to Parent
or its designee the Termination Fee by wire transfer of same day funds prior to or simultaneously with (and as a condition to
the effectiveness of) such termination;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>this Agreement is terminated by Parent pursuant to <B><I>&lrm;</I></B>Section 8.01(d), the Company shall pay to Parent
or its designee the Termination Fee by wire transfer of same day funds within one business day after such termination; or</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp; </FONT>(x)
this Agreement is terminated by Parent or the Company pursuant to Section 8.01(b) (but in the case of a termination by the
Company, only if at such time Parent would not be prohibited from terminating this Agreement pursuant to Section 8.01(b)(ii))
or by Parent pursuant to Section 8.01(f) resulting from a willful and material breach of Section 5.03 or Section 6.01, (y)
any Person shall have publicly disclosed a <I>bona fide </I>Acquisition Proposal, or such Acquisition Proposal has otherwise
been communicated to the Board of Directors or the Company&rsquo;s stockholders and shall have become publicly known, after
the date hereof and prior to such termination, and such Acquisition Proposal has not been unconditionally withdrawn prior to
such termination and (z) within twelve (12) months of such termination, the Board of Directors shall have approved or
recommended any Acquisition Proposal (regardless of when made) and the Company shall have entered into a definitive agreement
with respect to such Acquisition Proposal, which shall have been consummated (<I>provided</I> that for purposes of this <U>clause
(z) </U>the references to &ldquo;20%&rdquo; in the definition of &ldquo;Acquisition Proposal&rdquo; shall be deemed to be
references to &ldquo;50%&rdquo;), the Company shall pay to Parent or its designee the Termination Fee by wire transfer of
same day funds prior to the consummation of such Acquisition Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>It is understood that in no event shall the Company be required to pay the Termination Fee on more than one occasion. As
used herein, &ldquo;<U>Termination Fee</U>&rdquo; shall mean a cash amount equal to $732,052,638</FONT>. <FONT STYLE="font-size: 10pt">In
any circumstance in which the Termination Fee becomes due and payable and is paid by the Company in accordance with this <B>&lrm;</B>Section
8.03, the Termination Fee shall be deemed to be liquidated damages for, and the sole and exclusive monetary remedy available to
Parent and Purchaser in connection with, any and all losses or damages suffered or incurred by Parent, Purchaser, any of their
respective Affiliates or any other Person in connection with this Agreement (collectively, &ldquo;<U>Parent Related Parties</U>&rdquo;)
(and the termination hereof), the Transactions (and the abandonment thereof) or any matter forming the basis for such termination,
and none of Parent, Purchaser or any of their respective Affiliates shall be entitled to bring or maintain any claim, action or
proceeding against the Company or any of its Affiliates arising out of or in connection with this Agreement, any of the Transactions
or any matters forming the basis for such termination. For the avoidance of doubt, Parent and Purchaser may seek specific performance
to cause the Company to consummate the Transactions in accordance with <B>&lrm;</B>Section 9.05 or the payment of the Termination
Fee pursuant to this <B>&lrm;</B>Section 8.03(c), but in no event shall Parent or Purchaser be entitled to both (i) specific performance
to cause the Company to consummate the Transactions in accordance with <B>&lrm;</B>Section 9.05 and (ii) the payment of the Termination
Fee pursuant to this <B>&lrm;</B>Section 8.03(c).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Parent&rsquo;s right to receive payment from the Company of the Termination Fee and any other payments pursuant to <B>&lrm;</B>Section
8.03 shall be the sole and exclusive remedy of the Parent Related Parties against the Company and any of their respective former,
current or future officers, directors, partners, stockholders, optionholders, managers, members or Affiliates (collectively, &ldquo;<U>Company
Related Parties</U>&rdquo;) for any loss suffered as a result of the failure of the Offer or the Merger to be consummated or for
a breach or failure to perform hereunder or otherwise, and upon payment of such amount(s), none of the Company Related Parties
shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Parties acknowledge (i) that the agreements contained in this <B>&lrm;</B>Section 8.03 are an integral part of the
transactions contemplated by this Agreement, (ii) that the Termination Fee is not a penalty, but a reasonable amount that will
compensate Parent and Purchaser in the</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">circumstances
in which such payment is payable for the efforts and resources expended and opportunities foregone while negotiating this Agreement
and in reliance on this Agreement and on the expectation of the consummation of the Transactions and (iii) that, without these
agreements, the Parties would not enter into this Agreement; accordingly, if the Company fails to timely pay any amount due pursuant
to <B>&lrm;</B>Section 8.03(b), and, in order to obtain the payment, Parent commences a Legal Proceeding which results in a judgment
against the Company, the Company shall pay Parent its reasonable and documented costs and expenses (including reasonable and documented
attorneys&rsquo; fees) in connection with such suit, together with interest on such amount at the prime rate as published in the
Wall Street Journal in effect on the date such payment was required to be made through the date such payment was actually received.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">Article
9<BR>
MISCELLANEOUS PROVISIONS</FONT></P>

<P STYLE="font: small-caps 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.01.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Amendment</I>. Prior to the Offer Acceptance Time, this Agreement may be amended with the approval of the respective
Boards of Directors of the Company, Parent and Purchaser at any time; <I>provided </I>that, following the consummation of the
Offer, this Agreement may not be amended in any manner that causes the Merger Consideration to differ from the Offer Price. This
Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.02.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Waiver</I>. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate
as a waiver of such power, right, privilege or remedy. No single or partial exercise of any such power, right, privilege or remedy
shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No Party shall be deemed
to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless
the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered
on behalf of such Party and any such waiver or failure to insist on strict compliance with an obligation, covenant, agreement
or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. At any time prior
to the Offer Acceptance Time, Parent and Purchaser, on the one hand, and the Company, on the other hand, may (a) extend the time
for the performance of any of the obligations or other acts of the other, (b) waive any breach of the representations and warranties
of the other contained herein or in any document delivered pursuant hereto or (c) waive compliance by the other with any of the
agreements or covenants contained herein. Any such extension or waiver shall be valid only if is expressly set forth in a written
instrument duly executed and delivered on behalf of the Party or Parties to be bound thereby, but such extension or waiver or
failure to insist on strict compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of,
or estoppel with respect to, any subsequent or other failure. The rights and remedies provided herein shall be cumulative and
not exclusive of any rights or remedies provided by any Legal Requirement except to the extent set forth in <B>&lrm;</B>Section
8.03.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.03.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>No Survival of Representations and Warranties</I>. None of the representations and warranties contained in this Agreement,
the Company Disclosure Schedule or in any certificate or schedule or other document delivered by any Person pursuant to this Agreement
shall survive the Merger.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.04.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Entire Agreement; Counterparts</I>. This Agreement (including its Exhibits, Annexes and the Company Disclosure Schedule)
and the Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings, both
written and oral, among or between any of the Parties and their respective Affiliates, with respect to the subject matter hereof
and thereof. The Confidentiality Agreement shall survive the execution and delivery of this Agreement except that the restrictions
on disclosure (to the extent to be included in SEC filings in connection with the Transactions) in the Confidentiality Agreement
shall terminate immediately following the execution and delivery of this Agreement solely for purposes of permitting the actions
contemplated hereby to be consummated. This Agreement may be executed in one or more counterparts, including by facsimile or by
email with .pdf attachments, all of which shall be considered one and the same agreement, and shall become effective when one
or more counterparts have been signed by each of the Parties and delivered to the other Parties.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.05.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts of laws thereof. In any action or proceeding arising
out of or relating to this Agreement or any of the Transactions: (i) each of the Parties irrevocably and unconditionally consents
and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and any state appellate court
therefrom or, if (but only if) such court lacks subject matter jurisdiction, the United States District Court sitting in New Castle
County in the State of Delaware and any appellate court therefrom (collectively, the &ldquo;<U>Delaware Courts</U>&rdquo;); and
(ii) each of the Parties irrevocably consents to service of process by first class certified mail, return receipt requested, postage
prepaid, to the address at which such Party is to receive notice in accordance with <B>&lrm;</B>Section 9.09. Each of the Parties
irrevocably and unconditionally (1) agrees not to commence any such action or proceeding except in the Delaware Courts, (2) agrees
that any claim in respect of any such action or proceeding may be heard and determined in the Delaware Courts, (3) waives, to
the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction or
laying of venue of any such action or proceeding in the Delaware Courts and (4) waives, to the fullest extent permitted by law,
the defense of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. The Parties agree
that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit
on the judgment or in any other manner provided by applicable Legal Requirements; <I>provided</I>, <I>however</I>, that nothing
in the foregoing shall restrict any Party&rsquo;s rights to seek any post-judgment relief regarding, or any appeal from, such
final trial court judgment.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy,
would occur in the event that the Parties do not perform their obligations under the provisions of this Agreement in accordance
with its specified terms or otherwise breach such provisions. The Parties acknowledge and agree that (i) the Parties shall be
entitled to an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches of this Agreement
and to enforce specifically the terms and provisions hereof in the courts described in <B>&lrm;</B>Section 9.05(a) without proof
of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement, and (ii)
the right of specific performance is an integral part of the Transactions and without that right, neither the Company nor Parent
would have entered into this Agreement. The right to specific enforcement hereunder shall include the right of the Company, on
behalf of itself and any third party</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">beneficiaries
to this Agreement, to cause Parent and Purchaser to cause the Offer, the Merger and the other Transactions to be consummated on
the terms and subject to the conditions set forth in this Agreement. Each of the Parties agrees that it will not oppose the granting
of an injunction, specific performance and other equitable relief on the basis that the other Parties have an adequate remedy
at law or an award of specific performance is not an appropriate remedy for any reason at law or equity. The Parties acknowledge
and agree that any Party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement in accordance with this <B>&lrm;</B>Section 9.05(b) shall not be required to provide
any bond or other security in connection with any such order or injunction.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES (WHETHER
BASED ON CONTRACT, TORT OR OTHERWISE), INCLUDING ANY COUNTERCLAIM, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF.
EACH PARTY (I) MAKES THIS WAIVER VOLUNTARILY AND (II) ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN THIS <B>&lrm;</B>SECTION 9.05.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.06.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Assignability</I>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit
of, the Parties and their respective successors and permitted assigns; <I>provided</I>, <I>however</I>, that neither this Agreement
nor any of the rights hereunder may be assigned by a Party without the prior written consent of the other Parties, and any attempted
assignment of this Agreement or any of such rights without such consent shall be void and of no effect; <I>provided further</I>,
<I>however</I>, that Parent may designate, by written notice to the Company, another wholly-owned direct or indirect Delaware
corporate Subsidiary of Parent to act as Purchaser, in which event all references to Purchaser in this Agreement shall be deemed
references to such other Subsidiary; <I>provided </I>such assignment shall not impede or delay the consummation of the Transactions
or relieve Parent of its obligations hereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.07.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>No Third Party Beneficiaries</I>. Nothing in this Agreement, express or implied, is intended to or shall confer upon
any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement;
except for: (a) if the Offer Acceptance Time occurs, (i) the right of the Company&rsquo;s stockholders to receive the Offer Price
or Merger Consideration, as applicable, pursuant to <B>&lrm;</B>Article 1 or <B>&lrm;</B>Article 2 following the Offer Acceptance
Time or the Effective Time, as applicable, in accordance with the terms of this Agreement, and (ii) the right of the holders of
Company Options or Company RSUs to receive the applicable treatment pursuant to <B>&lrm;</B>Section 2.08 following the Effective
Time in accordance with the terms of this Agreement; (b) the provisions set forth in <B>&lrm;</B>Section 6.05 of this Agreement
with respect to the Persons referred to therein; and (c) the right of the Company to pursue damages, on behalf of its stockholders,
against Parent and/or Purchaser for the loss of the Merger Consideration in the event of any breach of this Agreement by Parent
or Purchaser.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.08.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Transfer Taxes</I>. Except as otherwise provided in <B>&lrm;</B>Section 2.06(b), all transfer, documentary, sales, use,
stamp, registration and other similar Taxes and fees imposed on the Company with respect to the transfer of Shares pursuant to
the Offer or the Merger shall be borne by the Company and expressly shall not be a liability of holders of Shares, expressly excluding
any such Taxes imposed on the holders of Shares. The Company shall cooperate with</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">Purchaser and
Parent in preparing, executing and filing any Tax Returns with respect to such Taxes.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.09.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Notices</I>. Any notice or other communication required or permitted to be delivered to any Party under this Agreement
shall be in writing and shall be deemed properly delivered, given and received (a) upon receipt when delivered by hand, (b) two
business days after being sent by registered mail or by courier or express delivery service, or (c) upon confirmation of successful
transmission if sent by email followed up within one business day by dispatch pursuant to one of the other methods described herein;
<I>provided </I>that in each case the notice or other communication is sent to the physical address or email address set forth
beneath the name of such Party below (or to such other physical address or email address as such Party shall have specified in
a written notice given to the other Parties):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">if to Parent
or Purchaser (or following the Effective Time, the Surviving Corporation):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Gilead Sciences, Inc.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">333 Lakeside Drive&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Foster City, California
94404</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Attention: General Counsel&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Email:&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="color: Blue"><U>generalcounsel@gilead.com</U></FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">with a copy
(which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Davis Polk &amp; Wardwell
LLP</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">450 Lexington Avenue&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">New York, NY 10017</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Attention: &#9;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: -11pt 0pt 0pt 1.75in"><FONT STYLE="font-size: 10pt">Marc O.
Williams&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in"><FONT STYLE="font-size: 10pt">Cheryl
Chan</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Email:&#9;<FONT STYLE="color: blue"><U></U></FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: -11pt 0pt 0pt 1.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="color: blue"><U>marc.williams@davispolk.com</U></FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt; color: Blue"><U>cheryl.chan@davispolk.com</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; color: blue; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">if to the
Company (prior to the Effective Time):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 249pt 0pt 1in">Immunomedics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 249pt 0pt 1in">300 The American Road,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 249pt 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 214pt 0pt 1in">Morris Plains, New Jersey 07950</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 214pt 0pt 1in">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jared
Freedberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 214pt 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="color: blue"><U>jfreedberg@immunomedics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">with a copy
(which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Wachtell, Lipton, Rosen&nbsp;&amp; Katz</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">51 West 52nd Street&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">New York, New York 10019</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Attention: &#9;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: -11pt 0pt 0pt 1.75in"><FONT STYLE="font-size: 10pt">Adam O.
Emmerich&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in"><FONT STYLE="font-size: 10pt">Victor
Goldfeld</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Email:&#9;<FONT STYLE="color: blue"><U></U></FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: -11pt 0pt 0pt 1.5in"><FONT STYLE="font-size: 10pt"><FONT STYLE="color: blue"><U>aoemmerich@wlrk.com</U></FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt; color: Blue"><U>vgoldfeld@wlrk.com</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; color: blue; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Severability</I>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability
of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">of a court
of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree
that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases
or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing
the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified.
In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid
or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the
economic, business and other purposes of such invalid or unenforceable term or provision.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Obligation of Parent</I>. Parent shall ensure that Purchaser duly performs, satisfies and discharges on a timely basis
each of the covenants, obligations and liabilities applicable to Purchaser under this Agreement, and Parent shall be jointly and
severally liable with Purchaser for the due and timely performance and satisfaction of each of said covenants, obligations and
liabilities.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section 9.12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT><I>Construction</I>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa;
the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter
genders; and the neuter gender shall include masculine and feminine genders.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting
Party shall not be applied in the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>As used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, shall not
be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Except as otherwise indicated, all references in this Agreement to &ldquo;Sections,&rdquo; &ldquo;Exhibits&rdquo; or &ldquo;Annexes&rdquo;
are intended to refer to Sections of this Agreement and Exhibits or Annexes to this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a
part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The term &ldquo;dollars&rdquo; and character &ldquo;$&rdquo; shall mean United States dollars.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>Signature
page follows</I>]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>IN WITNESS
WHEREOF</B>, the Parties have caused this Agreement to be executed as of the date first above written.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt"><B>IMMUNOMEDICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Jared Freedberg</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-size: 10pt">Jared Freedberg</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel and Corporate Secretary</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt"><B>GIILEAD SCIENCES, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Daniel O&rsquo;Day</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-size: 10pt">Daniel O&rsquo;Day</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><I>[Signature Page to Agreement and Plan of Merger]</I></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt"><B>MAUI MERGER SUB, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Christina Carlson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-size: 10pt">Christina Carlson</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assistant Secretary&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Agreement and Plan of Merger]</I></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">Exhibit
A</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Certain
Definitions</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For purposes
of the Agreement (including this <B><U>Exhibit A</U></B>):</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Acceptable
Confidentiality Agreement</B>&rdquo; shall mean any customary confidentiality agreement that is (a) in effect as of the execution
and delivery of this Agreement or (b) executed, delivered and effective after the execution and delivery of this Agreement that
(i) contains provisions that are not less favorable in the aggregate to the Company than those contained in the Confidentiality
Agreement (it being understood that such agreement need not contain any &ldquo;standstill&rdquo; or similar provisions or otherwise
prohibit the making of any Acquisition Proposal) and (ii) does not prohibit the Company from providing any information to Parent
in accordance with <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 5.03.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Acquired Companies</B>&rdquo;
shall mean the Company and each of its Subsidiaries (including, for the avoidance of doubt, IBC Pharmaceuticals, Inc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Acquisition Proposal</B>&rdquo;
shall mean any proposal or offer from any Person (other than Parent and its Affiliates) or &ldquo;group&rdquo;, within the meaning
of Section 13(d) of the Exchange Act, including any amendment or modification to any existing proposal or offer, relating to, in
a single transaction or series of related transactions, any (i) acquisition or license of assets of the Acquired Companies equal
to 20% or more of the Acquired Companies&rsquo; consolidated assets, (ii) acquisition or exclusive license of the Product Candidates,
(iii) issuance or acquisition of 20% or more of the outstanding Company Common Stock or 20% or more of any class of equity securities
of one or more Acquired Companies whose assets, individually or in the aggregate, constitute 20% or more of the consolidated assets
of the Acquired Companies, (iv) recapitalization, tender offer or exchange offer that if consummated would result in any Person
or group beneficially owning 20% or more of the outstanding Company Common Stock or 20% or more of any class of equity securities
of one or more Acquired Companies whose assets, individually or in the aggregate, constitute 20% or more of the consolidated assets
of the Acquired Companies or (v) merger, consolidation, amalgamation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction involving the Company that if consummated would result in any Person or group beneficially owning
20% or more of the outstanding Company Common Stock or 20% or more of any class of equity securities of one or more Acquired Companies
whose assets, individually or in the aggregate, constitute 20% or more of the consolidated assets of the Acquired Companies, in
each case other than the Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo; shall
mean, as to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common control
with, such Person. For this purpose, &ldquo;control&rdquo; (including, with its correlative meanings, &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo;) shall mean the possession, directly or indirectly, of the power to direct or cause
the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership
interests, by Contract or otherwise; provided, that the Persons set forth on Section 9.13 of the Company Disclosure Schedule shall
not be deemed to be Affiliates of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Agreement</B>&rdquo;
is defined in the preamble to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Anti-Corruption
Laws</B>&rdquo; shall mean the Foreign Corrupt Practices Act of 1977, as amended, the Anti-Kickback Act of 1986, as amended, the
UK Bribery Act of 2012, and the Anti-Bribery Laws of the People&rsquo;s Republic of China or any applicable Legal Requirements
of similar effect, and the related regulations and published interpretations thereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Antitrust
Laws</B>&rdquo; shall mean the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission
Act, as amended, all applicable foreign antitrust laws and all other applicable Legal Requirements issued by a Governmental Body
that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint
of trade or lessening of competition.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Board
of Directors</B>&rdquo; is defined in <U>Recital <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(C)</U>
to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Book-Entry
Shares</B>&rdquo; shall mean non-certificated Shares represented by book-entry.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>business
day</B>&rdquo; has the meaning set forth in Rule 14d-1(g)(3) of the Exchange Act; <I>provided, however</I>, that any day on which
banks in the City of New York are authorized or required by Legal Requirements to be closed shall not be a &ldquo;business day&rdquo;.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Capitalization
Date</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.03(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Certificates</B>&rdquo;
is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.06(b) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Change
of Control Payment</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.10(a)(vii)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Closing</B>&rdquo;
is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.03(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Closing
Date</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.03(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>CMS</B>&rdquo;
is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.02(d) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Code</B>&rdquo;
shall mean the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Collaboration
Partner</B>&rdquo; is defined in <U>Section 3.13(b)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company</B>&rdquo;
is defined in the preamble to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Adverse Change Recommendation</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section
6.01(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Associate</B>&rdquo; shall mean each current and former officer or other employee, or individual who is or was at any time an
independent contractor, consultant or director, of or to any Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Board Recommendation</B>&rdquo; is defined in <U>Recital (C)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0.5in">&ldquo;<B>Company Bonus Plan</B>&rdquo; shall mean
the Immunomedics, Inc. Annual Cash Bonus Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Common Stock</B>&rdquo; shall mean the common stock, $0.01 par value per share, of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Disclosure Documents</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.05(g)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Disclosure Schedule</B>&rdquo; shall mean the disclosure schedule that has been prepared by the Company in accordance with the
requirements of the Agreement and that has been delivered by the Company to Parent on the date of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Equity Plans</B>&rdquo;
shall mean the Immunomedics, Inc. 2014 Long-Term Incentive Plan and the Immunomedics, Inc. Amended &amp; Restated 2014 Long-Term
Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Company ESPP</B>&rdquo; shall mean the
Immunomedics, Inc. 2020 Employee Stock Purchase Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Company IP</B>&rdquo; shall mean
any and all Intellectual Property Rights owned or purported to be owned by any Acquired Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Company IT Assets</B>&rdquo;
shall mean computers, computer software, firmware, middleware, servers, workstations, routers, hubs, switches, data communications
lines and all other information technology equipment, and all associated documentation owned by any Acquired Company or licensed
or leased by any Acquired Company (excluding any public networks).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Company Licensed IP</B>&rdquo;
shall mean any and all Intellectual Property Rights owned by a third party and exclusively licensed to any Acquired Company for
a Product Candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Options</B>&rdquo; shall mean all options to purchase Shares (whether granted by the Company pursuant to the Company Equity Plans,
assumed by the Company in connection with any merger, acquisition or similar transaction or otherwise issued or granted).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Preferred Stock</B>&rdquo; shall mean the preferred stock, $0.01 par value per share, of the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Related Parties</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 8.03(d)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
Returns</B>&rdquo; is defined in <U>Section 3.16(a)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
RSUs</B>&rdquo; shall mean all restricted stock units to acquire Shares (whether granted by the Company pursuant to the Company
Equity Plans, assumed by the Company in connection with any merger, acquisition or similar transaction or otherwise issued or
granted).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Company
SEC Documents</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.05 of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Confidentiality
Agreement</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 5.01(a) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Consent</B>&rdquo;
shall mean any approval, consent, ratification, permission, waiver or authorization.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Continuing
Employees</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.03 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Contract</B>&rdquo;
shall mean any written binding agreement, contract, subcontract, lease, settlement agreement, understanding, instrument, loan,
credit agreement, bond, debenture, note, option, warrant, license, sublicense, commitment or undertaking, but shall not include
any Employee Plan.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Copyrights</B>&rdquo;
is defined in the definition of Intellectual Property Rights.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>COVID-19</B>&rdquo;
shall mean SARS-CoV-2 or COVID-19, and any evolutions thereof or related or associated epidemics, pandemic or disease outbreaks.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>COVID -19 Measures</B>&rdquo;
shall mean any quarantine, &ldquo;shelter in place,&rdquo; &ldquo;stay at home,&rdquo; social distancing, shut down, closure, sequester
or any other Law, decree, judgment, injunction or other order, directive, guidelines or recommendations by any Governmental Body
in connection with or in response to COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Delaware
Courts</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 9.05(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Depository
Agent</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.06(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Determination
Notice</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.01(b)(i) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>DGCL</B>&rdquo;
shall mean the Delaware General Corporation Law, as amended.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Dissenting
Shares</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.07 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>DOJ</B>&rdquo;
shall mean the U.S. Department of Justice.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Effective
Time</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.03(b) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>EMA</B>&rdquo;
is defined in <U>Section 3.13(a)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Employee
Plan</B>&rdquo; shall mean each deferred compensation and each bonus or other incentive compensation, stock purchase, stock option
and other equity and equity-linked compensation plan, program, agreement or arrangement; each severance or termination pay, medical,
surgical, hospitalization, life insurance, disability, paid time off, and other &ldquo;welfare&rdquo; plan, fund or program (within
the meaning of section 3(1) of ERISA (whether or not subject to ERISA)); each profit sharing, stock bonus or other &ldquo;pension&rdquo;
plan, fund or program (within the meaning of section 3(2) of ERISA (whether or not subject to ERISA)); each employment, consulting,
termination, severance, change in control, retention or similar agreement; and each other employee benefit plan, fund, program,
agreement or arrangement, in each case, that is sponsored, maintained or contributed to or required to be contributed to by any
Acquired Company or by any trade or business, whether or not incorporated, that together with any Acquired Company would be deemed
a &ldquo;single employer&rdquo; within the meaning of section 4001(b) of ERISA (an &ldquo;<B>ERISA Affiliate</B>&rdquo;), or to
which an Acquired Company or an ERISA Affiliate is party, whether written or oral, for the benefit of any employee or former employee
or other individual service provider of any Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Encumbrance</B>&rdquo;
shall mean any lien, pledge, charge, hypothecation, mortgage, security interest, encumbrance, claim, option, right of first refusal,
preemptive right, community property interest or similar restriction of any nature.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>End
Date</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 8.01(b) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Entity</B>&rdquo;
shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint
stock company), firm, society or other enterprise, association, organization or entity.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Environmental
Law</B>&rdquo; shall mean any federal, state, local or foreign Legal Requirement relating to pollution or protection of worker
health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any
Legal Requirement relating to emissions, discharges, Releases or threatened Releases of Hazardous Materials, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>ERISA</B>&rdquo;
shall mean the Employee Retirement Income Security Act of 1974, as amended.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>ERISA
Affiliate</B>&rdquo; is defined in the definition of Employee Plan.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Exchange
Act</B>&rdquo; shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Excluded
Shares</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Expiration
Date</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(c) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Extension
Deadline</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(c) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>FDA</B>&rdquo;
shall mean the United States Food and Drug Administration.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>FDCA</B>&rdquo;
shall mean the Federal Food, Drug and Cosmetic Act, as amended, and all related rules, regulations and guidelines.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Final
Offering</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.04 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Financial
Advisors</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.23 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>FTC</B>&rdquo;
shall mean the U.S. Federal Trade Commission.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>GAAP</B>&rdquo;
is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.05 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Good
Clinical Practices</B>&rdquo; shall mean the FDA&rsquo;s standards for the design, conduct, performance, monitoring, auditing,
recording, analysis, and reporting of clinical trials, including those standards contained in 21 C.F.R. Parts 50, 54, 56 and 312,
and all comparable standards of the EMA and any other applicable Governmental Body or other Entity with authority over the safety,
efficacy, approval, development, testing, labeling, manufacture, storage, marketing, promotion, sale, commercialization, shipment,
import, export or distribution of pharmaceutical products.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Good
Laboratory Practices</B>&rdquo; shall mean the FDA&rsquo;s standards for conducting non-clinical laboratory studies, including
those standards contained in 21 C.F.R. Part 58, and all comparable standards of the EMA and any other applicable Governmental
Body or other Entity with authority over the safety, efficacy, approval, development, testing, labeling, manufacture, storage,
marketing, promotion, sale, commercialization, shipment, import, export or distribution of pharmaceutical products.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Good
Manufacturing Practices</B>&rdquo; shall mean the requirements set forth in the quality systems regulations for drugs contained
in 21 C.F.R. Parts 210 and 211, and all comparable</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">standards of
the EMA and any other applicable Governmental Body or other Entity with authority over the safety, efficacy, approval, development,
testing, labeling, manufacture, storage, marketing, promotion, sale, commercialization, shipment, import, export or distribution
of pharmaceutical products.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Governmental
Authorization</B>&rdquo; shall mean any: permit, license, certificate, approval, consent, grant, franchise, permission, clearance,
registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any
Governmental Body or pursuant to any Legal Requirement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Governmental
Body</B>&rdquo; shall mean any: (i)&nbsp;nation, state, commonwealth, province, territory, county, municipality, district or other
jurisdiction of any nature; (ii)&nbsp;federal, state, local, municipal, foreign, international, multinational, supranational or
other government; or (iii)&nbsp;governmental or quasi-governmental authority of any nature including any governmental division,
department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit or body and
any court, arbitrator or other tribunal.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Hazardous
Materials</B>&rdquo; shall mean any waste, material, or substance that is listed, regulated or defined under any Environmental
Law and includes any pollutant, chemical substance, hazardous substance, hazardous waste, special waste, solid waste, asbestos,
mold, radioactive material, polychlorinated biphenyls, per- and polyfluoroalkyl substances, petroleum or petroleum-derived substance
or waste.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Health
Care Data Requirements</B>&rdquo; is defined in <U>Section 3.13(h)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Health
Care Laws</B>&rdquo; shall mean all health care Legal Requirements applicable to the pricing, reimbursement, safety, efficacy,
approval, development, testing, labeling, manufacture, storage, marketing, promotion, sale, commercialization, import, export
or distribution of pharmaceutical products or otherwise applicable to the operation of the Acquired Companies&rsquo; businesses
as currently conducted and as contemplated by the Acquired Companies to be conducted, including (i) the FDCA and the regulations
promulgated thereunder, including, as applicable, those requirements relating to the FDA&rsquo;s current Good Manufacturing Practices,
Good Laboratory Practices, Good Clinical Practices, investigational use, pre-market approval and applications to market new pharmaceutical
or biological products; (ii) the Clinical Laboratory Improvement Amendments of 1988; (iii)&nbsp;the Health Insurance Portability
and Accountability Act of 1996, the Health Information and Technology for Economic and Clinical Health Act, and the regulations
promulgated pursuant thereto; (iv)&nbsp;the U.S. Patient Protection and Affordable Care Act, (v)&nbsp;the Physician Payment Sunshine
Act (42 U.S.C. &sect; 1320a-7h); (vi) federal and state anti-kickback laws (including the federal Anti-Kickback Statute (42 U.S.C.
&sect; 1320-7(b))); (vii)&nbsp;the Stark Law (42 U.S.C. &sect; 1395nn); (viii)&nbsp;Legal Requirements governing the development,
conduct, monitoring, patient informed consent, auditing, analysis and reporting of clinical trials (including the Good Clinical
Practice regulations and guidance of the FDA); (ix)&nbsp;Legal Requirements governing data gathering activities relating to the
detection, assessment, and understanding of adverse events (including pharmacovigilance and adverse event regulations and guidance
of FDA and the International Conference on Harmonization); (x)&nbsp;the federal Medicare and Medicaid statutes, as applicable;
(xi)&nbsp;any Legal Requirement the violation of which is cause for exclusion from any federal health care program; and (xii)&nbsp;all
comparable state, federal or foreign Legal Requirements relating to any of the foregoing, including Regulation (EC) No 726/2004.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>HIPAA</B>&rdquo;
is defined in <U>Section 3.13(h)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>HITECH</B>&rdquo;
is defined in <U>Section 3.13(h)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>HSR
Act</B>&rdquo; shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.5in">&ldquo;<B>In-bound License</B>&rdquo;
shall mean any and all Contracts to which any Acquired Company is a party, or by which it is bound the primary or a material subject
of which is the licensing, assignment or other conveyance or grant of Intellectual Property Rights, pursuant to which any Acquired
Company is granted any license, non-assert, option, or other rights to (including rights to use, register, or enforce), or assigned,
sold, conveyed or otherwise transferred any rights in, to or under, any Intellectual Property Rights that are material to the operation
of the business of the Acquired Companies, and that remains in effect as of the date of this Agreement. Notwithstanding the foregoing,
&ldquo;In-bound License&rdquo; excludes agreements (and such agreement are deemed not material) entered into in the ordinary course
of business consistent with past practice, such as personnel agreements, licenses to IT, ERP or accounting systems, and commercially
available software agreements, clinical trial agreements and material transfer agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Indebtedness</B>&rdquo; shall
mean (i) any indebtedness for borrowed money (including the issuance of any debt security) to any Person, including all liabilities
under any lease which has been recorded as a capital lease, (ii) any obligations evidenced by notes, bonds, debentures or similar
Contracts to any Person other than any Acquired Company, (iii) any obligations in respect of letters of credit (including standby
and commercial) and bankers&rsquo; acceptances (other than letters of credit used as security for leases), bank guarantees, surety
bonds and similar instruments, in each case to the extent drawn upon, including the principal, interest and fees owing thereon,
(iv) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property
acquired or deferred purchase price of property or services (other than trade accounts payable in the ordinary course), (v) net
obligations of any interest rate, swap, currency swap, forward currency or interest rate Contracts or other interest rate or currency
hedging arrangements, or (vi) any guaranty of any such obligations described in <U>clauses (i)</U> through <U>(v)</U> of any Person
other than any Acquired Company (other than, in any case, accounts payable to trade creditors and accrued expenses, in each case,
arising in the ordinary course of business); <I>provided, however</I>, that no agreements, understandings or other arrangements
exclusively by and between the Company and its wholly owned Subsidiaries shall be deemed to be Indebtedness for purposes of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Indemnified
Persons</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.05(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Initial
Expiration Date</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(c)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Intellectual Property
Rights</B>&rdquo; shall mean all intellectual property and industrial property rights of every kind and description throughout
the world, including the rights associated with all U.S. and foreign (i) patents, patent applications, invention disclosures, and
all related continuations, continuations-in -part, divisionals, reissues, re-examinations, substitutions, and extensions thereof
(&ldquo;<U>Patents</U>&rdquo;), (ii) trademarks, service marks, names, corporate names, trade names, domain names, URLs, social
media addresses, logos, slogans, trade dress, design rights, and other similar designations of source or origin, together with
the goodwill symbolized by any of the foregoing (&ldquo;<U>Trademarks</U>&rdquo;), (iii) copyrights in copyrightable subject matter
(&ldquo;<U>Copyrights</U>&rdquo;), (iv) trade secrets or rights in confidential information or know-how (&ldquo;<U>Trade Secrets</U>&rdquo;)
and (v) all applications and registrations for any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Intervening
Event</B>&rdquo; shall mean an event, occurrence, fact or change that materially affects the business, assets or operations of
the Acquired Companies (other than any event,</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">occurrence,
fact or change resulting from a breach of this Agreement by the Company) occurring or arising after the date hereof that was not
known or reasonably foreseeable to the Board of Directors as of the date hereof, which event, occurrence, fact or change becomes
known to the Board of Directors prior to the Offer Acceptance Time, other than (i)&nbsp;changes in the Company Common Stock price,
in and of itself (however, the underlying reasons for such changes may constitute an Intervening Event), (ii)&nbsp;any Acquisition
Proposal or (iii)&nbsp;the fact that, in and of itself, the Company exceeds any internal or published projections, estimates or
expectations of the Company&rsquo;s revenue, earnings or other financial performance or results of operations for any period,
in and of itself (however, the underlying reasons for such events may constitute an Intervening Event).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>IRS</B>&rdquo;
shall mean the Internal Revenue Service.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>ISRA</B>&rdquo; is defined in Section 5.04
of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>knowledge</B>&rdquo;
with respect to an Entity shall mean with respect to any matter in question the actual knowledge of such Entity&rsquo;s executive
officers.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Leased
Real Property</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.08(b) of
the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Legal
Proceeding</B>&rdquo; shall mean any action, suit, complaint, litigation, arbitration or any administrative proceeding (including
any civil, criminal, administrative, investigative or appellate proceeding) commenced, brought, conducted or heard by or before,
or otherwise involving, any Governmental Body.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Legal
Requirement</B>&rdquo; shall mean any federal, state, local, municipal, foreign, international, multinational, supranational,
or other law, statute, constitution, resolution, ordinance, common law, code, edict, decree, rule, regulation, ruling, treaty,
order or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority
of any Governmental Body (or under the authority of NASDAQ or other stock exchange).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 41pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Licensed Registered IP</B>&rdquo;
shall mean all Registered IP included in the Company Licensed IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 41pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Material Adverse Effect</B>&rdquo;
shall mean any change, circumstance, condition, development, effect, event, occurrence or state of facts which, individually or
when taken together with all other events, occurrences, circumstances, changes, conditions, states of facts, developments or effects
that have occurred in the applicable determination period for a Material Adverse Effect, has had or would reasonably be expected
to have a material adverse effect on the business, assets, financial condition or results of operations of the Acquired Companies,
taken as a whole; <I>provided</I>, <I>however</I>, that no change, circumstance, condition, development, effect, event, occurrence
or state of facts to the extent resulting from or relating to any of the following shall be deemed to constitute or be taken into
account in determining whether there is, or would reasonably be expected to be, a Material Adverse Effect: (i) any change in the
market price or trading volume of the Company&rsquo;s stock or change in the Company&rsquo;s credit ratings; <I>provided</I> that
the underlying causes of any such change may be considered in determining whether a Material Adverse Effect has occurred to the
extent not otherwise excluded by another exception herein; (ii) any event, occurrence, circumstance, change or effect resulting
from the announcement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">pendency or performance of the Transactions (other than for
purposes of any representation or warranty contained in Section 3.22 and the condition set forth in <U>clause (b)(iv)</U> of <U>Annex
I</U> solely as such condition relates to Section 3.22, but in any event subject to the disclosures set forth in the Company Disclosure
Schedule); (iii) any event, occurrence, circumstance, change or effect generally affecting the industries in which the Acquired
Companies operate, or in the economy generally or other general business, financial or market conditions; (iv) any event, occurrence,
circumstance, change or effect arising directly or indirectly from or otherwise relating to fluctuations in the value of any currency
or interest rates; (v) any change, circumstance, condition, development, effect, event, occurrence or state of facts arising directly
or indirectly from or otherwise relating to any act of terrorism, war, national or international calamity, natural disaster, pandemic,
epidemic or disease outbreak (including COVID-19) or any other similar event; (vi)&nbsp;the failure of the Company to meet internal
or analysts&rsquo; expectations or projections; <I>provided</I> that the underlying causes of such failure may be considered in
determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception herein; (vii)&nbsp;any
adverse effect arising from or otherwise relating to (x) any action taken or omitted to be taken by the Company at the written
direction of Parent or where the Company has requested Parent&rsquo;s consent in accordance with Section 5.02 and Parent has unreasonably
withheld, conditioned or delayed such consent or (y) compliance with Section 6.02; (viii) any change, circumstance, condition,
development, effect, event, occurrence or state of facts arising directly or indirectly from or otherwise relating to a change
in, or action taken required to comply with any change in any Legal Requirement (including COVID-19 Measures) or GAAP; (ix) any
event, occurrence, circumstance, change or effect resulting or arising from the identity Parent or Purchaser as the acquiror of
the Company; or (x) any regulatory, clinical or manufacturing events, occurrences, circumstances, changes, effects or developments
relating to any Product Candidate, in each case, not involving any wrongdoing by any Acquired Company or any of their respective
Affiliates or Representatives, or with respect to any product of any competitor of the Company (including, in each case, for the
avoidance of doubt, with respect to any pre-clinical or clinical studies, tests or results or announcements thereof, any increased
incidence or severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports
of new side effects, adverse events or safety observations); <I>provided</I> that the underlying causes of any such change may
be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception
herein; <I>provided</I> that any change, circumstance, condition, development, effect, event, occurrence or state of facts referred
to in the foregoing <U>clauses (iii)</U>, <U>(iv)</U>, <U>(v)</U> and <U>(viii)</U> may be taken into account in determining whether
there is, or would be reasonably expected to be, a Material Adverse Effect to the extent such change, circumstance, condition,
development, effect, event, occurrence or state of facts disproportionately affects the Acquired Companies relative to other participants
in the industries in which the Acquired Companies operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0"></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Material
Contract</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.10 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Maximum
Amount</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.05(b) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Merger</B>&rdquo;
is defined in <U>Recital <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(B)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Merger
Consideration</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.05(a)(iii)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Minimum
Condition</B>&rdquo; is defined in <U>Annex I</U> to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>NASDAQ</B>&rdquo;
shall mean Nasdaq Stock Market LLC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer</B>&rdquo;
is defined in <U>Recital (A)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer
Acceptance Time</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(h)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer
Commencement Date</B>&rdquo; shall mean the date on which Purchaser commences the Offer, within the meaning of Rule 14d-2 under
the Exchange Act.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer
Conditions</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(b) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer
Documents</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(e) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer
Price</B>&rdquo; is defined in <U>Recital <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(A)</U> of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Offer
to Purchase</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(b) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 92pt 0pt 0.5in">&ldquo;<B>Offering</B>&rdquo; is defined in Section
6.04 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 92pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Ordinary 2020 Bonus Payment Date</B>&rdquo;
is defined in Section 6.03(f) of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Out-bound License</B>&rdquo;
shall mean any and all Contracts to which any Acquired Company is a party, or by which it is bound pursuant to which any Acquired
Company grants any license, non-assert, option, or other rights (including rights to use, register, or enforce) to, or assigned,
sold, conveyed or otherwise transferred any rights in, to or under, any material Intellectual Property Rights, to any third party,
and that remains in effect as of the date of this Agreement. Notwithstanding the foregoing, &ldquo;Out-bound License&rdquo; excludes
agreements entered into in the ordinary course of business consistent with past practice, such as clinical trial agreements, contract
service agreements and material transfer agreements, in each case pursuant to standard form agreements entered into in the ordinary
course of business consistent with past practice or that are not otherwise material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Owned
Registered IP</B>&rdquo; shall mean all Registered IP owned or purported to be owned by any Acquired Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Parent</B>&rdquo;
is defined in the preamble to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Parent
401(k) Plan</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 6.13 of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Parent
Material Adverse Effect</B>&rdquo; shall mean any change, circumstance, condition, development, effect, event, occurrence or state
of facts which, individually or when taken together with all other events, occurrences, circumstances, changes, conditions, states
of facts, developments or effects that have occurred in the applicable determination period for a Parent Material Adverse Effect,
would or would reasonably be expected to materially impair, prevent or materially delay Parent&rsquo;s or Purchaser&rsquo;s ability
to consummate the Transactions prior to the End Date on the terms set forth in this Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Parent
Related Parties</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 8.03(c)
of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Parties</B>&rdquo;
shall mean Parent, Purchaser, and the Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Patents</B>&rdquo;
is defined in the definition of Intellectual Property Rights.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Paying
Agent</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.06(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Payment
Fund</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 2.06(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Permitted
Encumbrance</B>&rdquo; shall mean (a) any Encumbrance for Taxes (i) that are not due and payable or (ii) the validity of which
is being contested in good faith by appropriate proceedings and for which adequate reserves have been established in accordance
with GAAP in the Company&rsquo;s latest financial statements included in the Company SEC Documents, (b) mechanics&rsquo;, materialmen&rsquo;s,
carriers&rsquo;, workmen&rsquo;s, warehouseman&rsquo;s, repairmen&rsquo;s, landlords&rsquo; and similar liens granted or which
arise in the ordinary course of business consistent with past practice, (c) in the case of real property, Encumbrances that are
easements, rights-of-way, encroachments, restrictions, conditions and other similar Encumbrances incurred or suffered in the ordinary
course of business consistent with past practice and which, individually or in the</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">aggregate,
do not and would not materially impair the use (or contemplated use), utility or value of the applicable real property or otherwise
materially impair the present or contemplated business operations at such location, or zoning, entitlement, building and other
land use regulations imposed by Governmental Bodies having jurisdiction over such real property or that are otherwise set forth
on a title report, (d) in the case of Intellectual Property Rights, non-exclusive licenses granted to use such Intellectual Property
Rights in the ordinary course of business consistent with past practice and (e) in the case of any Contract, Encumbrances that
are restrictions against the transfer or assignment thereof that are included in the terms of such Contract.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
shall mean any individual, Entity or Governmental Body.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Pre-Closing
Period</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 5.01(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0; text-indent: 0.5in">&ldquo;<B>Product Candidates</B>&rdquo;
shall mean all drug, pharmaceutical, biological or diagnostic products and product candidates being developed, tested, labeled,
manufactured, distributed, marketed, sold, stored or otherwise commercialized by or on behalf of any Acquired Company, including
IMMU-132 (Trodelvy), IMMU-130 and IMMU-140.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Purchaser</B>&rdquo;
is defined in the preamble to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Registered
IP</B>&rdquo; shall mean all Patents, Trademarks (including, for clarity, domain names), Copyrights and other Intellectual Property
Rights that are registered, filed or issued under the authority of, with or by any Governmental Body or other intellectual property
registrar, and all applications for any of the foregoing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Release</B>&rdquo;
shall mean any presence, emission, spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring, emptying, dumping,
disposal, migration, or release of Hazardous Materials from any source into or upon the environment, including the air, soil,
improvements, surface water, groundwater, the sewer, septic system, storm drain, publicly owned treatment works, or waste treatment,
storage, or disposal systems.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Representatives</B>&rdquo;
shall mean officers, directors, employees, attorneys, accountants, investment bankers, consultants, agents, financial advisors,
other advisors and other representatives.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Sarbanes-Oxley
Act</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 3.05 of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Schedule
14D-9</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.02(a) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>SEC</B>&rdquo;
shall mean the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Securities
Act</B>&rdquo; shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Shares</B>&rdquo;
is defined in <U>Recital <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(A)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Specified
Agreement</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 8.01(e) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Specified
Governmental Bodies</B>&rdquo; is defined in <U>Section 3.13(a)</U> of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Stockholder
List Date</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.02(b) of the
Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Subsidiary</B>&rdquo;
An Entity shall be deemed to be a &ldquo;<U>Subsidiary</U>&rdquo; of another Person if such Person directly or indirectly owns,
beneficially or of record, (i) an amount of voting securities or other interests in such Entity that is sufficient to enable such
Person to elect at least a majority of the members of such Entity&rsquo;s board of directors or other governing body, or (ii)
at least 50% of the outstanding equity or financial interests of such Entity.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Superior
Offer</B>&rdquo; shall mean a <I>bona fide </I>written Acquisition Proposal that the Board of Directors determines, in its good
faith judgment, after consultation with outside legal counsel and its financial advisor, is reasonably likely to be consummated
in accordance with its terms, taking into account all legal, regulatory and financing aspects of the proposal and the Person making
the proposal and other aspects of the Acquisition Proposal that the Board of Directors deems relevant, and if consummated, would
result in a transaction more favorable to the Company&rsquo;s stockholders (solely in their capacity as such) from a financial
point of view than the Transactions (including after giving effect to proposals, if any, made by Parent pursuant to <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section
6.01(b)(i)<U>)</U>; <I>provided </I>that for purposes of the definition of &ldquo;Superior Offer,&rdquo; the references to &ldquo;20%&rdquo;
in the definition of Acquisition Proposal shall be deemed to be references to &ldquo;50%.&rdquo;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Surviving
Corporation</B>&rdquo; is defined in <U>Recital <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(B)</U> of
the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Takeover
Laws</B>&rdquo; shall mean any &ldquo;moratorium,&rdquo; &ldquo;control share acquisition,&rdquo; &ldquo;fair price,&rdquo; &ldquo;supermajority,&rdquo;
&ldquo;affiliate transactions,&rdquo; or &ldquo;business combination statute or regulation&rdquo; or other similar state anti-takeover
laws and regulations (including Section 203 of the DGCL).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Tax</B>&rdquo;
shall mean any tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated
tax, unemployment tax, national health insurance tax, excise tax, premium, alternative or minimum tax, ad valorem tax, transfer
tax, stamp tax, sales tax, use tax, property tax, business tax, escheat or unclaimed property, withholding tax or payroll tax,
or other tax of any kind whatsoever (including any levy, assessment, tariff, impost, imposition, or duty (including any customs
duty) in the nature of a tax), and including any penalty, interest or other additions thereto, imposed, assessed or collected
by or under the authority of any Governmental Body.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Tax
Return</B>&rdquo; shall mean any return (including any information return), report, statement, declaration, estimate, schedule,
form, election, certificate or other document or information filed with or supplied to, or required to be filed with or supplied
to, any Governmental Body in connection with the determination, assessment, reporting, withholding, collection or payment of any
Tax and any attachments thereto or amendments thereof.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Termination
Condition</B>&rdquo; is defined in <U>Annex I</U> to the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Termination
Fee</B>&rdquo; is defined in <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 8.03(c) of the Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trademarks</B>&rdquo;
is defined in the definition of Intellectual Property Rights.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trade
Secrets</B>&rdquo; is defined in the definition of Intellectual Property Rights.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Transactions</B>&rdquo;
shall mean (i) the execution and delivery of the Agreement and (ii) all of the transactions contemplated by the Agreement, including
the Offer and the Merger.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Treasury
Regulations</B>&rdquo; shall mean the regulations promulgated under the Code by the U.S. Department of the Treasury.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exh&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt; font-weight: normal">Annex
I</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Conditions
to the Offer</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The obligation
of Purchaser to accept for payment, and pay for, Shares validly tendered (and not validly withdrawn) pursuant to the Offer is
subject to the satisfaction of the conditions set forth in <U>clauses <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>(a)
</U>through <U>(h)</U> below. Accordingly, notwithstanding any other provision of the Offer or the Agreement to the contrary,
Purchaser shall not be required to accept for payment or (subject to any applicable rules and regulations of the SEC, including
Rule 14e-1(c) under the Exchange Act) pay for, and may delay the acceptance for payment of, or (subject to any such rules and
regulations) the payment for, any tendered Shares, and, to the extent permitted by the Agreement, may terminate the Offer: (i)
upon termination of the Agreement; and (ii) at any scheduled Expiration Date (subject to any extensions of the Offer pursuant
to <FONT STYLE="font-family: Times New Roman, Times, Serif">&lrm;</FONT>Section 1.01(c) of the Agreement), if: (A) the Minimum
Condition, the Termination Condition and conditions set forth in <U>clauses (e)</U> and <U>(g)</U> shall not be satisfied by one
minute after 11:59 p.m. Eastern Time on the Expiration Date; or (B) any of the additional conditions set forth below shall not
be satisfied or waived in writing by Parent:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>there shall have been validly tendered and not validly withdrawn Shares that, considered together with all other Shares
(if any) beneficially owned by Parent and its Affiliates, represent one more Share than 50% of the total number of Shares outstanding
at the time of the expiration of the Offer (the &ldquo;<U>Minimum Condition</U>&rdquo;); <I>provided</I>, <I>however</I>, that
for purposes of determining whether the Minimum Condition has been satisfied, the Parties shall exclude Shares tendered in the
Offer pursuant to guaranteed delivery procedures that have not yet been &ldquo;received&rdquo; (as such term is defined in Section
251(h)(6)(f) of the DGCL);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>(i) the representations and warranties of the Company set forth in the first sentence of <B>&lrm;</B>Section 3.01 (Due
Organization; Subsidiaries, Etc.), <B>&lrm;</B>Section 3.02 (Organizational Documents), <B>&lrm;</B><U>clauses
(i) &ndash; (ii)</U> of <B>&lrm;</B>Section 3.03(c) solely as such representations relate to the Company, Section 3.04 (Authority;
Binding Nature of Agreement), <B>&lrm;</B>Section 3.21 (Takeover Laws), <B>&lrm;</B>Section 3.23 (Opinions of Financial Advisors)
and <B>&lrm;</B>Section 3.24 (Brokers and Other Advisors) of the Agreement shall be true and correct in all material respects
as of the date of the Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time (except
to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date
or period);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>the representations and warranties of the Company set forth in the first sentence of <B><I>&lrm;</I></B>Section 3.03(a), <U>clauses (i) &ndash; (iii)</U> of <B><I>&lrm;</I></B>Section 3.03(d) and <B><I>&lrm;</I></B>Section 3.03(e) (Capitalization, Etc.)
of the Agreement shall be true and correct (except for <I>de minimis </I>inaccuracies) in all respects as of the date of the Agreement
and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time (except to the extent any such representation
or warranty expressly relates to an earlier date or period, in which case as of such date or period);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>the representation and warranty of the Company set forth in <B><I>&lrm;</I></B>Section 3.06(b) (No Material Adverse Effect)
of the Agreement shall be true and correct in all respects;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>the representations and warranties of the Company set forth in the Agreement (other than those referred to in <U>clauses
(i)</U> through <B><I><U>&lrm;</U></I></B><U>(iii)</U> above) shall be true</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">and
correct (disregarding for this purpose all &ldquo;Material Adverse Effect&rdquo; and &ldquo;materiality&rdquo; qualifications
contained in such representations and warranties) as of the date of the Agreement and at and as of the Offer Acceptance Time as
if made on and as of the Offer Acceptance Time (except to the extent any such representation or warranty expressly relates to
an earlier date or period, in which case as of such date or period), except where the failure of such representations and warranties
to be so true and correct has not had, and would not reasonably be expected to have a Material Adverse Effect;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>the Company shall have complied with or performed in all material respects the obligations, covenants and agreements it
is required to comply with or perform at or prior to the Offer Acceptance Time;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>since the date of the Agreement, there shall not have occurred any change, circumstance, condition, development, effect,
event, occurrence or state of facts which, individually or in the aggregate, has had, or would reasonably be expected to have,
a Material Adverse Effect that is continuing;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
the waiting period applicable to the Offer under the HSR Act shall have expired or been terminated, and, if Parent and the Company
have entered into an agreement with any Governmental Body regarding the timing of the consummation of the Offer, that agreement
shall permit such consummation;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0; text-indent: 34.6pt">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Parent and Purchaser shall have received a certificate executed on behalf of the Company by the Company&rsquo;s Chief Executive
Officer and Chief Financial Officer confirming that the conditions set forth in <U>clauses <B>&lrm;</B>(b)</U>, <U>(c)</U> and
<U>(d)</U> of this <U>Annex I</U> have been satisfied;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>there shall not have been issued by any Governmental Body of competent jurisdiction in any jurisdiction in which Parent
or the Company has material business operations, and remain in effect, any judgment, temporary restraining order, preliminary
or permanent injunction or other order, decree or ruling restraining, enjoining or otherwise preventing the acquisition of or
payment for Shares pursuant to the Offer or the consummation of the Offer or the Merger or subsequent integration, nor shall any
Legal Requirement have been promulgated, enacted, issued or deemed applicable to the Offer or the Merger by any Governmental Body
in any jurisdiction in which Parent or the Company has material business operations which prohibits or makes illegal the acquisition
of or payment for Shares pursuant to the Offer or the consummation of the Merger or subsequent integration; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-indent: 33.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>the Agreement shall not have been terminated in accordance with its terms (the &ldquo;<U>Termination Condition</U>&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The foregoing
conditions shall be in addition to, and not a limitation of, the rights of Parent and Purchaser to extend, terminate or modify
the Offer pursuant to the terms of the Agreement. The foregoing conditions are for the sole benefit of Parent and Purchaser, may
be asserted by Parent or Purchaser regardless of the circumstances giving rise to any such conditions (including any action or
inaction by Parent or Purchaser) and (except for the Minimum Condition) may be waived by Parent and Purchaser, in whole or in
part, at any time and from time to time, in the sole and absolute discretion of Parent and Purchaser. The failure by Parent or
Purchaser at any time to exercise any of the foregoing rights shall not be deemed a waiver of any such right and each such right
shall be deemed an ongoing right which may be asserted at any time and from time to time.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-size: 10pt; font-weight: normal">Annex
II</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">AMENDED AND
RESTATED<BR>
<BR>
CERTIFICATE OF INCORPORATION<BR>
<BR>
OF</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Immunomedics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 171pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>FIRST</U>: The name of the Corporation is Immunomedics,
Inc. (the &ldquo;Corporation&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>SECOND</U>:
The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of
New Castle, Delaware, 19801. The name of its registered agent at that address is The Corporation Service Company.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>THIRD</U>:
The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General
Corporation Law of the State of Delaware as set forth in Title 8 of the Delaware Code (the &ldquo;DGCL&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>FOURTH</U>:
The total number of shares of stock which the Corporation shall have authority to issue is 100 shares of Common Stock, each having
a par value of $0.01.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>FIFTH</U>:
The following provisions are inserted for the management of the business and the conduct of the affairs of the Corporation, and
for further definition, limitation and regulation of the powers of the Corporation and of its directors and stockholders:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The directors shall have concurrent power with the stockholders to make, alter, amend, change, add to or repeal the By-Laws
of the Corporation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The number of directors of the Corporation shall be as from time to time fixed by, or in the manner provided in, the By-Laws
of the Corporation. Election of directors need not be by written ballot unless the By-Laws so provide.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>In addition to the powers and authority hereinbefore or by statute expressly conferred upon them, the directors are hereby
empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation, subject,
nevertheless, to the provisions of the DGCL, this Amended and Restated Certificate of Incorporation, and any By-Laws adopted by
the stockholders; provided, however, that no By-Laws hereafter adopted by the stockholders shall invalidate any prior act of the
directors which would have been valid if such By-Laws had not been adopted.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>SIXTH</U>:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex II&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement
of expenses to) directors, officers and agents of the Corporation (and any other persons to which applicable law permits the Corporation
to provide indemnification) through By-Law provisions, agreements with such agents or other persons, vote of stockholders or disinterested
directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable
law is amended after approval by the stockholders of this Article SIXTH to authorize corporate action further eliminating or limiting
the personal liability of directors, then the liability of a director to the Corporation shall be eliminated or limited to the
fullest extent permitted by applicable law as so amended.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
</FONT>Any repeal or modification of this Article SIXTH shall only be prospective and shall not affect the rights or protections
or increase the liability of any director under this Article SIXTH in effect at the time of the alleged occurrence of any act
or omission to act giving rise to liability or indemnification.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>SEVENTH</U>:
Meetings of stockholders may be held within or without the State of Delaware, as the By-Laws may provide. The books of the Corporation
may be kept (subject to any provision contained in the DGCL) outside the State of Delaware at such place or places as may be designated
from time to time by the Board of Directors or in the By-Laws of the Corporation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>EIGHTH</U>:
The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate
of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are
granted subject to this reservation.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[<I>Signature
Page Follows</I>]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex II&nbsp;-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">IN WITNESS
WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to be executed on its behalf this [&#9679;]
day of [&#9679;], 2020.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt"><B>Immunomedics, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 81; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Amended and Restated Certificate of Incorporation of Immunomedics</I></P></DIV>
    <!-- Field: /Page -->






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>dp136480_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 41px; width: 146px">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 24px; width: 210px"></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: left">Gilead Contacts:</TD>
    <TD STYLE="font-weight: bold; text-align: right">Immunomedics Contacts:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Douglas Maffei, PhD, Investors</TD>
    <TD STYLE="text-align: right">Dr. Chau Cheng</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(650) 522-2739</TD>
    <TD STYLE="text-align: right">(862) 260-3727</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: blue">ccheng@immunomedics.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Amy Flood, Media</TD>
    <TD STYLE="text-align: right">Darren Opland, PhD, Media</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(650) 522-5643</TD>
    <TD STYLE="text-align: right">(646) 627-8387</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: blue">darren@lifescipublicrelations.com</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: left"><U>For Immediate Release</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: left">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>GILEAD SCIENCES TO ACQUIRE IMMUNOMEDICS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">--
Gilead Adds Trodelvy<SUP>TM</SUP>, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Negative Breast Cancer,
With Promise in Other Forms of Breast Cancer and Additional Solid Tumors --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>-- Acquisition Transforms
Gilead&rsquo;s Portfolio with First-in-Class Commercial Product with Significant Revenue and Best-in-Class Potential --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>-- Trodelvy will
Accelerate Gilead&rsquo;s Emerging and Complementary Oncology Pipeline, Building on Agreements Executed Earlier This Year --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>-- Immunomedics
to Present Latest Clinical Findings on Trodelvy at European Society for Medical Oncology Virtual Congress 2020 This Coming Week
--</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.55pt 0pt 44.15pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify"><B>Foster City, Calif. &amp;
Morris Plains, N.J., September 13, 2020 &ndash; </B>Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced
today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00
per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the
Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">The agreement will provide
Gilead with Trodelvy<SUP>TM</SUP> (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC)
that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients
with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics
plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in
the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">In the Phase 3 ASCENT study,
which was halted early due to efficacy based on the unanimous</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- more -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 24pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">September 13, 2020</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">&nbsp;</P></TD><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">&nbsp;</P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">recommendation of the independent
Data Safety Monitoring Committee, Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in
previously treated patients with advanced mTNBC. Detailed results from this study are expected to be presented at the upcoming
European Society for Medical Oncology (ESMO) Virtual Congress 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">Beyond mTNBC, Trodelvy is
also being studied in an ongoing Phase 3 trial in third line HR+/HER2- breast cancer and a registrational Phase 2 study in bladder
cancer. Additional ongoing studies are evaluating the potential of Trodelvy as a treatment for non-small cell lung cancer and other
solid tumor types. Trodelvy is being studied as both a monotherapy and in combination with checkpoint inhibitors and other non-immuno-
oncology products by Immunomedics and independent investigators. Additional clinical data for Trodelvy in bladder cancer and other
solid tumors will also be presented at ESMO this coming week.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&ldquo;This acquisition
represents significant progress in Gilead&rsquo;s work to build a strong and diverse oncology portfolio. Trodelvy is an approved,
transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential
to treat many other types of cancer, both as a monotherapy and in combination with other treatments,&rdquo; said Daniel O&rsquo;Day,
Chairman and Chief Executive Officer, Gilead Sciences. &ldquo;We look forward to welcoming the talented Immunomedics team to Gilead
so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&ldquo;We are very pleased
that Gilead recognized the value of Trodelvy &ndash; both for the important role it has already begun to play for patients with
metastatic triple-negative breast cancer and for its potential to help many other patients with cancer in the future,&rdquo; said
Behzad Aghazadeh, PhD, Executive Chairman of Immunomedics. &ldquo;We are excited for the opportunities ahead of us as we join with
Gilead to advance our shared mission in defeating cancer. By working with Gilead, we have the opportunity to accelerate our progress
and improve care for patients in need of new therapies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>Compelling Strategic
Benefits</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.55pt"><FONT STYLE="font-size: 10pt"><B>Rapidly Expanding Trodelvy&rsquo;s Benefit
for Patients Globally: </B>After closing Gilead intends to initiate numerous additional mid- and late-stage studies in the near
term to determine which patients will benefit from Trodelvy as both a monotherapy or in combination with other products. Gilead
brings commercial, medical, regulatory and manufacturing expertise, which will help rapidly advance Trodelvy through development
and reach additional patients. Gilead will also bring to Immunomedics an established infrastructure and operations in Europe and
Japan to support the launch of Trodelvy in those regions, pending approval. After closing, Gilead will retain global rights to
Trodelvy outside of greater China, South Korea and certain Southeast Asian countries.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.5pt"><FONT STYLE="font-size: 10pt"><B>Trodelvy is Foundational to Gilead&rsquo;s
Oncology Franchise: </B>Trodelvy will bring to Gilead a cornerstone product that broadens and deepens the company&rsquo;s solid
tumor pipeline, building on current marketed products and late-stage clinical candidates for patients with hematological malignancies
at Kite and Gilead, including Yescarta<SUP>&reg;</SUP>, Tecartus<SUP>&reg;</SUP> and magrolimab.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 41.2pt; text-align: justify">Trodelvy is approved as
a third-line treatment for mTNBC and has shown promise for earlier stages of the disease. TNBC represents approximately 15 to 20
percent of all breast cancer cases and is generally considered the most aggressive form of breast cancer. HR+/HER2- breast cancer
accounts for more than 70 percent of all breast cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 41.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 66.1pt; text-align: center">- more -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 66.1pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">September 13, 2020</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">&nbsp;</P></TD><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">&nbsp;</P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.2pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.5pt"><FONT STYLE="font-size: 10pt"><B>Accelerates Gilead&rsquo;s Revenue and
EPS Growth:</B> Trodelvy was launched in May of 2020 and has significant commercial potential in mTNBC and other solid tumors.
In addition to immediately accelerating Gilead&rsquo;s revenue growth, the acquisition of Immunomedics is expected to be neutral
to accretive to Gilead&rsquo;s non-GAAP EPS in 2023 and significantly accretive thereafter.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: left"><U>Transaction Terms and Financing</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">Under the terms of the merger
agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of
Immunomedics&rsquo; common stock. The $88.00 per share acquisition price represents a 108 percent premium to Immunomedics&rsquo;
closing price on September 11, 2020. Following successful completion of the tender offer, Gilead will acquire all remaining shares
not tendered in the offer through a second step merger at the same price as the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">The consummation of the
tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Immunomedics shares,
the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">The tender offer is not
subject to a financing condition and will be funded through approximately $15 billion in cash on hand, as well as approximately
$6 billion in newly issued debt. Gilead expects to retain an investment grade credit rating following this transaction and this
agreement does not alter Gilead&rsquo;s stated capital allocation strategy or its commitment to maintain and grow its dividend
over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">Lazard and Morgan Stanley
&amp; Co. LLC are acting as financial advisors to Gilead. Centerview Partners LLC and BofA Securities are acting as financial advisors
to Immunomedics. Cowen &amp; Company, LLC also provided advice to Immunomedics. Davis Polk &amp; Wardwell LLP is serving as legal
counsel to Gilead and Wachtell, Lipton, Rosen &amp; Katz is serving as legal counsel to Immunomedics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>Conference Call</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5.2pt; text-align: justify">At 5:00 p.m. Eastern Time
today, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. A live webcast of
the call can be accessed at Gilead&rsquo;s Investors page at <FONT STYLE="color: blue"><U>http://investors.gilead.com</U></FONT>.
Please connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download
that may be required. Alternatively, please call 877-359- 9508 (U.S.) or 224-357-2393 (international) and dial the conference
ID 5776009 to access the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">Telephone replay will be
available approximately two hours after the call through 8:00 p.m. Eastern Time, September 15, 2020. To access the replay, please
call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 5776009. The webcast will be archived on www.gilead.com
for one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>About Trodelvy</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">Trodelvy (sacituzumab govitecan-hziy)
is a Trop-2 directed antibody-drug conjugate indicated for the treatment of adult patients with metastatic triple-negative breast
cancer (mTNBC) who have received at least two prior therapies for metastatic disease. This indication is approved under accelerated
approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon
verification and description of clinical benefit in confirmatory trials. To learn more about TRODELVY<SUP>TM</SUP> (sacituzumab
govitecan-hziy), please visit <FONT STYLE="color: blue"><U>https://www.trodelvy.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 66.1pt; text-align: center">- more -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 66.1pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">September 13, 2020</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">&nbsp;</P></TD><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">&nbsp;</P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5.2pt; text-align: justify">Trodelvy carries a black
box warning for severe neutropenia and severe diarrhea. The most common adverse reactions occurring in 25 or more percent of patients
included nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash and abdominal
pain. The most common Grade 3 or 4 adverse events occurring in more than 5 percent of patients were neutropenia, white blood cell
count decreased, anemia, hypophosphatemia, diarrhea, fatigue, nausea and vomiting. Two percent of patients discontinued treatment
due to adverse events. There were no deaths related to treatment and no severe cases of neuropathy or interstitial lung disease.
See trodelvy.com for additional U.S. important safety information and full Prescribing Information, including Boxed Warning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>About Immunomedics</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">Immunomedics is a leader
in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat
cancers. The company&rsquo;s proprietary ADC platform centers on using a novel linker that does not require an enzyme to release
the payload to deliver an active drug inside the tumor cell and the tumor microenvironment, thereby producing a bystander effect.
Trodelvy, the company&rsquo;s lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative
breast cancer and is also the first FDA-approved anti-Trop-2 ADC. For additional information on the Company, please visit its
website at <FONT STYLE="color: blue"><U>http://www.immunomedics.com</U></FONT>. The information on its website does not, however,
form a part of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>About Gilead Sciences</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">Gilead Sciences, Inc. is
a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical
need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences,
please visit the company&rsquo;s website at www.gilead.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>Forward-Looking Statements</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5.2pt; text-align: justify">This communication contains
forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Immunomedics
and the acquisition of Immunomedics by Gilead that are subject to risks, uncertainties and other factors. All statements other
than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding
the intent, belief or current expectation of the companies&rsquo; and members of their senior management team. Forward-looking
statements include, without limitation, statements regarding the business combination and related matters, prospective performance
and opportunities, post-closing operations and the outlook for the companies&rsquo; businesses, including, without limitation,
the ability of Gilead to advance Immunomedics&rsquo; product pipeline and successfully commercialize Trodelvy; expectations for
achieving full U.S. Food and Drug Administration approval based on Immunomedics&rsquo; confirmatory data for Trodelvy and Immunomedics&rsquo;
development of Trodelvy for additional indications; clinical trials (including the anticipated timing of clinical data; the funding
therefor, anticipated patient enrollment, trial outcomes, timing or associated costs); the possibility of unfavorable results from
clinical trials; regulatory applications and related timelines, including the filing and approval timelines for Biologics License
Applications and supplements; filings and approvals relating to the transaction; the expected timing of the completion of the transaction;
the ability to complete the transaction considering the various closing conditions; difficulties or unanticipated expenses in connection
with integrating the companies; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties and are cautioned</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 31.3pt; text-align: center">- more -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 31.3pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">September 13, 2020</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">&nbsp;</P></TD><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">&nbsp;</P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">not to place undue reliance
on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks
and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking
statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Immunomedics&rsquo;
stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various
closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay
or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees,
other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or
actions, if any; Immunomedics&rsquo; ability to meet post-approval compliance obligations (on topics including but not limited
to product quality, product distribution and supply chain requirements, and promotional and marketing compliance); imposition of
significant post-approval regulatory requirements on Immunomedics&rsquo; products, including a requirement for a post-approval
confirmatory clinical study, or failure to maintain (if received) or obtain full regulatory approval for Immunomedics&rsquo; products
due to a failure to satisfy post-approval regulatory requirements, such as the submission of sufficient data from a confirmatory
clinical study; the impact of competitive products and pricing; other business effects, including the effects of industry, economic
or political conditions outside of the companies&rsquo; control; transaction costs; actual or contingent liabilities; adverse impacts
on business, operating results or financial condition in the future due to pandemics, epidemics or outbreaks, such as COVID-19;
and other risks and uncertainties detailed from time to time in the companies&rsquo; periodic reports filed with the U.S. Securities
and Exchange Commission (the &ldquo;SEC&rdquo;), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual
reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Immunomedics and the Schedule TO and related tender offer documents
to be filed by Gilead and Maui Merger Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking statements are based
on information currently available to Gilead and Immunomedics, and Gilead and Immunomedics assume no obligation and disclaim any
intent to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify"><U>Additional Information
and Where to Find It</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">The tender offer described
in this communication has not yet commenced. This document is for informational purposes only and is neither an offer to purchase
nor a solicitation of an offer to sell shares of Immunomedics, nor is it a substitute for any tender offer materials that Gilead,
Purchaser or Immunomedics will file with the SEC. A solicitation and an offer to buy shares of Immunomedics will be made only pursuant
to an offer to purchase and related materials that Gilead intends to file with the SEC. At the time the tender offer is commenced,
Gilead will file a Tender Offer Statement on Schedule TO with the SEC, and Immunomedics will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the tender offer. IMMUNOMEDICS&rsquo; STOCKHOLDERS AND OTHER INVESTORS
ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER
TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD
BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">Purchase, the related
Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be
sent to all stockholders of Immunomedics at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation
Statement will be made available for free at the SEC&rsquo;s web site at <FONT STYLE="color: blue"><U>www.sec.gov</U>. </FONT>Additional
copies may be obtained for free by contacting Gilead or Immunomedics. Free copies of these materials and certain other offering
documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 40.5pt; text-align: center">- more -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 40.5pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">September 13, 2020</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: -1pt">&nbsp;</P></TD><TD STYLE="width: 50%"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right; text-indent: -1.75pt">&nbsp;</P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">will be made available
by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone
at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which
will be named in the Tender Offer Statement. Copies of the documents filed with the SEC by Immunomedics will be available free
of charge under the &ldquo;Investors&rdquo; section of Immunomedics&rsquo; internet website at Immunomedics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">In addition to the Offer
to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation
Statement, Gilead and Immunomedics file annual, quarterly and current reports, proxy statements and other information with the
SEC. Gilead&rsquo;s and Immunomedics&rsquo; filings with the SEC are also available for free to the public from commercial document-
retrieval services and at the website maintained by the SEC at <FONT STYLE="color: blue"><U>www.sec.gov</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 5.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 66.1pt; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 66.1pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.55pt 0pt 8.15pt; text-align: center"><I>For more information
on Gilead Sciences, please visit the company&rsquo;s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call
Gilead Public Affairs at 1-800-GILEAD-5 or</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.55pt 0pt 8.15pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 68.8pt; text-align: center"><I>1-650-574-3000.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.45pt 0pt 68.8pt; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1"  I )(# 2(  A$! Q$!_\0
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F0"2HBPVW_@6!7444 8,'_"1FWC+20YV#.^+YNG?!ZT5O44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 -(# 2(  A$! Q$!_\0
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B2V%LL>M&!!$H6)GYC&!A3[CI1116+Q<V[V7W(OV2[L__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gild-20200913.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9a85s7xRiXgen8uCZHRMWaaJ6aP9x5V6yZkxtmt0fbkqfy8mD6jmPyiW8c32Ae4J -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:GILD="http://gilead.com/20200913" elementFormDefault="qualified" targetNamespace="http://gilead.com/20200913">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://gilead.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="gild-20200913_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="gild-20200913_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>gild-20200913_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>gild-20200913_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gilead.com/role/Cover" xlink:href="gild-20200913.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gilead.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>dp136480_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gild-20200913.xsd" xlink:type="simple"/>
    <context id="From2020-09-13to2020-09-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-09-13</startDate>
            <endDate>2020-09-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-09-13to2020-09-13">0000882095</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-09-13to2020-09-13">false</dei:AmendmentFlag>
    <dei:PreCommencementTenderOffer contextRef="From2020-09-13to2020-09-13" id="xdx2ixbrl0023">true</dei:PreCommencementTenderOffer>
    <dei:DocumentType contextRef="From2020-09-13to2020-09-13">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-09-13to2020-09-13">2020-09-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-09-13to2020-09-13">Gilead Sciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-09-13to2020-09-13">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-09-13to2020-09-13">0-19731</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-09-13to2020-09-13">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-09-13to2020-09-13">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-09-13to2020-09-13">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-09-13to2020-09-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-09-13to2020-09-13">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-09-13to2020-09-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-09-13to2020-09-13">574-3000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-09-13to2020-09-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-09-13to2020-09-13">false</dei:SolicitingMaterial>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-09-13to2020-09-13">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2020-09-13to2020-09-13">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-09-13to2020-09-13">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-09-13to2020-09-13">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-09-13to2020-09-13">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139682690607384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 13,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gilead Sciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  Y0"Y1JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( #E +E%ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  Y0"Y1)!Z;HJT   #X 0
M&@              @ &^$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  Y0"Y199!YDAD!  #/ P  $P              @ &C$0
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #M$@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="dp136480_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dp136480_8k.htm">dp136480_8k.htm</File>
    <File>dp136480_ex0201.htm</File>
    <File>dp136480_ex9901.htm</File>
    <File>gild-20200913.xsd</File>
    <File>gild-20200913_lab.xml</File>
    <File>gild-20200913_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dp136480_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "dp136480_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20200913_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20200913_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20200913.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "GILD",
   "nsuri": "http://gilead.com/20200913",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "dp136480_8k.htm",
      "contextRef": "From2020-09-13to2020-09-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://gilead.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "dp136480_8k.htm",
      "contextRef": "From2020-09-13to2020-09-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000950103-20-017822-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950103-20-017822-xbrl.zip
M4$L#!!0    ( #E +E$7>66JBB8  '*R   /    9' Q,S8T.#!?.&LN:'1M
M[5U9=QK)DG[7.?H/.<SM.=)<0(#0;FL. B1C:S-(W;9?=(JJ!-(JJNA:A.A?
M/Q&1F;512+*,;+5OS]*VJ5PB(V/Y(C*RZLW_W8]M=L<]7[C.VT*U7"DP[IBN
M)9SAVT(8#$J[A?\[7%UY,PJ@';1U_+>%41!,]C<VIM-I>;I9=KWA1G5O;V_C
M'ML49*/]^]QVM4JENO'I[+1GCOC8* G'#PS'Y%$G6SBWB\?'IU'3OF>+5%/\
M14^RN3$W-#RUX@[)QML;\F&J:9#;=$LV#713X;OU6G7G(3IDBZC#_:*V5:09
M5L@_'75/X^9!?ONXZ4;@&8X_<+VQ$< >XDA;I4JM5-M.#%+RN9D:"/Y='KIW
MCXZS6]JLZG'F-B>]4GS<-_R(XQ;/L%O/"0]P]+U2I9H8W>.#A8-O;\!3W3#T
M2T/#F$2-!X;?IX;J0<[8\,1S;>[G]J$G.9U,-W0";Y:_!O40N^VDN_E>,#\-
M_)@SPTGGM!6U'0J;&U;9=,?0$M:\5]TLD.+!K_ GP_]Y$XC YH=O-N2?\'3,
M X/A""7^9RCNWA::KA-P)RA=S2:P$Z;\U]M"P.^##:F?&]AO0PW[YK]*)78L
MN&WMLQX/#MBY,>;[[-ZZ/V"=%OWEIE*KWESW?JNU3AJ-2_@#%\)*I:?VWFS>
MX$)OX@7>Z 5^PRCU>M3K.=VW]FXXR!U0#__7=H!_LR8PQC/LCF/Q^P]\=E.!
M_]G=K57VMIX[;F/,'0O^/SBVC>'-P+!]_@U#;1\!EULWU1ME,N28\-.WC%&[
MZ8T,C_LWM1NRD'(0GW[[EG%:2,NE&FMSCJ2%@_==:\;\8&;SMX4!"-\^JU8F
M ;L28VARSJ>LZXX-IRA_* (!GAB0F%OB3O>SA#^QC=D^<UR'TT-QOX_RRCU2
M!/JGL"SN*+W 'Z#M>3B&X4PI]/=!%PW*L>>.45Q*E;U2=3-PX[\7F ,+A]FX
MV,\5B,)A+!%O-E)3?-^\TL:^+8!=WN^[8'T,AV0E25%*E J']/REB0B\$&@0
MUML"R$!-X!97*K44HRX]WG3'0)?)D;@K())[%X,!]PJ'V'T!B1OI'4.2P:!S
M#\?Q=2/T'_L^ 0.@GI&WWQ^16P#3896TUI?O?:N@'@=@Y=X6?#&>V%Q:MFB^
MS 1R3M\-O<24),7[BF6T\@=8IHVP[L9):*)?H]^%A4\&@GN,5L-S'6^S\R$M
M8-G.\70;N?.IV2; 9]>:IP+0CQ>TC( ?QDO0(\7/YKK!AB[HI)]DR4H1H']4
M+$WS.72$9#(8D#ENCKGAAQX_5)9F']KHP?2C]!0XVH+QI=E:.(5B C5Z]ARQ
M>9R;!TP9;.,\;[$O*881N%[B\;?S($MCWJB)25O<<<?">6S:Q_F2G3=O8/T\
MQ84\AF[,::2T$]K0O]F (>!/_-\W$^T<QH8W%,X^JQ0 !DT.TP^EQ^F[ML6J
M]<?<S@&+QH*FE0.&$ELR;#&$GTS0-C1JT1P)K]D-;5ZZ-(;DW)..2XY7"MP)
MN+W:)- SE/IN$+CC?;:)OTV%%8S0+U9^*Z2Z]UT/5BZ[']F&><M@#.:[MK .
MF'JH1Y+/J_%S7'K)%W^!*X=?"X?_\]_5[<J!Y*'Z;V()&ZDUO#03K\\[5^T6
MZUTUKMJ]'[IK+SA'K]V\[G:N.NT>:YRW6/M3\UWC_*3-FA=G9YU>KW-Q_O-7
M6EO*''\8_D@XP\"%SJURL\QJE:WZWC,T@Q2 &6'@1EI0>UP)7ES(E\,ES8^\
M>9:UV?W#XXON&7OC3PQ' [6;O<HFQ2"E4LLU0X)E@(INS"A<B@.GOSY>MG^_
M?Q=.9I4^#/>]L#DY7^%PM_0A"__>;""E\$=_H:"^L!X\'GT\E?/-T ,X&; N
MG[A>\."2EC3GBR_I,O3\$' _"USH:&+:AT%4[7JLNK5FK?\2:W0'+!AQ7%[H
MB4# @.U[<V0X8!0:9L#@<75OL_Y++!7A.2Y(2BA;T_]N&P"]N!^P]ATT7EV1
MS[FUC@F 2<#'?0A5JO4B0RUG:UGKLIVQ+I<$^-LR',@W,^/+[FSS3.S=A_5G
MFYED@&K!3&/H-[*,V8P#/G7RS%"*,'#0\=HVY=H6F*>TH/^-W=G?0U+U*A>[
MR]K25"(KRPTERS+AT^5#X6/:.\ <6+XH#S;#P?$GX5Z>6$OPF'GS%@Y/*#/*
M>J:@?$61=1RS_ Q?NBR^O;BE6FO?&V!\<?728&E^,,-GO0DW,0-BK:X(V+O
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M60 QV0!B:>*TI2ZDIXZ7E'S11&76&: HT+9 _&@![+<@()P(Y1J2$BE)@\T
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M(1@I=?'%Q2YK8/;-@]T&QXC9'K(TB>SKSC;LM0]V:RPS3<]R+^]Z71QQSK7
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M__73WD_T[_/3X5OU;WFN<Y7CC\]\@:(TGL+27,<%*N54_96/T%V,;-'8%^]
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MA@YS;.T9A:MPZD4\CO$M>NOYM(?=ZB>D%^XD,'][Z.IMH.?CEC%W[C/F\,:
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M?W9P&R1:,XNC#">%=7:*K>[ 9'=B0Z$V'%<#R].'X<_E\5VI' D;V)%3$TE
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M(JA&%@)MW+K'S'&S76TPK0L^9JP58"A*>8+U,2^-:%--MUF AM(SDZ(Z [5
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M!&AB)P0U>?)%5.1<Q.0D39Q:@M8OM['L1P(V+#X;$^=JS^5J7_&LL)FN.R[
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MC&<F>X._)I"]2>9XAX+E!$1_/ZJ3%%\!KY\F3%S_[SSC1T]BLPHM[M/.9S=
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MK%^T[.+E&B0]S+!UY=&X_[1BF_S@4-7<B2737!P]P42J$>)R%UN#F\Z\'AN
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MC-&7>INH?(#E7G:,PWG..CH@).Z*[@S4D-(9)=?OM;7<UDKOXJMXN@8JHKA
M60S>*.-;E\$Q!='*"$@_$^B4+/LSJT',M7 FV!U43#UBQ6W>N!R1 /#N;UG9
M*Z2GM,P-NZW, :L_[UU 8?.ZE%C%M,8.=IH_K_.)3L7.0$I ,M/S+@PNDRGQ
M*&$ %==6H>2D6]WG.761<>-S"#AE\@,%E&AC%!8[.3N)J25P.D6B<9!<<L>?
M?(9A_[$5?T$\!M:D8Q "8R92U4#_Z/BQ&2M5S?!WQQ&L#WS3@ZU8-&XBX.-
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M%T-)B=%A?);T]6(L%/P:['1%TL]B:/&'VK%7QF!Q>V7SWD$K6JWZFW/L1Y6
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M3,</A\=T7'"52X =+Y.?"1">O ="E2/.XQL@"10S9KNY=D#58=.84]MMJ]P
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MK)$*%5-A,51@$.I\7.4DZ@RY1>>MKL!H67G4;[MW0C_P>QPZ#Q7H\.,1Z(!
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M]C_#"0W/4)!?:[IB, $.0K2KU8S_],=Z<BG41G^L%V/)+TR@X2.HL*T7HB(
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M77ZU*&?EY49_A"!YA6^XY4;T%*N,#I0)]$V52_ L]L"K(?Q_C0KNK3?.SX"
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MB#*H&<%] <A:$[_O#]DP]/WY.PY'LC,:WGI#[Y>D(!^"LW.P]9K9.,G2>;\
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M1TL[6YG>'2") ^<99JO.9\,AV MGMH!N#U BY?J2+-.:9F>\KIWO YT<'!P
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M6E@@C%0'3*^H;OO<.:(4:4 U@P/HZ TX.0I=HJ3EI,I-^#;C@05*6<H3R=.
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MC<=U<+=^;\"9!Z RP;2X<YGFJ07QX_#U."2)1\'FMT9?0'Z#Q!C@*;Y@OAX
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M,T\<%WIJ$M#/W6D]SADGKT94.O@0P"5BB=ZFP@3>QJP:Z46"7M@GIXW+W7O
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M\"LDR82:$P82TP)$&O0;+I)B9E#XZH?<Q17PQ0::Q5.^$L&%1JW"_ K;F0T
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M9FN1K)=H53/U,;#3*A3X\NUZEJ+,/$[C:0X/ZOB3IU<F![:%;TOUAK<&.UC
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M8DOO$5OZL=U;S0YC>)9S3S98780R<,B*60BE:^%RAE*^VPO$WJP*V5#5Y+4
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MQX?O)_N%.C]3P/91PQ(8YW-$$[KCY-A2=H\M97#DOP<"*L@""^>P)_G?H@6
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M #%BD&77LL(J1>GNCXL4H]3%BE2%W;H9:]\YT;?]L5Z,@_0ZW9:ASK"#;#,
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M L5/-35/61M8N$=4#1Q7VOJ$R2&P"N5:.KFU !+B8-DI021F>X.A96IK=<F
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MFWDW #?XUI;Y)J3L=>?A8R6$]SIW )P ?"3N>$1H# !#FSU+::NG6IW-(1,
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MX19L>*/IMM^SWA3U,=<Y5?RZ^G().04#J ILC9LV.@CCQQ/$:R*OIO3*:90
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M/QYIY(P#V3K*;4&)E LD>NE*,GDW&<F0PL.C2TQ8P2 :H +"H_Q+4:^$G8=
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M80J#Z*8&$VLXT^O29^K-2^#!X5N0&8DD#>OU/*?"H-UV 5/)5D_AX6[+[:6
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M'+V3<4!\A_"R9L$O?NOZ-V,XT7/WY;R:=Q.ME#4L:$!<-J$:(0R&'X[Z8YI
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M(<62R7(W+G9;JX39"L4OC[ EXW+AN%$)PF[#$W4A<YVR,% NZT7):204U!A
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M&U8/2[]A4##A8F;P<.BSC6,X@E!UQ^19A;4_+Y!O):?\!$)4$#XM*TQ6 /^
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M\)JKQ0<Q_\!(+WQ\U>CK*B]*Q<! Q&X(...1GL;8Y<I^@I:)"!7EF,'F:6N
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M'\72\K"3.V(D"\L,6T:NE_PNF/CB8Q_.Y"/,+^RWH?V:BEXX]SD:DT/\YUZ
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MU:M&3ZVF1RM?]Z5.S6,:DF_2\[QO4?-NW6@YZ.UE>TG+SF(9V?JZ[;A^Q0[
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M8#&YC@BUI0RAO!Y#E#(*06,T&Z1F8&IPN GYCZF@$;?)/A7HVH;3@53K4L4
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M43=G<^QVN &W3CNF[1B-@D-\M;DM5F.2,!O^:3$GG(A?#;5Q<,P^0 -M&7+
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MOW"./R;L7%$'M/_W6&^T!BNO[<DF]>0O[\^._TGK^9>K3R?O_C]02P,$%
M  @ .4 N43/<U]@%)   :9X  !,   !D<#$S-C0X,%]E>#DY,#$N:'1M[7UI
M<]O(LN5W1O _U'CNZ[%C2%J[%[D=ER(IFZ^U/9%NAS]-%($BB38(H+%(IG_]
MG,RJ @HD)<NWO75;[\9KVR102U9FULF5+UZ/3T]>-ALO7@^Z??PIZ/]>C(?C
MD\'+%X_UG_CVL?GZQ=%Y_YT8C=^=#'Y],(VC_+G8WDIR,0X6*A-GZEI<Q@L9
MM?0'+3%2:3!]@!?QZH5]+U<?\K8,@UGT7*3!;)X?BH5,9P'^N?7@Y8NCEX,/
M\V 2Y.+9L\[VB\='6,C%RA#.\[]$DRPYO/61\LMQ]^AD('J#DY/11;<W/'OU
MZX.M!_SOBVZ_;_]M!K@._'Q.^]OZKT-QU[T>BDF<^BIM>W$8RB13SX7]&Y'A
MQ?C2#G^ETCSP9&@ID<?) W, +\;]E47L;_T7MG%\?C9VB=_.@H]*KPK?#D]?
MB=%E[]<'P4+.U/_;VMKN_)','HCNR?C7!^6NYHHH_ESL;2<?#H7=X]Y!\J$B
M)<U#I]]?7\^&L_LK2]RY;8D[>\X2=S#$!SK*:G'XS^7GT+3<WYTV]L!]_ >>
MJD;M:T.Z21SZA\*=*%13S/,J")7T10_/2B_/GF]>X">&,FL>+A9%%"^4'WC9
MRH@_,+E>]N-B%LI,G,KI5 4M<3'OM\0PNE)9'J?9G9?03SNB-Y<%_J.BV7^V
ME(<'^UN/Q/[.3GOGR>ZS.T_]\.G!SB.Q<[#5WGVR\^0O,<V&T>^\C-MD_9"T
M7IR">\("BL_SB$C_#AR.Z7CQXN\BS-W%4AR'<>RWQ"D6+^_.)#)-523.DU!&
MOF&U:H2_P"_[!WN[=^>7@[V#1^)@YTG[Z>[3_XQ?/N>P?=[TO\-@JC(O2(I)
M&'BI"F4>Q-':L?]S]/ 7F.HQXY.7+HK1N(-T\)W 1PEZ\.@6_W>_LT,GM'X5
MO'CS\CA.!;0X,62NQ*7"W9"I%X_?; !<7V\=-^$W]TE/1;E*/P>%Z06T<42\
MB/*#29SG\8(_8ZCY:G@"9"M&O>'@K#<8B?&YZ/;^Y\WP<B"&IZ=OSLY/!_UA
M;[09A7Z#)=Y$'3U-D&-V[W./Y=8IZT>D=_7@9;O=;!CLT/7]3(S3V%?AU?+%
MZ,W%R_'IB\?T9TL<!VF6MS%@#S=L)KI1'DQB?]GNI\6,(,(?Q8PXK9LD:7RE
M?$@01E(2ZTZ#)%3M[[[/FQ;P=2<%;PU?GBG0)KA2X@@4R7+1DY&GTE:S\3;(
MY^(BC1=!ID2 VR2?JU1 =A>9B*?UQP7N&3JA@)2M#,4H#@-?C(L%H(UH@[[#
MEYM9^1ML\W96_@84;K=%U_NS"#*F#GA.1MF4R&AY^Y<T^[.(#S-Q$:?Y%*2+
M87V ^"MLW8NA,U,O 'UQ+'[AY?JQ$>8,IK@AHAS*]$I%A>+S.%+NVQ=QCE71
MR_?G4>H1$# ,FXVNY^$22DE'K)S( !3'T#,F* X VF*!P62Z%.<1P8_94EP$
MB0J#2+7$41&$/CV-8^[.4L7/8I /RBMRZ)V!3,, TC*>!YEXIV1Z?Q9MX=IS
MS094\T6J,CPD3G >I&% 6X(_$(>(B)L)%B)S@%#B@R*-$R4C:!TO4/D2=V'*
M<)=>*D_I]R#-"WR ZP G X'8V=K9TB>!<Z5#>ZO4^V;C2YZ(!B+;NYW]?0(D
M^/^]O<[V_M<^#3/M5L?.N@$$_5%D>3!=\CD<QQGF%[T@7[:@T(&@.^(7N4@.
MFXW3.$U!H8M0!A&F.>O\=X<F2W*UF."5[=V6IN,OD2^S^:$@NID+>X3#P-V0
MD97K=<3#,YGY\L_G M"G_XCEJ6;)E]\3_J'OH[C ZSZQA"^7(I_CJ'$% ?0O
M$AD%(,-<XMIBVD&V@@BL(X6OIF 7OM"DE4"1%&E6D'K$(]?SP)L;,6?Q%Y*4
M<ZKJRR$>^M?3IYVMK68CP4ZSN4SY&O2PSP[X1HF<%+GT2*FWS+!7$J9(5A\)
MRY8$/#X$"S!TN!3_VMD6$TRLWY.9*"+L9Q$7&;Z4%J-,EL =T.[8<HF!UHAV
M%,O4Y^NXCQUXY$G@AP+Z T9#D,A<XQTOC'&-^T5*G$YDG,9%BN'_+&1*AX\A
MZ" [WYC[OCS+WV56.KV*.Y@)B.J!7Y&:;]:-<%,\Q*$'>?&Q6,B)F.&U7.'N
M;<\_!LM'+;#@U%[;'E^\&"1I[PB?#TCY?#",3GU"IUZ)3A]V^[U'X';B<^**
M&=B+GR\O)]]P![389,F'^*8SZ@"2Q9HU&.YV?2BS( -S,MIX>-SO/B*^[29I
M$#);Y\R[@+^\>QR\](L00H(7Z+IJ-GCO"Y4#W^$S#P\S2HXL4IQHZ.=IZ/=P
M,3X[ZCV"!,1:(K%/%1 +8R,A/YE?QR!PH.=.94+"2RMQYO"!,F$%=E:N _)@
M9,2_63%9!) D_"6QEW HC@)2[B0))P&T:,88'Y#=[/WH!'OGEY,$T$I,"Q)W
M2T/LO+Q&0""F)U0'%C[*Z>K!AW0<-XI*711)Y,(LILL)M/?>T[Q3\!)O-%6S
M(I00SV4U/:;4-Y>=G/D&) RG9HKM+RJ-WUX<;[3 R_F&>N<7<QR]V!7=46]P
M-A997OA+6"!:IY(L@"AT+D!,4)$^\"V(JZ:$>3VH2;SL,]TQ5*E+O]TFOB.(
M:@M86$K<:,!^[F:?;'?V+)_L[-T-IV#6_P48=QRHT'\N+N1,'6+H/PNZ_+&"
M0W&>L ON.2UAI/B^/!2_TTWY7.P  5NW57_X>SV(I@ERL($@_)F)>-G/CD*2
MNFVL/"/K$\AF/297=VV\>(PI-\R>8 ]M4G+OVQ,%\<4Z97@MEUG]I&Y8V(T3
M\Y3?.13X*;?B#2% \66D:/L&&3(? M\K&KR]3>1:1YE,P&^_$)=AR&OZ;4ED
MHITKZ^H\V:>ED;0)5_RLX!V*\3+!R7=3.0F\0W$F%TH+YUE,(K?COO38OD7?
M?$4BW[J552J3;]IZIF\3*%>&W3TQ:5BY?+OK$\B'?#2PA1A_X!:G*XFVFBC>
M;[/1E[D4(SDE._4T!MR(&9&3;R?(<Z5:%2;)*K\.;KU@80P#_,$&+&9H3X%A
M@6[2JX 0Q<.+XY&VK/!@*H%UJJ_.1X\8SR2IN@JTJ<$8D 8TP$]C7NE?$:[S
M!<.ZCN@#HP'&^, P&6 B@%L:+[ OX!V^IP791>I#HL$M[N6)PA+9@M<0D&_E
MQ&,;N]FXF['^<# Z/7^TV6;_FX.B.QI&1VH91^80')X(@(D99DX4L0V=0,#&
M+XX=$&@6TZ<63@&W:YR)TTI]03XJ\?KR_SY^/;C<::^@>.(:23BU-!W(S<@#
M[9B#QD"34/JX6IH-_5;']?G:V?6:,LT79!!C-&-S)J4/TL7>P'?2,4B((2+P
M=K8@#H;M$XJPP #.0F,R(YH-ON=%3EYFD4/=91V74"LDPBQL3TM IBC6=LA2
M&\L1^10F0:2EEJ7 FROO?8+]Y/B:LX*L:<VO\@)U6+G=;,26;1/MELW(/*O[
M 'B:4@W@[Q3W#V9D$F0U*GK6V^63HB!:N#:*H?_MM,B,6T.S25T82:ZT\&J!
M%-=*O?_;&_U[=YHU],FGRQX_6?GCFXU4&1)EKLHM]2S1?<4K?!VG;-]-R-]+
M-FF>QL9'[,/R32$T%4]8GWZ=.2&NUM4#2R>W,0$K><PW)*_$ <P'"Y(9<^[L
M(\ @B20(!\N2S"(/1E*H(O968VTL4!WQ5FENB.)K\C5 %(WU]"$)R70(L.M2
M+-G]RB^"PM'2\#J+5C5[R\A1=D=1,H-8^<Y:OZ1\$"*3X-@^N?*@^0UM^Y(,
MO]Y<!J!%I+WN\T!-C0^=O _G9/?1,E;\C!UA3AA;#N/X/1'M6J9\)UVKT/ [
M.S]DJ 6B)J.YD@MZ5@]+$H77:,\UNIGK4<L0[F2<+C%+!$ZMG1G-,U&1F@;L
M8JG?L>88P4:A#PRI.H8DWUPDOHOWK3HFNB(@+A 23@'PC??+'"RA*8CC1X(5
MH";[5FL7AW4Z,S]:HE=GDL8A\;>8$ZN&X#_<81,U*R(ZQR24&GO43J;9N+/;
MBUB3WJ\)$(T\5V'BBL_&H[<NGR(O4E63B&;C2,T_4L![-I?X4\U- D\E :5X
M@!@N"[L2H%&9Q^XL2YJ8O6 %N<?I?IX3D3%$D9$P@]?_P'UGR&".P&'XN#!.
M<("2@-$G;<)74Z7O=XL(CI:L'OENH0WKD5HT/GL'ZPM9\A15^(UFL8H72(=4
MBL:]&#]5]0/#])%2O 42O]*U^!6DZ0O@Q"^;PU*%;]Z\I+ D4!)1?$38#1C.
M(RYBY9-]N[R:FPA1N3Q<%\>J"^3ML#]^_>L#\G4\6#FOG2^5=_/)G*IUVWYG
MES;ZX";3?_MILC$E<2H70;B$/;Y<@,C:>5/+2?YE$?A^G->RGF](W"I]$PG
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M("8V> %Q(VCDI""<!-S&AD:_5"Q_E*J$Y[>?/=MON=:#K1NK-_BTB.*VA%H
M"MN/@-0+B;23[),&V7NLFIH%<P&HSHPH<Z6H/%<WV:%^6.4V;=\<EE_WXZD
MW:@K%ZDU>EG/5SW!:X"X@U,FBFKX%AJ#W$A/)_.LOH04*"3UN2V6[A.6,XB:
M )&I*5E0ML)/9PS54LK*+L@VMY(KZMAA99-! S+T(XH4.#%QZG+"JL9=;K/A
MK,I8Z9H/Z$(, Z!>8U-M6KWN=4*XE$"#6V:MZY@U!T"?Y7PE $=EM!W2^]"G
MK.HXAJLKDIT6%7@6NK)M\S@=[6NY!LNSK5XV4\4N2[GGL'%K^@SD) A-[M]Z
M"XQ-*:VVNM.6:.KKITPEM=FT]M8K0W"'[J%R!(=JW^:!XGP7-FP_W=QW/6"S
M.>O6B9&LMY5:;2I=YL\Z)>FUFN_I*N"UD9WLL(K1Z%@,Q7,M\S-YW:;4P<*H
MEEK/JT/3&"4J!2,EO=*JO6L\'#!OTC@,C>W!W<YPJB X';<='XO-LM@+=,X;
M&"I[=&BZD6594)UW$4WE59QRH-SM=4>)Q+5-':ZT\[7]AK,:OU/"!#%$30%H
MFR*T/RA0GE_Y,!-WK:MQL]%=G:9J@XSUZ"&SVIC&<V.[0=43630!JBJ%\BBL
M$*UD/SMOUN6$.HOKQ]7JDV5EJ-UXF95KY+E*73T$9*2N3J Y*6^0@-KX5L=-
M"XTRC0Y-D@MW[F)\16IS9M(D:SI ZT3"B6" 8J&[T.JX9[C41["T.Z0P"[>O
MZSA).I)]6P6]I^S=0ZBS\.:K"K^F024[T'(Q ^JC'M[:*:![_;@JS[3,NHI#
MBO32-<:?K-]DM87\4.ZKOQ+.V]WN['Z/,.)M\WY.&''O/HQX'T:\#R-^QS#B
M_GT8\2N8[%RSQ!WR/.JG3\$B0(E @W3MTM1M)VZP>#ID E+;7HNB*.&'+GA%
ME@C4;,"-(TP?86H>9.P<*FUT;GT;I:)V4A-=IL.7I+84:K=D1US><'TZUII'
MH3-C;-;6QPF_O#Q>4PV8D\FL%HG&=)/EK?>^L9R>K][@68G :CBK5L6BS3<J
M_CK<^/H\OC9-!:>;T3H7U<WCT%>V :P9WUB"]'6M FT=!!M:+2B RLN<EF/!
MTEU(7]WPCD%V5<E=!>T<[WR%#(DAB,LF5.*6!]F4&O3BN6M)N6YUP$R@BU+V
M5!J9'_V@>E_,3(, ZG)S7G(TAG()]J1LM2F?<ZQ_064U%VUC-=D&;,RQBFS#
M]V1FE;\K.@\2D^1'3!(O%?OGM.>A-(D36\>!!:SOA)&J;M=B,# ?<D+U/UZ)
M:BMKQE@X.O5N[6=%:!*R)&W5VY0@Z^%&N]#!\ NE<FULE]1B6!_HUH^3T/AX
M8-!Q[73"@;7RE"8PI>D\V9S6/]E4&L9_0M+8U6D_\,E^#29%Z2%@4X;[UP:1
MC5T9UPE]366IL;$U==L@:G>DN<PN$18=!8M+_Q'$P>WD6]N80S1WLINL9]M4
MJ5Y!Z+QI6O36)N&ZO,KH+@U(_<LF=(I3&81D#KAE50^#:9GPR:G1\80_9V_
MII^0F>H?4KUQS56DWYU/B]SR;F1I:7/'E)_RK_#HYI]@OZP@AF5#7+L52'O*
MFK_!,9YY[X>V1ZO47D*C;;0SR&U?156O(/6A6)$E(Y>K1K4CKKB3<9.E(#/5
MU<8+:H9) 0# :1NK*)63TUUNH_N(M']*_17J=FU&1K>Y1,A-5V6R@AU9JK3Y
M:?(K]'8SOCSM1EK6G84-V'N(V**LX:KJ%FN]8NVM2(T<%?:&@502Z+\:[<"8
MWSFXWOGOPWY[^]FA<;$Q06\R-WW;[E]?SX$.'O.?9AUK1-)5K8%'6?]Q2EX3
M'H"U8FY_I*IR&>M5##Y WD$S_<L'FJ4>TM.FA>UHT#-M7!^Y9VT]HG:J..)?
M)!5/V[^U[ \TA<NUK[>WVO]CO %10>*YX8'?:K6=M)01]:,H0B6V]_KM9Z:7
M@][<I@;OM5?&YW5OD'O7^[%7+'1*U,J83H'<J2P"<:K+P4?%1(?CJFI^<7,U
MOW9UWXS/V)TPT?V6F;VJ:),#Q,JBD7K=GKOKEM,/;OVWZ=CIPIE$U?UAZCDR
M+Y0!1>J6E)&1F_+2(O%U?OEF%XN+,'^6*);SPP!.:I.6H+><K06ZT>]BBF'^
MCXAK_4<5X+I.8$+\K'_L8C7N1>DBA$^6*B^;6_BF/,(*(^5]<#_OBL[47J9(
M<4V2 R\*ES8])%(!ZU#NP&T:8^!!;\[Y-1'# ?+>>$$5LW&?S4C'E*TR5D2*
M7J=Z"?U;=Q/*GRORJO2NMG%K31DSQT38FHT+LYA4K  $#>;Y9^E*]0Q-2W6-
MM05K55FM>%(L;UAPS3S05+*_MJG;W6R@T6I<:'T/;E?A3:O-+296ZY:4.7T^
MXY;S>XYVXU*,]>/G_'@9&.8.(8[Z=J=LK:LW=\"10[O'E[4? 6HV-D^@KQ1W
M#OT/JJ9Q:CAK_3YJ/PUO;]_1^+SWV^OSD_[@<B2Z9WUQ/GX]N!3#L]\'^.IR
MU&QT+P?BS>6K09]V=4D_.X\GQ'APAE?$^?$Q_GO:'0\NA]V3D7@X/.N=O"$7
M'@8SW^*UBS>7O=?=T: %3KD<G.#QOC@9C,<\@AA?=L]&I\/QN'O"2^@-+L?=
MX9E>2K-1FZI_WGMS.C@;CQ[QH[24T?G)L#<<=\?#\[/'EX/>^2D>Z/,_L3W,
M1<^+HT&O^V8TH#?>B;?#DQ, FS.>9GAZ<8X)\<SP[/C\\E2_^?;UL/=:C%Z?
MOSGI-QM' [WU'JAQ_.;DY!W&P[,#+.*=Z ]ZPQ&],QR!%/T!AA^_QO.CBT%O
M3-M?)9A.0SDWC/UCW49?J\>"52HM4^$9ZJ*Q$Y6;'\7DMDR4(&D,-=N0V?P
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MEWC'@N31ULQ'NWS"E^:_+KZL+?'3FWM\=-Y_1ZWV'[\>GYZ\_/]02P,$%
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ME)6)^2CY1,66?]/LZ6-]O;;L3!*6?P%02P,$%     @ .4 N4<2\8=O]"@
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M'U!+ 0(4 Q0    ( #E +E$7>66JBB8  '*R   /              "  0
M  !D<#$S-C0X,%\X:RYH=&U02P$"% ,4    "  Y0"Y1:P6"#I14 0"KE0@
M$P              @ &W)@  9' Q,S8T.#!?97@P,C Q+FAT;5!+ 0(4 Q0
M   ( #E +E$SW-?8!20  &F>   3              "  7Q[ 0!D<#$S-C0X
M,%]E>#DY,#$N:'1M4$L! A0#%     @ .4 N47#FQ3]& P  B0P  !$
M         ( !LI\! &=I;&0M,C R,# Y,3,N>'-D4$L! A0#%     @ .4 N
M4<2\8=O]"@  WX<  !4              ( !)Z,! &=I;&0M,C R,# Y,3-?
M;&%B+GAM;%!+ 0(4 Q0    ( #E +E$UQ>T35@<  #!9   5
M  "  5>N 0!G:6QD+3(P,C P.3$S7W!R92YX;6Q02P4&      8 !@"$ 0
&X+4!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
